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Abstract 
 
Dialysis patients have a 10-50 fold increased risk of cardiac death compared to the general 
population. Key factors underpinning this heightened risk are fluid overload-induced 
cardiomyopathy and ischaemic heart disease. Progress in modifying these outcomes has been 
hampered by our inability to assess patients’ fluid status and cardiac risk in an accurate and 
dynamic manner. The overarching aim of this thesis is to advance our understanding of the roles of 
two cardiac biomarkers, the amino terminal fragment of pro-B-type natriuretic peptide (NT-
proBNP) and high sensitivity cardiac troponin-T (hs-cTnT), in diagnosing and monitoring 
cardiovascular disease in the dialysis population. 
 
Two multi-centre, prospective cohort studies were performed. The aim of the first study was to 
estimate the biological variation of NT-proBNP and plasma hs-cTnT in 55 prevalent haemodialysis 
and peritoneal-dialysis patients, and to use these estimates to derive the critical difference between 
serial measurements needed to detect a clinically significant change with 90% confidence. Patients 
were reviewed weekly for 4 consecutive weeks then monthly for a further 4 months. Assessments 
were conducted at the same dialysis-cycle time point and entailed clinical review, bioimpedance 
spectroscopy, electrocardiography, hs-cTnT and NT-proBNP testing. Patients were excluded if they 
underwent a change in cardiac medication, dialysis prescription, ischaemic symptomatology, 
extracellular volume >1L, new arrhythmia or hospitalisation between visits.  
 
137 weekly and 114 monthly NT-proBNP and hs-cTnT measurements from 42 stable patients were 
analysed. Between-person(CVG) and within-person(CVI) coefficients of variation were estimated 
using nested analysis of variance. For weekly measurements CVG, CVI, and the critical difference 
were 153%, 27%, and -46% and +84% respectively for NT-proBNP, and 83%, 7.9%, and -25% and 
+33% respectively for hs-cTnT. For monthly measurements CVG, CVI, and the critical difference 
were 148%, 35%, and -54% and +119% respectively for NT-proBNP, and 79%, 12.6%, 2.4% and -
37% to +58% respectively for hs-cTnT. The CVI:CVG ratios for weekly and monthly measurements 
were 0.18 and 0.24 respectively for NT-proBNP, and 0.10 and 0.16 respectively for hs-cTnT. CVG 
was not significantly different by dialysis modality, hydration status, history of ischaemic heart 
disease, NT-proBNP or hs-cTnT concentration, severity of left ventricular hypertrophy, systolic or 
diastolic dysfunction. Thus, serial NT-proBNP levels need to double or halve and hs-cTnT levels 
need to increase by at least 20-34% or fall by 17-25% to confidently exclude change due to 
analytical & biological variation alone. The low CVI:CVG implies the best strategy for applying 
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these biomarkers in dialysis is relative change monitoring after a baseline estimate rather than 
comparing results to reference intervals. 
 
The second study performed was a longitudinal cohort study of 103 prevalent haemodialysis and 
peritoneal dialysis patients, of whom 78 patients also participated in an echocardiographic sub-
study. The aim of the echocardiographic sub-study was to determine the cross-sectional associations 
between each of plasma NT-proBNP and hs-cTnT, and measures of hydration status, and functional 
and structural cardiovascular indices. Patients underwent clinical review, bioimpedance 
spectroscopy, electro- and echo-cardiography, hs-cTnT and NT-proBNP testing. Multivariable 
analysis found that plasma NT-proBNP was independently associated with hydration status 
(standardised β=0.313, P<0.01), left ventricular mass indexed to body surface area (standardised 
β=0.238, P<0.01), residual renal function (standardised β=-0.086, P=0.05), and left ventricular 
systolic dysfunction assessed using global longitudinal strain (standardised β=0.233, P<0.01) but 
not using ejection fraction (standardised β=-0.038, P=0.71). Plasma hs-cTnT was independently 
associated with hydration status (standardised β=0.379, P<0.01), and with pulse wave velocity 
(standardised β=0.250, P=0.04) in multivariable analysis. These findings suggest that NT-proBNP 
testing may have a role in monitoring the risk of adverse cardiac events related to hydration state 
and cardiomyopathy in the dialysis population, and that hs-cTnT testing may have role either alone 
or together with plasma NT-proBNP in monitoring hydration status in the dialysis population. 
 
The aim of the longitudinal cohort study was to determine the longitudinal correlation of plasma 
NT-proBNP and hydration status assessed using bioimpedance spectroscopy. Patients were 
reviewed monthly at the same dialysis-cycle time point and underwent clinical review, 
bioimpedance spectroscopy, electrocardiography, and NT-proBNP testing. 103 patients were 
assessed for a median of 14-months (IQR 9-22 months) yielding 1431 paired bioimpedance and 
plasma NT-proBNP measurements. The correlation coefficient between plasma NT-proBNP and 
hydration status was estimated for each study participant, followed by meta-analysis of the 
correlation coefficients across the entire study cohort. Plasma NT-proBNP and hydration status 
were found to be independently correlated across time (r=0.273 (95% CI 0.200-0.342,  I2=48.3%), 
and meta-regression found that the significant correlation between plasma NT-proBNP and 
hydration did not differ between subgroups of dialysis modality, left ventricular hypertrophy, 
systolic or diastolic function. These findings support the use of plasma NT-proBNP testing as a 
means of monitoring hydration state in the dialysis population. 
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The findings presented in this thesis advance understanding of the pathophysiological factors 
underpinning plasma NT-proBNP and hs-cTnT in the dialysis population and improve 
interpretation of serial measurements of these biomarkers in clinical practice. 
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Chapter 1 – Introduction. 
 
The overarching aim of this thesis is to advance understanding of the roles of two cardiac 
biomarkers, the amino terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) and high 
sensitivity cardiac troponin-T (hs-cTnT), in diagnosing and monitoring cardiovascular disease in the 
dialysis population. 
 
Cardiovascular disease is the leading cause of death among patients on dialysis (6-11 deaths per 100 
patient years)(1). Indeed, observed cardiovascular mortality rates in dialysis patients are 10-60 
times greater than those of the non-dialysis population. Of particular concern is the fact that 
cardiovascular mortality in the dialysis population has declined by no more than 5% over the past 
decade whereas cardiovascular mortality in the non-dialysis population has fallen by 27-33% during 
the same period(2). A key factor underpinning the poor progress in combating the heightened 
cardiovascular risk among dialysis patients is an inability to identify patients at increased risk of 
cardiac morbidity and/or mortality in a timely manner or to monitor the efficacy of cardiac 
interventions in either the clinical or research settings(3). 
 
Both NT-proBNP and hs-cTnT have garnered considerable interest as candidate biomarkers for the 
diagnosis and monitoring of cardiovascular disease in the dialysis population. Numerous cohort 
studies have demonstrated an association between plasma concentrations of both NT-proBNP and 
hs-cTnT, and the risk of adverse cardiovascular outcomes in the dialysis population(4, 5). However, 
understanding of the pathophysiological factors underpinning these biomarkers and the 
interpretation of serial measurements in clinical practice remains poor, thereby hampering the 
adoption of these biomarkers in both the clinical and research settings. 
 
This thesis aims to improve overall understanding of these biomarkers by first undertaking a review 
of the burden and pathophysiology of cardiovascular disease in the dialysis population to identify 
key targets for monitoring, followed by a critical review of the published literature surrounding NT-
proBNP in the dialysis population. Thereafter, the rationale and design of two cohort studies are 
presented with the aims of answering four crucial questions needed for the interpretation of these 
cardiac biomarkers in clinical practice: 
 
1. How much change in serial measurements of plasma NT-proBNP and hs-cTnT can be attributed 
to biological variation and is therefore of no clinical significance? 
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2. What are the pathophysiological associations of plasma NT-proBNP and hs-cTnT in the dialysis 
population and which of these serve as potential targets for intervention? 
3. How accurate is serial testing of plasma NT-proBNP and hs-cTnT for monitoring cardiovascular 
risk and the pathophysiological factors underpinning this risk in the dialysis population? 
4. How often should these biomarkers be measured and what is their associated time to event? 
 
The results of the biological variation studies, the pathophysiological associations of the cardiac 
biomarkers from cross-sectional analyses, and the longitudinal correlation of plasma NT-proBNP 
and hydration status in the dialysis population are then presented. The ultimate aim of this research 
is to address all of the research questions posed above to develop a cardiac biomarker-based 
monitoring strategy, which can then be tested to determine if it improves patient-related outcomes 
in the dialysis population compared with current standard care. 
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Chapter 2 
 
Cardiovascular Disease in the Chronic Kidney Disease Population – Burden, 
Pathophysiology & End-organ Manifestations. 
 
This chapter reviews the epidemiology and pathophysiology of cardiovascular disease in the 
chronic kidney disease population with a particular focus on those mechanisms unique to 
chronic kidney disease, their physiological consequences and end-organ effects. An 
understanding of these mechanisms is the first step to developing effective cardiac risk 
monitoring strategies and therapies for this group. 
 
The following chapter was published as the peer reviewed book chapter: 
 
MA, Fahim and Hawley, CM. Cardiovascular Disease in the Chronic Kidney Disease 
Population – Burden, Pathophysiology & End-organ Manifestations. Colin Hutchinson (Ed). 
Renal Failure: Prevention, Causes and Treatment. Hauppauge, NY: Nova Science Publishers 
2013. 
 
  
21 
 
Chapter 2 
 
Cardiovascular Disease in the Chronic Kidney Disease Population – Burden, 
Pathophysiology & End-organ Manifestations.  
Magid A Fahim1,2 & Carmel M Hawley1,2 
1. Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia 2. The 
University of Queensland, Brisbane, Australia 
 
ABSTRACT 
 
Individuals with chronic kidney disease have a disproportionately elevated risk of cardiovascular 
disease which accounts for the majority of the morbidity and mortality in this population. While 
traditional cardiovascular risk factors are overrepresented in the chronic kidney disease 
population, this alone is not sufficient to explain the excess risk observed. Chronic kidney 
disease is also associated with a number of novel pathophysiological mechanisms including salt 
and water retention, bone and mineral disorders, sympathetic overactivity and oxidative stress 
which combine to cause a number of pathological cardiovascular changes unique to chronic 
kidney disease. A greater understanding of these mechanisms is the first step to developing 
effective cardiac risk monitoring strategies and  therapies. This chapter reviews the 
pathophysiology of cardiovascular disease in the chronic kidney disease population with a 
particular focus on those mechanisms unique to chronic kidney disease, their physiological 
consequences and end-organ effects. 
 
THE BURDEN OF CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE 
 
Cardiovascular disease is the leading cause of death in patients with chronic kidney disease who 
have a 1.5 - 30 fold increased risk of cardiovascular mortality compared with their non-dialysis 
counterparts(1-3). This is particularly evident in patients with end-stage renal disease on dialysis 
therapy among whom cardiovascular mortality accounts for 43% of all deaths or 6.6 - 9.6 deaths 
per 100 patient years(1, 4). Cardiovascular disease is also a major source of morbidity in this 
population accounting for 34.7 - 56 hospitalizations per 100 patient years(4, 5).  
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Unfortunately, the past decade has seen little(2) or no improvement(6) in cardiovascular 
mortality rates among patients with end-stage renal disease while cardiovascular mortality rates 
among the general population have fallen by 33%(7). 
 
Among the various causes of cardiovascular mortality, sudden cardiac death accounts for 15-
30% of all deaths in the dialysis population making it the single leading cause of death in this 
group(1, 2, 5, 8). In contrast to the general population, cardiomyopathy and not coronary artery 
disease is reported to be the primary pathology underlying sudden cardiac death in the dialysis 
population(1, 2, 9-11). This fact combined with the high prevalence of cardiomyopathy in the 
dialysis population (61.8 – 84.5%)(10, 12) have positioned sudden cardiac death and 
cardiomyopathy as key targets of efforts to improve current poor outcomes in dialysis. 
 
The excess burden of cardiovascular disease in populations with renal disease is explained by the 
fact that cardiovascular disease is both an important cause and consequence of chronic kidney 
disease. Compared with the general population, individuals with chronic kidney disease have a 
higher incidence and prevalence of cardiovascular risk factors especially diabetes and 
hypertension(13),(14), as well as established end-organ disease(5, 10, 13-15) which may be 
partly or wholly implicated in the aetiology and/or progression of their renal disease. Indeed 
over 80% of incident and prevalent chronic kidney disease patients treated with dialysis have at 
least one cardiovascular diagnosis(5, 10). In addition, end-stage kidney disease is itself an 
independent risk factor for cardiovascular disease(16),(17), mediated through a variety of 
pathophysiological mechanisms including volume overload, sympathetic overactivity, 
hyperphosphataemia, hyperparathyroidism, oxidative stress, and anaemia. This chapter reviews 
the pathophysiology of cardiovascular disease in the chronic kidney disease population with a 
particular focus on those mechanisms unique to chronic kidney disease. The physiological 
derangements and end-organ pathologies that characterize cardiovascular disease in chronic 
kidney disease result from a confluence of multiple inciting mechanisms (Figure 1). The 
physiological aberrations and their end-organ consequences will be discussed first before 
detailing the novel mechanisms that result in these changes. 
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END-ORGAN PATHOLOGY 
 
Cardiomyopathy 
Cardiomyopathy encompassing left ventricular hypertrophy, dilatation, systolic and/or diastolic 
dysfunction is highly prevalent in the dialysis population (61.8 - 84.5%)(10, 18-20) and carries a 
poor prognosis. A prospective cohort study of 433 incident dialysis patients followed for 41-
months found that the only independent predictors of overall mortality at ≥ 2-years were a 
diagnosis of cardiac failure and cardiomyopathic indices after adjusting for demographic, 
comorbid, traditional and non-traditional vascular risk factors(10). These results were echoed by 
a prospective cohort study of 220 prevalent peritoneal-dialysis patients followed for 5-years 
which found that the only independent predictors of sudden cardiac death were left ventricular 
systolic dysfunction, systolic and diastolic blood pressure(21). 
 
Heart failure is the most common non-fatal manifestation of cardiomyopathy in dialysis; is 
highly prevalent (30-40%) and portends an increased risk of overall mortality of 80-100%(10, 
12).  A prospective cohort study of 230 prevalent peritoneal dialysis patients followed for 4-
years(12), found that the only independent predictors of new-onset heart failure were 
cardiomyopathy and diabetes mellitus, while cardiomyopathy and low serum albumin (possibly 
reflecting fluid overload) were the only independent predictors of recurrent heart failure. 
 
Left ventricular hypertrophy may be classified morphologically into either concentric or 
eccentric hypertrophy. Concentric hypertrophy is characterized by the addition of new 
sarcomeres in a parallel formation leading to an increase in ventricular wall thickness without an 
increase in ventricular luminal diameter and usually occurs in response to pressure overload. In 
contrast, eccentric hypertrophy represents an adaptive response to volume overload in which 
sarcomeres are added in a serial formation leading to an increase in both ventricular luminal 
diameter and wall thickness(22, 23). In individuals with non-dialysis dependent chronic kidney 
disease eccentric hypertrophy is the predominant pattern observed(24), while both patterns are 
equally represented among the dialysis population(10).  
 
Cardiomyocyte hypertrophy is the histological hallmark of left ventricular hypertrophy 
irrespective of renal disease; however, the cardiomyopathy of chronic kidney disease is 
additionally characterized by excessive intermyocardic fibrosis. This was illustrated in a post-
mortem series with a case-control design comparing the cardiac fibrosis scores between 
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individuals with renal disease and matched individuals with normal renal function.  The 
myocardium of individuals with renal disease demonstrated the highest fibrosis scores and renal 
disease was found to be an independent predictor of intermyocardic fibrosis even after adjusting 
for demographic factors and co-morbid conditions. Furthermore dialysis duration was found to 
be strongly correlated with the severity of fibrosis(25). The fibrosis observed in these cases is 
due to the deposition of type I collagen fibres in between cardiomyocytes at the expense of 
myocardial capillaries resulting in impaired myocardial perfusion, reduced ventricular 
compliance and variances in electrical conduction and resistance which in turn predisposes to 
arrhythmia(26).  
 
A number of factors contribute to the genesis and evolution of cardiomyopathy in dialysis 
including hypertension, volume overload, vascular stiffness, sympathetic overactivity, 
cardiotonic steroids, direct fibrotic effects of angiotensin II and aldosterone, 
hyperparathyroidism and cardiac ischaemia. These factors are discussed in detail in subsequent 
sections of this chapter.  
 
Coronary Atherosclerosis and Microvessel Disease 
Individuals with chronic kidney disease have an increased incidence and prevalence of coronary 
artery disease compared to matched individuals in the general population(5, 13, 15, 27). 
Coronary atherosclerosis associated with chronic kidney disease is characterized histologically 
by plaque calcification, and concurrent medial hypertrophy and calcification(28).  
 
While myocardial ischaemia is more prevalent among the dialysis population, a disproportionate 
number of individuals on dialysis present with either symptomatic myocardial ischaemia or 
myocardial infarction but do not have a significant coronary artery stenosis on angiography(29). 
This finding is thought to be related to reduced myocardial capillary density caused by cardiac 
fibrosis, and to thickening of the walls of post-epicardial intramyocardial vessels – so called 
microvessel disease. Such vessel wall thickening has been documented in animal models(30) 
and in post-mortem myocardial biopsies from individuals with end-stage renal disease but not in 
biopsies taken from hypertensive individuals with normal renal function(25). Post-epicardial 
vessel wall thickening occurs in the absence of an increase in luminal area reducing myocardial 
perfusion and impairing oxygen diffusion into the surrounding myocardium.  
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Vascular Calcification 
 
Vascular calcification refers to ectopic accumulation of calcium-phosphate mineral in the arterial 
vasculature, myocardium and cardiac valves. This pathological phenomenon is frequently 
observed among individuals with chronic kidney disease and has been associated with an 
increased risk of cardiovascular mortality. A prospective cohort study of 439 individuals with a 
mean estimated glomerular filtration rate (MDRD eGFR) of 50.6 ml/min reported that the 
prevalence of any calcification in the coronary arteries, descending thoracic aorta, aortic valve, 
and mitral valve was 67, 49, 25, and 20% respectively(31). The prevalence of vascular 
calcification is even greater among individuals with end-stage renal disease on dialysis; a 
randomised controlled trial of 360 haemodialysis patients investigating the impact of two 
therapies on vascular calcification progression reported that the prevalence of calcification in the 
thoracic aorta, mitral valve and aortic valve at enrollment was 91, 50, and 46% respectively(32).  
 
The poor prognosis portended by vascular calcification is highlighted by the findings of a 
prospective cohort study of 110 haemodialysis patients followed for a mean duration of 53±21 
months assessing the association between the presence and severity of vascular calcification, and 
all-cause and cardiovascular mortality. The study reported a significant, graded increase in the 
risk of all-cause mortality with increasing numbers of vascular sites involved with calcification 
(Risk of all-cause mortality for 0 to 4 sites involved was 3, 17, 31, 50 and 73% respectively). 
Furthermore, a multivariate analysis adjusting for demographic factors, co-morbidities and 
vascular functional indices found that vascular calcification severity assessed using a 
calcification score was an independent predictor of both all-cause mortality (HR = 1.9 per unit 
increase in calcification score) and cardiovascular mortality (HR = 2.6 per unit increase in 
calcification score)(33). 
 
The mortality risk conveyed by vascular calcification is thought to be mediated by increased 
vascular stiffness which acts to promote left ventricular hypertrophy and reduce myocardial 
perfusion. This hypothesis is supported by findings of a prospective longitudinal study of 134 
dialysis and non-dialysis dependent chronic kidney disease patients assessing the association 
between change in vascular calcification severity and both vascular stiffness assessed using 
pulse wave velocity and pulse pressure, and all-cause mortality. The study demonstrated a 
significant correlation between progressive vascular calcification and increasing pulse pressure 
and pulse wave velocity, in addition to a significant association between increasing vascular 
26 
 
calcification and the risk of all-cause mortality(34). These findings were echoed by a prospective 
cohort study of 110 haemodialysis patients which demonstrated a significant association 
between measures of increasing vascular stiffness and increasing severity of vascular 
calcification(33). 
 
Vascular calcification associated with chronic kidney disease is characterized by accumulation 
of calcium phosphate mineral in the medial rather than the intimal layer of arterial vessels. 
Ultrastructural examination of vessels from patients end-stage renal disease undergoing renal 
transplantation reveals calcium-phosphate mineral in extracellular loci as either hydroxyapatite 
[Ca10(PO4)6OH2] and/or whitlockite [(Ca,Mg)3(PO4)2] crystals co-localizing to areas of damaged 
vascular smooth muscle cells, extracellular vesicles, and bone proteins including Type I collagen 
fibrils, osteopontin, bone sialoprotein and alkaline phosphatase(35-37). There is also 
inconclusive evidence that arterial elastin fibrils may be disrupted and/or calcified as part of the 
vascular calcification process(38). The pathogenesis of vascular calcification is discussed in the 
subsequent section entitled ‘Mineral & Bone Disorders and The Pathophysiology of Vascular 
Calcification’. 
 
PHYSIOLOGICAL DERANGEMENTS 
 
Hypertension 
Hypertension is highly prevalent in the dialysis population (75 – 86 %)(14, 39, 40), is principally 
related to volume overload and can be remedied in over 90% of cases by ultrafiltration(41, 42). 
Other contributing factors include sympathetic overactivity, activation of the renin-angiotensin 
axis, and vascular stiffness which are discussed in more detail below. 
 
Early studies examining the association between blood pressure and survival in the dialysis 
population suggested a ‘U’ shaped relationship whereby mortality risk was increased not only 
with extremely high post-dialysis blood pressures (systolic > 180 mm Hg or diastolic > 90 mm 
Hg), but also with blood pressures targets often prescribed in dialysis units (pre- or post- dialysis 
blood pressure < 110 mm Hg)(43, 44). These findings contrast with those of a longitudinal 
cohort study demonstrating that baseline hypertension at dialysis inception and residual 
hypertension at 1-year post-dialysis commencement were associated with a significantly 
increased risk of mortality without any survival disadvantage associated with low blood 
pressure(45), and those of a prospective cohort study of 692 haemodialysis patients which 
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reported that a mean arterial blood pressure > 110 mmHg was associated with an increased risk 
of all-cause and cardiovascular death after adjusting for demographic factors and co-morbid 
conditions(46). Finally, a recent meta-analysis of 8 randomised controlled trials of 
antihypertensive therapy in dialysis found significant reductions in the risks of fatal and non-
fatal cardiovascular events and all-cause mortality in actively treated patients compared with 
controls supporting the hypothesis that hypertension portends an adverse prognosis in the 
dialysis population(47). The discrepancy between early and contemporary studies regarding the 
association between hypertension and mortality is likely explained by a lack of adjustment for 
important confounding factors, particularly cardiac systolic dysfunction in which low blood 
pressure increases the risk of mortality(48).    
 
Vascular Stiffness 
Vascular stiffness refers to a reduction in the compliance and elastic properties of central arteries 
such as the thoracic aorta. The reduced compliance of these vessels impairs propagation of the 
cardiac pressure wave generated during systole, necessitating an increase in systolic blood 
pressure in order to maintain systemic perfusion. This increased myocardial work stimulates 
myocardial hypertrophy and increases myocardial oxygen demand. Furthermore, increased 
vascular stiffness accelerates the propagation of the pulse wave and earlier return of the reflected 
wave towards the myocardium which reduces diastolic blood pressure compromising coronary 
perfusion which occurs predominantly during diastole(49, 50). 
 
Vascular stiffness is most often measured as central pulse pressure and pulse wave velocity. This 
latter technique measures the rate of propagation of the pulse wave from the heart to a central 
artery using tonometry and oscillometric pulse recognition algorithms; increasing pulse wave 
velocity reflects worsening vascular stiffness(50). 
 
The adverse prognosis conveyed by vascular stiffness was demonstrated in a prospective cohort 
study of 265 haemodialysis patients followed for 63±23 months investigating the association 
between pulse wave velocity, and all-cause and cardiovascular mortality. When stratified around 
the cohort’s median value, increasing pulse wave velocity was shown to be an independent 
predictor both all-cause and cardiovascular mortality after adjusting for demographic and co-
morbid conditions including diabetes and hypertension(51). 
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Vascular stiffness observed in chronic kidney disease populations results from an interplay 
between several pathologic mechanisms including vascular calcification(52), reduction in the 
elastin content of central vessels(38), and vascular smooth muscle hypertrophy secondary to 
hypertension and the trophic effects of catecholamines, angiotensin II and aldosterone(53). 
 
Myocardial Ischaemia 
Ischaemic heart disease has a prevalence of 30 – 40 % in the dialysis population(5, 20) and is 
related to accelerated atherosclerosis of epicardial coronary arteries due to a higher prevalence of 
traditional ischaemic risk factors(13) and novel mechanisms including oxidative stress, 
sympathetic overactivity, and mineral and bone disorder. However, approximately 30% of 
dialysis patients presenting with symptomatic ischaemic heart disease (myocardial infarction or 
angina) do not have evidence of epicardial coronary stenosis(29). Myocardial ischaemia in these 
individuals is thought to be due to reduced myocardial oxygen reserve secondary to the 
reduction in myocardial capillary density that accompanies myocardial fibrosis and thickening of 
the vessel wall of post-epicardial arterioles(25, 30). Cardiac hypoperfusion may also be 
exacerbated by vascular stiffness which impairs coronary and myocardial perfusion during 
diastole as has been discussed previously. 
 
 
INCITING PATHOLOGICAL MECHANISMS  
 
Sodium & Water Excess  
Extracellular volume expansion as a result of sodium and water retention is common both among 
individuals with early stage chronic kidney disease(54) and those with end-stage renal disease on 
dialysis therapy(55, 56). Several studies have identified volume overload as a critical risk factor 
for both morbidity and mortality in the dialysis population. A cohort study of 269 prevalent 
haemodialysis patients followed for 3.5-years found that overhydration assessed by 
bioimpedance spectroscopy (an instrument to objectively assess volume state) was associated 
with an independent relative risk of all-cause mortality of 2.1 in multivariate analysis(56). 
Similarly, a cohort study of 3009 prevalent haemodialysis patients followed for 1-year 
demonstrated that increasing volume state conveyed a significant, graded increase in the risk of 
death. Indeed, the relative risk of death was as high as 2.83 for the most overhydrated patients 
following adjustment for demographic factors, co-morbid conditions and novel cardiovascular 
risk factors(55). A number of cohort studies have also demonstrated a significant association 
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between clinical and surrogate biochemical measures of overhydration, and cardiovascular 
mortality(55-59) and sudden cardiac death(21, 60). 
 
Sodium and water accumulation in chronic kidney disease results from hormonally induced 
adaptations to renal injury, a progressive overwhelming of tubular solute excretory capacity, and 
excessive sodium intake. Glomerular injury and subsequent nephron loss from any aetiology 
induces a compensatory response whereby the single nephron glomerular filtration rate (GFR) of 
remaining functioning nephrons increases to compensate for the reduction in absolute numbers 
of nephrons. This glomerular hyperfiltration is effected by an increase in renal perfusion due to 
extracellular fluid volume expansion, and concurrent dilatation of the afferent arteriole and 
relative vasoconstriction of the efferent arteriole which have the net effect of increasing 
glomerular transcapillary pressure and single nephron GFR. These adaptations are mediated in 
large part by activation of the intra-renal renin-angiotensin-aldosterone axis in response to the 
renal hypoperfusion caused by any aetiology. Angiotensin II plays a critical role in inducing the 
changes in arteriolar caliber described above, while aldosterone stimulates an increase in tubular 
sodium and hence water reabsorption producing extracellular volume expansion(61-63).  
 
Progressive chronic kidney disease is accompanied by tubular adaptations which increase 
fractional sodium excretion per nephron in order to maintain sodium homeostasis despite a 
reduction in functional nephron mass. However, despite this increase in relative sodium 
excretion per nephron, absolute sodium excretion is reduced contributing to excess sodium and 
water retention particularly in the latter stages of chronic kidney disease(54, 62). 
 
Extracellular volume expansion induced by sodium and water retention plays an important role 
in the genesis of hypertension in chronic kidney disease. This is particularly true of the end-stage 
renal disease population in whom hypertension can be attributed to volume overload in over 
90% of cases(41, 64) and can be effectively remedied using ultrafiltration(42). Volume 
expansion has been shown to be an independent predictor of cardiomyopathic changes including 
left ventricular hypertrophy, left atrial dilatation, and left ventricular systolic dysfunction in all 
stages of chronic kidney disease(10, 12, 18, 54), while control of volume state in dialysis has 
been shown to improve echocardiographic indices(65).  
 
In addition to its role in volume expansion, sodium excess has a number of independent adverse 
physiological effects including the direct stimulation of angiotensin II by vascular tissue(66) and 
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stimulating the secretion of the a cardiotonic marinobufagenin-like steroid by adrenal cortical 
cells(67, 68). This latter hormone has been implicated in the genesis of cardiomyopathy and 
cardiac fibrosis in animal models of chronic kidney disease(69, 70). 
 
Mineral and Bone Disorders & The Pathophysiology of Vascular Calcification 
Progressive chronic kidney disease and the consequent fall in GFR reduces the filtered 
phosphate load and increases plasma phosphate concentrations(71). The resulting 
hyperphosphataemia has a number of important consequences including (A) antagonizing 1α-
hydroxylase activity; reducing circulating concentrations of 1,25(OH)2 Vitamin D 
(calcitriol)(72) (B) inducing hypocalcaemia due to its effect on reducing circulating calcitriol 
concentrations and to a much lesser degree by directly binding ionized calcium to form calcium 
hydroxyphosphate(73) (C) inducing secondary hyperparathyroidism by directly upregulating 
parathyroid hormone synthesis(74, 75) and and through the effects of hyperphosphataemia on 
reducing calcium and 1,25 (OH)2 Vitamin D concentrations which in turn upregulate parathyroid 
hormone synthesis. 
 
The association between bone mineral disturbances and mortality is highlighted by a recent 
systematic review of 35 prospective, observational and interventional studies which examined 
the association between all-cause and cardiovascular mortality, and hyperphosphataemia, 
hypercalcaemia and hyperparathyroidism. Heterogeneity between studies with respect to 
participant characteristics, method of mineral parameter assessment (continuous vs. dichotomous 
vs. categorical) and control for confounding precluded meta-analysis of the studies’ findings, 
however, the studies were consistent in finding a significant association between 
hyperphosphataemia and both all-cause and cardiovascular mortality albeit of varying 
magnitudes. In addition, the majority of studies demonstrated a significant increase in the risk of 
all-cause mortality in association with hypercalcaemia and hyperparathyroidism(76). The 
increased risk of mortality conveyed by these mineral disturbances is thought to be mediated 
through their role in initiating and promoting vascular calcification and subsequent vascular 
stiffness. This is particularly true of hyperphosphataemia which has been shown to be an 
independent predictor of vascular calcification even after adjustment for CKD severity, 
demographic factors, co-morbidities, parathyroid hormone and 1,25(OH)2 Vitamin-D 
concentrations(31). 
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Vascular calcification represents an interplay between a number of pathological processes 
including the (1) osteogenic / chondrogenic differentiation of vascular smooth muscle cells 
(VSMC), (2) extracellular release of calcium-phosphate rich vesicles by VSMC (3) a reduction 
in circulating factors that inhibit calcification, and (4) apoptosis of vascular smooth muscle cells. 
Two receptors – Pit-1 and Pit-2 – located on VSMC play differing but complementary roles in 
vascular calcification. In the presence of hyperphosphataemia, the Pit-1 receptor increases 
intracellular phosphate concentrations in VSMC and induces osteogenic / chondrogenic 
differentiation through the upregulation of the osteogenic transcription factor Runx2. This 
transcription factor induces the synthesis of extracellular matrix bone proteins such collagen type 
I, osteopontin, and bone sialoprotein which are able to undergo calcification(77, 78). In contrast, 
the Pit-2 receptor plays a critical role in loading intracellular VSMC vesicles with calcium and 
phosphate(52). These vesicles are subsequently secreted and act as nidus for extracellular medial 
calcification(36). Vascular calcification is also promoted by a reduction in concentration of 
circulating calcification inhibitors such as fetuin-A and pyrophosphate which are reduced in 
chronic kidney disease its associated chronic inflammatory state(77, 79, 80). In addition to its 
metaplastic effect, phosphate is also able to induce apoptosis of VSMC with the resulting 
apoptotic bodies acting as nuclei for calcification(52). 
 
Sympathetic Overactivity 
Sympathetic activity measured in the form of circulating norepinephrine concentrations or using 
microneurography of the peroneal nerve (muscle sympathetic nerve activity) has been shown to 
be markedly elevated in patients with dialysis-(81, 82) and non-dialysis(83, 84) dependent 
chronic kidney disease and correlates with the severity of renal impairment(84) suggesting that 
chronic renal injury may stimulate sympathetic hyperactivity. This hypothesis is supported by 
the observations that patients with end-stage renal disease on dialysis who have undergone 
bilateral, but not unilateral, nephrectomy have sympathetic activity in keeping with that of 
healthy controls(82). 
 
The adverse prognosis portended by sympathetic hyperactivity was highlighted by a prospective 
cohort study of 228 haemodialysis patients followed for 34±15 months, 45% of whom had 
elevated circulating norepinephrine concentrations. After adjusting for demographic features, co-
morbidities and concurrent medication use, the authors reported a significant, graded association 
between plasma norepinephrine concentrations and the risk of fatal and non-fatal cardiovascular 
events, and all-cause mortality(85). These findings are also circumstantially supported by the 
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results of two pilot randomised controlled trials in dialysis demonstrating a reduction in 
mortality(86) and improvement in cardiac diastolic function with the use of the beta-blocker 
carvidelol(87), however the beneficial effects observed may be partly or wholly related to 
concurrent improvements in blood pressure.  
 
Sympathetic overactivity associated with renal injury is explained both by an increase in 
sympathetic outflow and reduced catecholamine breakdown. Animal studies have demonstrated 
that acute and chronic renal injury stimulate autonomic centers in the hypothalamus via afferent 
nerves in the spinothalamic tract resulting in increased sympathetic outflow(88) and that this 
sympathetic hyperactivity can abolished by denervation of the injured kidney(89). 
 
Angiotensin II and adenosine have been implicated as potential mediators between the kidney 
and the autonomic nervous system. As discussed previously both acute and chronic renal injury 
are characterized by upregulation of the renin-angiotensin axis. The increase in circulating 
concentrations of angiotensin II stimulates angiotensin receptors in the medulla oblongata which 
in turn stimulate the posterior hypothalamic nuclei leading to an increase in sympathetic efferent 
activity(90).  The importance of this pathway in promoting sympathetic hyperactivity was 
elegantly demonstrated in animal models in which sympathetic overactivity associated with 
renal injury could be abolished by either intravenous or targeted intracranial injection of an 
angiotensin receptor blocker(91). Angiotensin II is able to upregulate sympathetic nervous 
activity through direct peripheral, pre-synaptic binding which increases the secretion and reduces 
the reuptake of norepinephrine(90). Adenosine is released from the injured kidney following 
minor ischaemic insults and has also been implicated as an important mediator of sympathetic 
excitation. This was illustrated by experiments in 1-clip, 2-kidney dogs in which intrarenal 
adenosine infusion increased sympathetic activity and circulating norepinephrine concentrations 
which could be abolished by renal denervation or ganglionic blockade(92).  
 
In addition to increased stimulation of efferent activity, it is now also recognized that 
sympathetic hyperactivity associated with chronic kidney disease is related to reduced clearance 
of circulating catecholamines(93). The kidney has been identified as the synthetic site of the 
proenzyme prorenalase(94, 95), which in the presence of high circulating concentrations of 
catecholamines is activated to renalase which in turn metabolizes and inactivates catecholamines 
including dopamine, epinephrine and norepinephrine(96). Renalase synthesis and activity are 
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reduced in individuals with chronic kidney disease(94) which contributes to the increase in 
circulating catecholamine concentrations. 
 
Sympathetic hyperactivity has a number of direct and indirect adverse cardiovascular 
consequences. It contributes significantly to hypertension associated with chronic renal disease 
as is illustrated by the correlation between blood pressure and sympathetic nerve activity(97) and 
the profound blood pressure response to sympatholytic agents in haemodialysis(98). 
Norepinephrine is able to induce left ventricular hypertrophy directly through a trophic effect on 
cardiac myocytes(99, 100), contributes to increased vascular stiffness by promoting hypertrophy 
of vascular smooth muscle in the peripheral vasculature(101), and may play a role in triggering 
arrhythmias(102). 
 
Oxidative Stress & Inflammation 
Oxidative stress is defined as tissue injury caused by excess circulating anionic free radicals 
called reactive oxygen species (ROS). The increased concentration of these injurious free 
radicals is caused both by the increased generation of ROS and reduced synthesis of neutralizing 
anti-oxidant molecules(103). ROS cause cellular injury both directly and indirectly through the 
activation of cellular and humoral inflammatory processes. Increased concentrations of ROS and 
inflammatory cytokines, and reduced levels of antioxidants have been documented in the chronic 
kidney disease population and are associated with a poor prognosis. A prospective cohort study 
of 19 patients with stage 5 CKD, 15 of whom were on dialysis, reported significantly higher 
concentrations of two oxidative species (Carbonyls and F2-isoprostanes) and numerous 
inflammatory markers in the end-stage renal disease group compared to healthy controls. In 
addition, there was a significant positive correlation between the concentrations of F2-
isoprostanes and C-reactive protein(104).  The adverse prognosis associated with oxidative 
species and inflammation is illustrated by a cohort study of 94 prevalent haemodialysis patients 
followed for 2-years which reported a significant direct association between the concentrations 
of both C-reactive protein and anti-oxidized LDL antibody (a marker of oxidative stress) and the 
risk of all-cause mortality in a multivariate analysis(105).  These findings were echoed by a 
retrospective cohort study of 105 haemodialysis patients followed for 9-years which reported a 
significant inverse association between concentrations of anti-oxidant proteins and the risk of 
cardiovascular mortality(106). The possible role of renal dysfunction per se in promoting 
oxidative stress is supported by the finding that concentrations of oxidative species and 
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inflammatory markers fall following successful renal transplantation and approximate those of 
healthy controls(104). 
 
The mechanisms underlying the association between oxidative stress and heightened 
cardiovascular risk have not been fully elucidated but may include accelerated atherosclerosis 
related to oxidized LDL, carbonyl proteins and advanced glycation end-products(107, 108) or 
endothelial injury and dysfunction leading to hypertension, vascular stiffness and promoting 
atherosclerosis(109).  
 
Increased concentrations of oxidant species in chronic kidney disease may be due to an increase 
in the generation of ROS through reactions involving nitrogenous waste products including 
urea(110), derangements of the mitochondrial respiratory chain(111), and exposure to artificial 
dialysis membranes. In addition, chronic kidney disease is associated with reduction in 
concentration of antioxidant molecules such as thiols(112) and antioxidant enzymes such as 
superoxide dismutase which is normally expressed in renal tubules(113). 
 
CONCLUSION 
 
Individuals with chronic kidney disease have a disproportionate risk of cardiovascular disease 
which accounts for the majority of the morbidity and mortality in this population. While 
traditional cardiovascular risk factors are overrepresented in the chronic kidney disease 
population, this alone is not sufficient to explain the excess risk observed. Chronic kidney 
disease is also associated with a number of novel pathophysiological mechanisms including salt 
and water retention, bone and mineral disorders, sympathetic overactivity and oxidative stress 
which combine to cause a number of pathological cardiovascular changes unique to chronic 
kidney disease. A greater understanding of these mechanisms is the first step to developing 
effective cardiac risk monitoring strategies and  therapies. 
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Figure Legends 
 
Figure 1. The pathophysiology of cardiovascular disease in association with chronic kidney disease. 
Chronic renal injury incites several pathological mechanisms including sodium and water retention, 
sympathetic overactivity, mineral & bone disorders, oxidative stress and activation of the renin-
angiotensin-aldosterone axis. An interplay between these pathological mechanisms produces a 
number of adverse physiological changes including hypertension, volume overload, vascular 
calcification and stiffness, coronary and peripheral atherosclerosis, and coronary microvessel disease 
which result in cardiomyopathy, and cardiac and peripheral ischaemia.  
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Chapter 3 
 
B-type Natriuretic Peptides for Monitoring Cardiac Risk in Dialysis: Current Role and 
Future Directions. 
 
The following chapter discusses the emerging role of the B-type natriuretic peptides in monitoring 
volume state, cardiomyopathy and cardiac risk in the renal dialysis population and identifies those 
research areas that need to be addressed before use of this promising biomarker can be incorporated 
into routine clinical practice. 
 
The following chapter was published as the peer reviewed book chapter: 
 
Fahim, MA, Campbell SB, Johnson DW, Hawley CM. B-Type Natriuretic Peptides in The Dialysis 
Population – Current Knowledge and Future Directions. Research Advances in Nephrology, 
Dialysis and Transplantation. Dr R. M. Mohan (Ed). Global Research Network, 2012.   
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ABSTRACT 
 
Dialysis patients have a 50-100 fold increased risk of sudden cardiac death compared to the general 
population. Fluid overload-induced cardiomyopathy is a key factor underpinning this risk, and 
progress in mitigating it is hampered by our inability to assess fluid and cardiac risk status in an 
accurate and dynamic way. There is an urgent need for a biomarker-monitoring strategy that 
accurately detects the early stages of cardiac injury to enable and guide timely intervention. The B-
type natriuretic peptides (BNP / NT-proBNP) play a critical role in circulatory volume and pressure 
homeostasis in both health and disease, and are secreted from the myocardium during 
volume/pressure overload, ischaemia, inflammation and sympathetic overactivity. Preliminary 
studies in dialysis patients have shown that these peptides predict mortality and correlate with 
cardiomyopathy and fluid state. In this review we discuss the burden and impact of cardiomyopathy 
in the renal dialysis population and the evidence supporting the role of the B-type natriuretic 
peptides as biomarkers of volume state, cardiomyopathy and cardiac risk. We also highlight those 
areas that need to be addressed in order to advance this promising biomarker into clinical practice. 
 
CARDIOVASCULAR DISEASE IN RENAL POPULATIONS – BURDEN AND AVENUES 
FOR IMPROVEMENT 
 
Cardiovascular disease is highly prevalent in the end-stage kidney disease population treated with 
dialysis with over 80% of both incident and prevalent patients having at least one cardiovascular 
diagnosis(1, 2). Cardiovascular disease-related mortality rates are reported to be between 6.6 - 9.6 
per 100 patient years and account for 43% of all deaths in this group, making cardiovascular disease 
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the leading category of death(3, 4). These rates represent a 10 - 30 fold increased risk of 
cardiovascular death compared with age, gender and diabetic-status matched cohorts from the 
general population and holds true across geographic regions(5, 6). Indeed, it is likely that these 
figures underestimate the true mortal burden of cardiovascular disease as over a third of all 
withdrawals from dialysis therapy are also attributed to this entity(3). Cardiovascular disease is also 
a major source of morbidity; with a hospitalization rate of 34.7 - 56 per 100 patient years(1, 7) it is 
the leading cause of hospitalization among patients on haemodialysis irrespective of age. 
 
The excess burden of cardiovascular disease in populations with renal disease is explained by the 
fact that cardiovascular disease is both an important cause and consequence of chronic kidney 
disease. Individuals with end-stage kidney disease have a higher prevalence of traditional 
cardiovascular risk factors especially diabetes and hypertension(8), as well as established end-organ 
disease(1, 2, 5) compared with the general population. Furthermore, end-stage kidney disease is 
itself an independent risk factor for cardiovascular disease(9), mediated through a variety of 
pathophysiological mechanisms including volume overload(10), sympathetic overactivity(11), 
hyperparathyroidism(12) and oxidative stress(13). 
 
Among the various causes of cardiovascular mortality, sudden cardiac death accounts for 15-30% of 
all deaths in the dialysis population making it the single leading cause of death(1, 3, 4, 14). In 
contrast to the general population(15), cardiomyopathy and not coronary artery disease is reported 
to be the primary pathology underlying sudden cardiac death in the dialysis population(2-4, 16). 
This fact, combined with the high prevalence of cardiomyopathy in the dialysis population (61.8 – 
84.5%)(2, 17), have made it a focus of efforts aimed at improving current poor outcomes in dialysis. 
A number of groups are currently investigating pharmacological(18-20) and dialytic therapies(21) 
for cardiomyopathy. However, there remains a paucity of validated cardiac-risk monitoring 
strategies in dialysis. Monitoring is defined as a repeated testing strategy used to assess current 
health status, detect change in risk/health status over time and evaluate the efficacy of therapy and 
titrate it accordingly(22). The only guideline on the monitoring of cardiomyopathy in dialysis 
recommends performing an echocardiogram at 3-yearly intervals(23). The testing modality and 
interval recommended, however, are entirely opinion-based and the guideline does not detail which 
echocardiographic parameters to monitor nor the magnitude of change in parameters that should 
prompt action, making it inadequate as a monitoring strategy. Echocardiography monitoring is also 
limited pragmatically by the need for specialised training and equipment, and their associated 
expenses. 
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This review discusses the emerging role of the B-type natriuretic peptides in monitoring volume 
state, cardiomyopathy and cardiac risk in the renal dialysis population and identifies those research 
areas that need to be addressed before use of this promising biomarker can be incorporated into 
routine clinical practice. 
 
BIOCHEMISTRY AND ESTABLISHED CLINICAL APPLICATIONS OF THE B-TYPE 
NATRIURETIC PEPTIDES 
 
B-type natriuretic peptide (BNP) is one member of the natriuretic peptide system which additionally 
consists of the A-, C-, D- and V- type natriuretic peptides and urodilatin(24), although D- and V- 
natriuretic peptides are not endogenous to humans. These peptides exert endocrine, autocrine and 
paracrine actions that collectively play a crucial role in maintaining cardiovascular functional and 
structural homeostasis. BNP is primarily expressed and secreted by the heart, particularly the 
ventricular myocardium(25, 26). However, expression has also been localized to a number of extra-
cardiac sites, including the brain, adrenal gland, kidney, and lungs(27). Transcription of the BNP 
gene is induced by a number of pathophysiological stimuli, including mechanical myocardial 
stretch(28, 29) (volume overload) or strain (pressure overload)(30, 31), ischaemia(32, 33), pro-
inflammatory cytokines, such as interleukin-1β and TNFα(34, 35), α- and β- adrenergic agonists 
(sympathetic overactivity)(36, 37), and vasoactive factors, such as endothelin-1(29) and 
angiotensin-II(38). It is noteworthy that these stimuli overlap significantly with the pathological 
milieu implicated in the genesis and progression of cardiomyopathy in the dialysis population, 
positioning BNP as a potentially important biomarker of cardiac risk in this group. 
 
Cardiac myocytes synthesize and secrete relatively low concentrations of BNP at a basal rate under 
normal physiological conditions. However, in response to the aforementioned stimuli, BNP gene 
transcription is upregulated leading to the synthesis of the intracellular 134 amino-acid precursor, 
pre-proBNP. This peptide undergoes cleavage of a 26 amino-acid signal peptide to form the pro-
hormone, proBNP1-108, which is in turn cleaved by the convertases furin and corin yielding 
equimolar amounts of BNP1-32 and its biologically inactive amino-terminal fragment, NT-proBNP1-
76, which are secreted into the circulation(24, 39). The secretory pathway of the B-type natriuretic 
peptides is illustrated in Figure 1. 
 
BNP exerts most of its physiological actions by binding to natriuretic peptide receptor-A (NPR-A), 
a guanylyl cyclase-coupled receptor located in the kidneys, adrenal glands, vascular smooth muscle, 
myocardium, adipose tissue, brain and lungs(40). In concert with the other natriuretic peptides, 
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BNP counteracts haemodynamic stress caused by volume, vasoactive and neurohormonal related 
mechanisms by inducing vaso- and veno- dilation of the systemic and pulmonary vasculature, 
natriuresis, diuresis, lowering the activation threshold of vagal efferents and inhibiting the secretion 
of renin and aldosterone(41). Circulating BNP is cleared by neutral endopeptidases, receptor 
mediated binding to NPR-A and by endocytosis following binding to natriuretic peptide receptor-C 
(NPR-C), while NT-proBNP undergoes glomerular filtration followed by tubular degradation and 
reabsorption(42).  In addition, both peptides are partially excreted unchanged renally with a 
fractional renal excretion of 15-20%(43). 
 
BNP and NT-proBNP have a number of proven clinical applications in the general population, 
including improving the accuracy of clinical assessment for diagnosing cardiac failure in patients 
presenting with dyspnoea(44, 45) and estimating prognosis in patients with an established diagnosis 
of cardiac failure(46). Over the last decade, 9 randomised controlled trials have examined the role 
of BNP / NT-proBNP monitoring in guiding heart failure therapy compared to specialist care alone. 
Two recent meta-analyses of these randomised controlled trials reported that BNP/NT-proBNP-
guided heart failure pharmacotherapy resulted in significant reductions in mortality in patients 
under 75 years of age compared to specialist care alone (adjusted hazard ratio [HR] 0.69, 95% 
confidence interval [CI] 0.55-0.86(47) and HR 0.76, 95% CI 0.63-0.91(48)). These findings have 
led to the recommendation that hormonal monitoring be incorporated into specialist care of heart 
failure patients(49). Both BNP and NT-proBNP have established analytic methods with sufficiently 
low imprecision(50, 51). However, NT-proBNP has the significant advantage of being less 
susceptible to pre-analytic variation, including postural, diurnal, and storage effects(52), making it a 
more robust biomarker for use in daily clinical situations. 
 
CHARACTERISTICS AND CORRELATES OF B-TYPE NATRIURETIC PEPTIDES IN 
THE DIALYSIS POPULATION 
 
Concentrations of the B-type natriuretic peptides are markedly elevated in virtually all incident and 
prevalent patients on dialysis including those without a prior diagnosis of cardiac failure. Using a 
cut-off value for NT-proBNP of 300 pg/ml (the concentration used to exclude heart failure with 
98% certainty in non-dialysis patients presenting with dyspnoea(53)), NT-proBNP concentrations in 
the dialysis population are elevated in the order of 3 – 55 times this diagnostic cut-off(54-60). These 
concentrations far exceed the increment expected due to reduced renal clearance alone and reflect 
the high burden of cardiomyopathy in the renal dialysis population. 
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Concentrations of the B-type natriuretic peptides in the general population are known to be 
influenced by a number of demographic and non-cardiac physiological variables, including age(61), 
gender(62), adiposity(63, 64) and glomerular filtration rate. Concordant with observed correlations 
in the general population, BNP/NT-proBNP concentrations in the dialysis population vary directly 
with age(54, 65), and indirectly with residual renal function(55, 57) and increasing body mass 
index(54, 56). 
 
The dialysis procedure has also been shown to affect concentrations of BNP / NT-proBNP, an 
important consideration when interpreting changes in serial results in both clinical and research 
practice. The effect of a single haemodialysis session on circulating concentrations of the B-type 
natriuretic peptides varies according to the ultrafiltration coefficient (flux) of the dialyser membrane 
and the peptide in question. With low-flux membranes, there is a reduction of 2 – 16% in BNP 
concentrations and an increase in NT-proBNP concentrations of 0 – 12%(68-71) measured before 
and after the session. The differential effect of low-flux dialysis on BNP / NT-proBNP is explained 
by the fact that BNP has a lower molecular weight of 3.5 kDa as compared to 8.5 kDa for NT-
proBNP, leading to preferential clearance of BNP. The increase in NT-proBNP concentration likely 
reflects the effect of haemoconcentration following haemodialysis and ultrafiltration, since BNP 
and NT-proBNP are secreted in equimolar amounts from the myocardium. In contrast, 
haemodialysis using a high-flux membrane reduces the concentration of both BNP and NT-proBNP 
by 9 – 40% and 9.4 – 35%, respectively(68-72). Haemodiafiltration results in even greater clearance 
of natriuretic peptides due to its even larger dialyser membrane pore size and increased convective 
clearances(73). Measurement of pre-/post- haemodialysis B-type natriuretic peptide concentrations 
is of limited clinical value as observed changes reflect dialysis-related clearance rather than short 
term changes in volume state or cardiac function. This fact has been demonstrated by several 
investigators who found no correlation between changes in BNP / NT-proBNP concentration across 
a single haemodialysis session and ultrafiltration volume or changes in blood pressure or weight(73-
75). These observations are potentially explained by the extended half-life of B-type natriuretic 
peptides in the dialysis population. 
 
The ability of peritoneal dialysis to clear plasma BNP / NT-proBNP remains unclear. A recent study 
of eight peritoneal dialysis patients demonstrated that BNP is present in peritoneal dialysis fluid at 
mean concentration of 19% ± 4% that of circulating BNP concentrations, suggesting that BNP is 
cleared by peritoneal dialysis(76). Whether the same holds true for the larger molecular weight 
peptide, NT-proBNP, was not investigated, nor was the effect of transporter status and/or 
ultrafiltration volume on clearance kinetics. In contrast, a study of 11 patients on nocturnal 
 53 
 
intermittent peritoneal dialysis (NIPD) investigating the effect of a dialysis session on plasma 
concentrations of BNP / NT-proBNP found no change in circulating concentrations of either 
peptide across the procedure. Indeed, there was also no difference in concentrations during or 
between dialysis procedures(77). The discordance between these studies may reflect the small 
sample sizes used. The clearance of BNP / NT-proBNP by peritoneal dialysis warrants further 
investigation to aid the interpretation of serial natriuretic peptide measurements.  
 
B-TYPE NATRIURETIC PEPTIDES AS MARKERS OF VOLUME STATE IN DIALYSIS 
 
While BNP / NT-proBNP concentrations have not been shown to correlate with short term changes 
in volume state(74, 75), their role as volume markers in the medium to long-term remains an 
important, unresolved issue. Given the crucial role of volume overload in the genesis and 
progression of cardiomyopathy in end-stage renal disease(18, 78-80) and the independent mortality 
risk conveyed by volume excess(81-83), a reliable biomarker of volume state would prove to be an 
invaluable monitoring tool in dialysis. 
 
A minority of cross-sectional studies have found no association between circulating levels of BNP / 
NT-proBNP and volume state assessed by clinical examination(84) or bioimpedance(85). However, 
these studies are limited by their very small sample sizes and potential measurement error 
introduced by the inaccuracy of clinical examination for assessing volume state(86, 87), both of 
which bias towards a null association. In contrast, seven larger cross-sectional studies have reported 
significant direct correlations between BNP / NT-proBNP and volume state assessed objectively by 
bioimpedance analysis(58, 88-91), or a combination of clinical assessment, echocardiography 
and/or chest X-ray findings(92, 93). The correlation co-efficients for the association between 
volume state assessed by bioimpedance analysis and NT-proBNP reported in these studies ranged 
between 0.57 and 0.66 (P < 0.05)(88, 89). These findings are also supported by two longitudinal 
studies, which demonstrated a significant association between change in BNP and change in clinical 
and surrogate measures of volume state(94, 95). 
 
Thus, the bulk of available evidence suggests that circulating B-type natriuretic peptide 
concentrations reflect, at least in part, volume state in end-stage renal disease over the medium-long 
term. Answering this question definitively will require a longitudinal study with an adequate sample 
size in which natriuretic peptides, volume state and other covariates affecting B-type natriuretic 
peptide concentrations (inflammation, medication, etc.) are assessed accurately and repeatedly to 
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delineate the dynamic relationship between volume state and natriuretic peptide concentrations after 
controlling for other confounders. 
 
B-TYPE NATRIURETIC PEPTIDES AS BIOMARKERS OF CARDIOMYOPATHY IN 
END-STAGE RENAL DISEASE 
 
Several cross-sectional and cohort studies in dialysis have demonstrated that BNP / NT-proBNP 
have an independent and powerful direct correlation with left ventricular (LV) mass(65, 96-98), and 
cardiac diastolic(99, 100) and systolic dysfunction(55, 60, 65, 97).   
 
A multivariate analysis of the predictors of cardiomyopathy in a cohort of 246 prevalent haemo- 
and peritoneal- dialysis patients found that log-transformed BNP concentration was a significant 
predictor of LV ejection fraction (β = -0.48, P < 0.0001) and LV mass indexed to height (β = 0.36, P 
< 0.0001) after adjusting for blood pressure, age, diabetes, albumin, haemoglobin, treatment 
modality, small molecule clearance, and time on renal replacement therapy(65). These results were 
echoed by a cross-sectional study of 62 prevalent haemodialysis patients in which NT-proBNP 
concentration was found to be highly correlated with LV ejection fraction (ρ = -0.77, P < 0.0001), 
and to be the only independent predictor of LV ejection fraction < 45% (β = 0.69, P < 0.0001) after 
adjusting for age, haemoglobin, blood pressure, left ventricular hypertrophy, diastolic dysfunction, 
volume state, haemodialysis vintage, C-reactive protein concentration and erythropoiesis 
stimulating agent dose(60). 
 
Similar relationships have been demonstrated between BNP and cardiac diastolic dysfunction. In a 
cross-sectional study of 99 haemodialysis patients with preserved systolic function, investigators 
reported significantly higher BNP concentrations in individuals with diastolic dysfunction 
compared to those without cardiac dysfunction (314 ± 162 ng/l vs. 131 ± 77 ng/l, P = 0.01). In a 
multivariate analysis, gender, interdialytic weight gain, left atrial diameter and diastolic dysfunction 
were found to be independent predictors of BNP concentration after adjusting for age, BMI, 
hypertension, diabetes mellitus, dyslipidaemia, haemoglobin concentration, albumin, C-reactive 
protein and left ventricular mass index(99). 
 
The role of BNP as a biomarker for cardiomyopathy is further highlighted by the findings of a 
cohort study of 199 dialysis patients investigating the relationship between baseline BNP as the 
exposure and increase in left atrial volume as the outcome. The study demonstrated that baseline 
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BNP concentration was a powerful, independent predictor of increase in left atrial volume(101). 
Finally, a longitudinal study of 21 haemodialysis patients undergoing serial measurement of NT-
proBNP and LV mass at baseline, 6- and 12- months demonstrated a powerful direct correlation 
between change in NT-proBNP concentration and change in LV mass (r = 0.78, P < 0.001)(98).  
 
The majority of current research into the clinical applications of BNP in the dialysis population has 
focused on deriving an absolute cut-off value for excluding LV systolic dysfunction in a manner 
analogous to its use in the general population. This approach has yielded conflicting results and is 
unlikely to be clinically useful given the multitude of factors affecting natriuretic peptide 
concentrations, the relatively low prevalence of systolic dysfunction in the dialysis population, and 
the high prevalence and poor prognosis of diastolic dysfunction. A more meaningful use of this 
potentially important marker is as a dynamic marker of clinical risk mediated by evolving 
cardiomyopathy – namely, a monitoring tool of cardiac risk. 
 
B-TYPE NATRIURETIC PEPTIDES AS PROGNOSTIC BIOMARKERS IN END-STAGE 
RENAL DISEASE 
 
In addition to the important cardiac and physiological correlations discussed previously, cohort 
studies using a single baseline concentration of BNP / NT-proBNP as the exposure have 
demonstrated that it is a powerful, independent predictor of heart failure(55, 102), sudden cardiac 
death(103), and cardiovascular(54-57, 59, 65) and all-cause mortality(54-57, 65) in end-stage renal 
disease. 
 
Wang et al conducted a cohort study of 230 prevalent peritoneal dialysis patients followed for 3-
years examining the association between baseline NT-proBNP concentrations, non-fatal 
cardiovascular congestion and all-cause and cardiovascular mortality. Patients were stratified 
according to quartiles of baseline NT-proBNP concentrations. Compared to the referent group in the 
lowest quartile, the group in the highest quartile demonstrated a significant increase in the relative 
risk (RR) of all-cause mortality (RR = 4.97, 95% CI 1.35 – 18.28), cardiovascular mortality (RR = 
7.5, 95% CI = 1.36 – 41.39), and non-fatal cardiovascular congestion (4.25, 95% CI = 1.56 – 11.62) 
after adjusting for age, gender, dialysis vintage, haemoglobin, high sensitivity C-reactive protein, 
vascular co-morbidity, LV mass, LV ejection fraction, diabetes, valvular calcification, albumin 
concentration, systolic blood pressure, history of non-fatal cardiovascular congestion and residual 
renal function(55). 
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Similar findings were reported in a cohort study of 150 prevalent haemodialysis patients followed 
for a median duration of 24-months. Compared to referent group with the lowest quartile of NT-
proBNP concentrations at baseline, groups in the 3rd and 4th quartiles had a significantly higher 
relative risk of both all-cause (3rd quartile HR = 4.78, 95% CI 1.58 – 14.51, 4th quartile HR = 4.03 
95% CI 1.31 – 12.40) and cardiovascular death (3rd quartile HR = 10.95, 95% CI 1.38 – 86.73, 4th 
quartile HR = 8.54 95% CI 1.04 – 69.98)(56). 
   
The strongest support for the potential role of the B-type natriuretic peptides as biomarkers of 
cardiac risk in the renal dialysis population comes from longitudinal studies employing limited 
numbers of repeated natriuretic peptide measurements to investigate the relationship between 
change in peptide concentration and change in risk of mortal events. These studies demonstrate that 
change in B-type natriuretic peptide concentration correlates directly with change in risk of 
cardiovascular and all-cause mortality in both incident and prevalent haemodialysis patients(54, 59, 
95, 104). While these studies are an important first step in delineating the clinical application of this 
biomarker in dialysis they are limited by their paucity of repeated measures, and lack of time to 
event and accuracy measures (sensitivity and specificity); all of which are essential components to 
advance this promising marker into clinical practice(105). 
 
CONCLUSION 
 
Dialysis patients have a 50-100 fold increased risk of cardiac death compared to the general 
population. This heightened risk has remained unchanged over the last decade, whilst patient 
numbers on dialysis have grown exponentially. A key factor underpinning this mortality risk is fluid 
overload-induced cardiomyopathy. Progress in improving outcomes has been hampered by our 
current inability to assess fluid state and cardiac risk status in an accurate and dynamic manner. NT-
proBNP is a promising biomarker that has been shown in preliminary studies to predict mortality 
and correlate with cardiomyopathy and fluid state. However, further research with longitudinal 
studies is needed to derive the essential parameters required to advance this promising biomarker 
into a clinically useful monitoring strategy. 
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Figure 1. Stimuli, processing pathway and physiological actions of the B-type natriuretic peptides. 
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Chapter 4 
 
Cardiac Troponins in the Dialysis Population: Current Concepts and Unanswered Questions 
 
The following chapter discusses the biochemistry, and the established and emerging clinical 
applications of cardiac troponins in the diagnosis and monitoring of cardiac disease in dialysis 
patients. In addition, it identifies those research areas that need to be addressed in order to advance 
the use of this biomarker in the acute and chronic care clinical settings.
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Chapter 4  
 
Cardiac Troponins in the Dialysis Population: Current Concepts and Unanswered Questions 
 
Introduction 
Patients with end-stage kidney disease on dialysis have high rates of emergency presentations with 
cardiac symptoms and cardiac hospitalizations (34.7 admissions per 100 patient years)(1, 2) and as 
such, cardiac troponins are amongst the most frequently performed investigations in this group. 
Recent studies have also demonstrated an association between chronically elevated cardiac troponin 
concentrations and adverse outcomes in dialysis patients in the absence of acute symptoms(3), 
implying that cardiac troponins may have a role as prognostic and/or monitoring biomarkers(4). 
However, several issues continue to confound the interpretation of cardiac troponins in both the 
acute and chronic settings in this population, including a lack of clarity regarding what constitutes a 
significant change in serial measurements, disagreement regarding the pathophysiological 
associations of troponins and hence potential therapeutic targets, and whether interpretation in 
chronic settings is best undertaken using single or serial measurements. The aims of this review are 
to discuss the biochemistry of cardiac troponins, their characteristics in the dialysis population and 
their use in acute and chronic settings. The review will highlight questions that remain unanswered 
and further research that needs to be undertaken to advance the understanding of cardiac troponins 
in dialysis and their use in clinical practice. 
 
Biochemistry, release kinetics, detection, and clearance. 
The troponin complex is composed of three subunits – Troponin C (TnC), Troponin I (TnI), and 
Troponin T (TnT) – which work in concert to regulate the interaction between actin and myosin 
required for myofibrillary contraction. In response to a membrane excitation potential, calcium ions 
are released from the sarcoplasmic reticulum into the cytoplasm and bind to TnC inducing the 
release of TnI from actin and TnT from tropomyosin. This in turn allows for the formation of cross-
bridges between actin and myosin in a ratchet-like manner to generate a contraction(5). The 
constituent proteins of the troponin complex are present in both cardiac and skeletal muscle, and 
while the gene encoding the TnC protein is identical in both muscle types(6), the genes encoding 
TnI and TnT differ between the two tissues resulting in cardiac- and skeletal-muscle specific TnT 
and TnI isoforms(7, 8).  
Approximately 6% of cTnT and 4% of cTnI are present unbound in the cytoplasm of cardiac 
myofibrils(9) and can be released rapidly into the circulation following ischemia (with or without 
necrosis)(10) or in response to myofibrillarly stretch/strain, which result in an increase in cell 
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membrane permeability(11). The remainders of cTnI and cTnT in cardiac myocytes are present in 
the form of the ternary troponin complex bound to actin and tropomysosin and are released into the 
circulation when cardiac myofibrils undergo necrosis following ischaemia, inflammation, 
infiltration or trauma. 
 
Cardiac troponins take various forms in the circulation depending on the type of troponin, the 
process inciting its release and the time elapsed since its release from the cardiomyocyte into the 
circulation. Following myocardial necrosis, cTnT is released in two forms; as part of the ternary 
troponin complex of TnC-TnI-TnT, as well as in the form of free intact cTnT detectable for up to 12 
hours following myocardial necrosis. Thereafter, cTnT undergoes proteolytic degradation to form 
peptide fragments of varying molecular weights which are detectable by commercial cTnT 
assays(12). However, in the absence of irreversible myocardial injury, circulating cTnT is only 
detectable as the intact molecule with a molecular weight of 37 kDa suggesting that degradation 
associated with irreversible myocardial damage may be mediated by enzymes released at the time 
of myocardial necrosis(13).  In contrast to cTnT, cTnI undergoes rapid proteolytic degradation in 
the circulation regardless of the process inciting its release(14), and is present in the circulation 
principally in the form of peptide fragments and to a lesser extent as a binary complex bound 
TnC(15). 
 
The precise mechanism by which cardiac troponins are cleared from the circulation has not been 
elucidated, although accumulating evidence suggests that renal clearance plays little, if any, role in   
the elimination of troponins. Firstly, several cohort studies have demonstrated that a large 
proportion of renal transplant recipients with elevated pre-transplant cardiac troponin concentrations 
continue to have elevated concentrations in the first year post-transplant despite a substantial 
improvement in their glomerular filtration rate(16-19). Secondly, the half-life of cardiac troponins is 
not significantly different between patients with and those without chronic kidney disease(20). 
Finally, the only circulating form of cTnT measurable in asymptomatic dialysis patients with 
elevated cTnT concentrations is the intact peptide, which has a molecular weight of 37 kDa thereby 
making it too large for glomerular filtration(13). Smaller cTnT peptide fragments resulting from 
proteolysis have been measured in plasma only after myocardial infarction, and while these are 
small enough to be filtered through the glomerulus, they have are not detectable in the urine of 
patients with high plasma cTnT concentrations and normal renal function post-myocardial 
infarction(21). 
 
 70 
 
Cardiac troponins in the dialysis population: frequency, distribution and effects of the 
haemodialysis procedure. 
A large proportion of dialysis patients have cardiac troponin concentrations which persistently 
exceed the 99th centile upper reference limit of troponin assays despite being asymptomatic(22-26). 
The prevalence of this finding varies according to the type of cardiac troponin measured and the 
sensitivity / generation of the assay employed.  
 
For cTnT, between 29 – 43% of patients have been reported to have elevated concentrations using 
first generation TnT assays(27, 28), as compared to 99% of dialysis patients when the latest, fifth 
generation high-sensitivity assays are employed(26). These differences are principally explained by 
advances in assay technology through generations, which have allowed for the detection of lower 
concentrations of circulating cTnT. cTnT assays utilise a twin antibody system composed of a 
capture antibody to isolate circulating TnT and a detection antibody for quantification. First 
generation TnT assays employed a detection antibody that cross-reacted with skeletal TnT; a 
limitation that was addressed in second generation assays through the use of capture and detection 
antibodies that only recognised cardiac specific epitopes thereby improving assay specificity(29). 
Subsequent generations of the cTnT assay have been characterised by improvements in both 
specificity and sensitivity through modifications of the capture antibody, and changes in sample 
volume and buffer optimization, respectively(30). 
As with cTnT, prevalence estimates of chronically elevated cTnI concentrations in the dialysis 
population have increased from 7% using first generation assays(31) to 33% when the latest high 
generation assays(32), which has been attributed to the use of increased sample plasma volumes and 
incubation times, and improvements in the microparticle capture bead(33). The frequency 
distributions of both cardiac troponins demonstrate a right skewed distribution in the dialysis 
population(32) and thus require appropriate mathematical transformation prior to statistical 
analysis. 
 
Observational studies have also consistently demonstrated that a higher proportion of dialysis 
patients have an abnormal cTnT concentration compared with cTnI when both cardiac troponins are 
measured simultaneously within the same dialysis cohort(31, 32, 34). The precise reasons for the 
discordance are unknown but may be related to uraemic associated modifications of circulating 
cTnI, which interfere with measurement, adsorption of cTnI to haemodialysis dialyser 
membranes(35), and/or anti-cTnI antibodies which interfere with assay performance(36). cTnT and 
cTnI are partially cleared during haemodialysis with high flux dialysis membranes, but not with low 
flux membranes(26, 34). This has important implications for the interpretation of serial troponin 
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measurements, whose measurement should be standardised with respect to the dialysis cycle, 
especially in the research setting. 
 
Interpretation of troponin measurements from dialysis patients in acute care settings. 
Patients on maintenance dialysis have a high incidence of acute coronary syndromes (9.8-16 per 
100-patient years), which are a leading cause of emergency presentations, hospitalisation and death 
in this population(1, 2, 37-40). Accurately diagnosing acute coronary syndromes in dialysis patients 
is challenging due to the high proportion of patients who present with atypical symptoms and 
electrocardiographic changes(41, 42). This has led to greater reliance on biomarkers of myocardial 
injury in this population. However, the interpretation of cardiac troponins from dialysis patients in 
acute settings is not straightforward given that the majority have cardiac troponin concentrations 
that persistently exceed the 99th centile upper reference limit of the assay used even when they are 
well; reflecting established rather than acute cardiovascular pathology (22-26). 
 
In an effort to address this conundrum, the current consensus guideline on the diagnosis of acute 
myocardial injury requires demonstration of a change in serial troponin concentrations with at least 
one concentration exceeding the 99th centile upper reference limit, occurring in an appropriate 
clinical context, in order to confirm a diagnosis of acute myocardial injury in dialysis patients (43). 
Unfortunately, this recommendation is not accompanied by a recommendation on precisely how 
much change in serial measurements constitutes a significant change. Guidelines have either 
provided no guidance on the magnitude of change in serial troponins(43, 44) or have based their 
guidance on the analytic performance of troponin assays rather than clinical studies, wherein a  20% 
magnitude of change has been recommended based on the fact that such a delta equates to 3 
standard deviations of the troponin assay’s analytic variation(45). 
 
Guidelines for interpreting serial troponin measurements should incorporate data on both the 
biological variation of cardiac troponins in stable dialysis patients and serial changes in troponins 
associated with adverse outcomes in dialysis patients. Biological or within-person variation 
describes the random fluctuation of biomarker levels around a homeostatic set-point in healthy 
individuals or those with stable disease; such fluctuations are of no clinical significance and must be 
distinguished from pathological changes(46). 
  
In an effort to address this important question with relevant patient-level data, several investigators 
have sought to estimate the within-person coefficient of variation of cardiac troponins from cohorts 
of dialysis patients. Pianta and colleagues measured pre-dialysis cTnI and hs-cTnT in 103 
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haemodialysis patients on two occasions at 3-weekly intervals; administering a cardiovascular 
symptom questionnaire concurrently and excluding two patients with active symptoms. The study 
reported a within-person coefficient of variation of 9.7%, which can be used to calculate a reference 
change value - a magnitude of change between two measurements needed to exclude change due to 
biological variation alone for a pre-specified degree of statistical confidence(47). In a similar study, 
Jacobs and colleagues(22) measured hs-cTnT and TnI pre-dialysis in 32 haemodialysis patients on 3 
occasions at 2-monthly intervals, excluding hospitalized patients from the final analysis. The 
reported within-person coefficients of variation of this longer two-monthly interval were 15% and 
13% for hs-cTnT and cTnI, respectively. These studies lend support to the premise that troponin 
concentrations can fluctuate in stable dialysis patients. However, they are limited by exclusion of 
peritoneal dialysis patients, a paucity of repeated measures, and, most importantly, a lack of rigour 
in ensuring patient stability insofar as they relied either on patient report or a history of 
hospitalization alone to determine stability. The latter introduces the possibility that unstable 
patients may have been included in the analyses of these studies and adversely impacted the 
accuracy of their findings. Thus, there remains a need for well-performed biological variation 
studies of cardiac troponin, which enrol both haemo- and peritoneal-dialysis patients and ensure the 
stability of important covariates, including dialysis and pharmacological prescriptions, cardiac 
rhythm, and patient volume status, while concurrently excluding patients who experience an 
adverse cardiovascular outcome from the study’s analysis. 
 
Reference change values, even when estimated robustly, cannot be used in isolation to set 
diagnostic and therapeutic decision limits. This is due to the fact that reference change values are 
principally aimed at excluding biological variation and one cannot assume that changes exceeding 
the reference change value are always associated with clinically important consequences. This 
critical question has not been studied in the end-stage kidney disease population, and should be 
addressed in a large, longitudinal cohort study examining the outcomes of patients with end-stage 
kidney disease who present emergently with a change in serial cardiac troponins exceeding 
reference change values. Such a study would then allow formulation of a guideline on both 
biological variation and clinically important changes(48).  
 
Cardiac troponins in the care of ambulatory dialysis patients. 
As previously noted, the majority of prevalent dialysis patients have cardiac troponin concentrations 
which persistently exceed the upper reference limit of troponin assays despite being systemically 
well and asymptomatic(26-28, 31, 32). This finding was initially ascribed to impaired renal 
clearance of troponins and thought to be spurious(49). However, several lines of evidence, which 
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have been alluded to in the section on the biochemistry of troponins, have largely discredited this 
explanation. Chief among the latter is the consistent finding by cohort studies that elevated troponin 
concentrations in asymptomatic, ambulatory dialysis patients are associated with adverse 
outcomes(3). A recent systematic review and meta-analysis of 98 cohort studies found that cTnT 
and cTnI concentrations exceeding the assay’s upper reference limit were associated with increased 
risks of all-cause mortality (HR = 3.00 [95% CI 2.36 – 4.26] and HR = 2.70 [95% CI 1.90 – 4.57] 
respectively), and cardiovascular mortality (HR = 3.31 [95% CI 1.81 – 5.53] and HR = 4.20 [95% 
CI 2.01 – 9.20] respectively) among asymptomatic dialysis patients even after adjustment for age 
and presence of cardiovascular co-morbidity(3). 
 
The pathophysiological mechanisms leading to the release of cardiac troponins in asymptomatic 
dialysis patients remain unclear, although they may include chronic, low level ischaemia caused by 
a mismatch between cardiac myocytes and perfusing capillaries in scarred, hypertrophied 
myocardium(50) or integrin-mediated release associated with myocardial stretch/strain in the 
context of left ventricular hypertrophy and volume overload(11). These putative mechanisms are 
supported by the findings of cross-sectional studies, which have demonstrated an independent 
association between troponin concentrations and structural cardiac pathologies in dialysis patients, 
although the precise  
association has varied among studies, including left ventricular hypertrophy(23, 51-55), systolic 
dysfunction(52, 56, 57) or hydration status(58). These conflicting findings can be attributed, at least 
in part, to inadequate adjustment for confounding variables, small sample sizes, use of surrogate 
measures of volume, and insensitive measures of myocardial contractility in these cross-sectional 
studies. 
 
The association between troponin concentrations and mortality risk in dialysis patients(3) led to the 
licensing of cardiac troponins by the United States Food and Drug Administration (FDA) for 
prognostication in this population(4). However, despite this regulatory approval, troponins have 
failed to enter routine clinical practice due to ambiguity regarding the ideal strategy for testing and 
interpreting cardiac troponins, and the resultant action that should be taken based on testing(59). In 
order to advance troponin testing in clinical dialysis practice, longitudinal cohort studies are needed 
to determine the ideal approach to interpreting significant elevations (absolute cut-off or relative 
change between serial measurements), the frequency of measurements, the time to event between an 
abnormal test and an adverse outcome, and the targets of therapy. 
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Conclusion 
The two cardiac troponins, cTnI and cTnT, represent potentially valuable biomarkers for the 
diagnosis and management of cardiovascular disease in dialysis patients. However, several 
challenges remain before these biomarkers can be confidently used in both acute and chronic care 
dialysis practice. In the acute setting, good quality studies are needed to estimate both the biological 
variation of cardiac troponins, and the magnitude of change in serial measurements associated with 
adverse outcomes in dialysis patients which should prompt intervention. In the ambulatory setting, 
longitudinal studies are needed to identify the ideal strategy for interpreting measurements, 
frequency of measurements, time to event, and targets of therapy. When these indices are 
characterised, management based on troponin needs to compared to current practice in a 
randomised controlled trial to establish whether it improves patient level outcomes.  
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Chapter 5 
 
Part A - Monitoring cardiovascular risk in the dialysis population: rationale and design of the 
Monitoring Oscillations of NT-proBNP In guiding Therapy and predicting Outcomes in Renal 
disease (MONITOR) longitudinal cohort study. 
 
Part B - Week-Week and Month-Month Biological Variation and Reference Change Values of 
NT-proBNP and hs-cTnT in the Stable Dialysis Population (Study Protocol). 
 
The following chapter details the rationale and design of the two prospective cohort studies 
conducted as part of this thesis whose aims are to: 
 
Part A - estimate a magnitude of change in serial NT-proBNP measurements that accurately 
predicts non-fatal and fatal cardiovascular events in prevalent dialysis patients, determine 
the optimal NT-proBNP monitoring interval and its associated time to event, and to define 
the pathophysiologic processes that underlie changes in NT-proBNP concentrations which 
may serve as potential interventional targets 
 
Part B – estimate the within- and between-person variation of NT-proBNP and hs-cTnT measured 
at weekly and monthly intervals in stable dialysis patients and to use these estimates to 
calculate the percentage change between serial biomarker measurements needed to exclude 
change due to biological and analytic variation alone. 
 
 
Both studies were conceived, designed, and conducted by the candidate. Part A of this chapter is in 
the process of being submitted for publication.  
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Chapter 5 – Part A 
 
Monitoring cardiovascular risk in the dialysis population: rationale and design of the 
Monitoring Oscillations of NT-proBNP In guiding Therapy and predicting Outcomes in Renal 
disease (MONITOR) longitudinal cohort study. 
 
 
BACKGROUND 
The past decade has seen steady growth in the number of individuals with end-stage renal disease  
receiving maintenance dialysis therapy, who now number over two million worldwide(1, 2). 
Unfortunately, patient outcomes on dialysis have not improved substantively over the same period, 
with cardiovascular disease continuing to be a major cause of morbidity and the leading cause of 
mortality in this group(2-4). Over 80% of dialysis patients have at least one form of cardiovascular 
disease and as compared to their non-dialysis counterparts, dialysis patients have a 10-60 times 
increased risk of cardiovascular mortality (6 – 11 deaths vs. 0.2 deaths per 100 patient years)(2, 3, 
5, 6) which has remained largely static over the past decade while cardiovascular mortality in the 
non-dialysis population has fallen by 27-33%(5, 6). 
 
One of the key reasons for these poor outcomes is our inability to reliably monitor cardiac risk in 
the dialysis population(7). Monitoring is defined as a repeated testing strategy used to detect 
changes in risk / health status over time and to evaluate the efficacy of therapy and titrate it 
accordingly(8, 9). In essence, it provides early warning of escalating risk or ineffective treatment 
and enables timely intervention to improve outcomes. At the present time there are no validated 
strategies for monitoring cardiac risk in the dialysis population, thus patients at increased risk of 
adverse cardiac events are often identified and managed late, and the efficacy of any therapies 
instituted cannot be reliably monitored. 
  
Cardiomyopathy as a monitoring target 
Cardiomyopathy describes abnormalities of cardiac structure and/or function including left 
ventricular hypertrophy, dilatation, systolic and/or diastolic dysfunction. It is highly prevalent in the 
dialysis population (61.8 - 84.5%)(10-13), and has been shown in national registries(14, 15), 
randomised controlled trials(16, 17) and prospective cohort studies(10, 18, 19) to be the strongest 
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predictor of cardiac-related hospitalization and mortality in the dialysis population. Thus, 
cardiomyopathy and the pathophysiological processes that underlie its genesis and progression 
emerge as potentially important targets for monitoring and intervention. Currently, the only 
guideline on monitoring cardiomyopathy in patients on dialysis recommends performing an 
echocardiogram at 3-yearly intervals(20). The testing modality and interval recommended, 
however, are entirely opinion based and the guideline does not detail which echocardiographic 
parameters to monitor nor the magnitude of change in parameters that should prompt action, 
making it inadequate as a monitoring strategy. Echocardiography is also limited by the fact that the 
most commonly performed two dimensional echocardiographic measurements have a high within-
person coefficient of variation and large inter-observer variability, such that only large changes in 
cardiac structure and function can be reliably detected(21, 22). Finally, timely access to 
echocardiography is frequently limited due to the need for specialised operators and equipment, and 
their associated expenses. 
 
NT-proBNP – a promising biomarker of cardiomyopathy and cardiac risk in dialysis patients 
The N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) is a biologically inactive 
peptide secreted primarily from the left ventricle in equimolar amounts to the active hormone B-
type natriuretic peptide (BNP). The principal stimuli for NT-proBNP secretion are increasing 
ventricular wall tension (cardiac hypertrophy) and/or stretch (systolic dysfunction and volume 
overload). Other stimuli include sympathetic overactivity, myocardial ischaemia and inflammation; 
a constellation of stimuli that overlap significantly with the pathological milieu implicated in the 
genesis of cardiomyopathy (23, 24). 
 
Several cross-sectional studies have demonstrated direct associations between NT-proBNP 
concentrations and the severity of cardiomyopathy and volume overload in dialysis patients, and 
cohort studies have demonstrated a direct association between baseline NT-proBNP concentrations 
and subsequent risk of fatal and non-fatal cardiovascular events in the dialysis population(25-27). 
Of even greater relevance, are longitudinal cohort studies which have demonstrated a direct 
association between changes in serial NT-proBNP concentrations and changes in volume state(28-
30), left ventricular mass(31), and the risk of cardiovascular and all-cause mortality(28, 29, 32, 33) 
in dialysis patients (Table 1). Taken together, these findings suggest that NT-proBNP monitoring 
may be useful for assessing and following cardiac risk in the dialysis population. 
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Moving beyond associations  
However, these promising findings alone do not provide the necessary detail needed to develop a 
NT-proBNP monitoring strategy for use in clinical practice. A clinically useful strategy (Figure 1) 
requires precise guidance on a magnitude of relative change in serial NT-proBNP concentrations 
that can safely be ignored (biological variation) versus that should prompt action, the associated 
time to event of such a change threshold, the ideal monitoring interval, clear targets for intervention, 
and evidence that such intervention improves patient level outcomes. Published longitudinal studies 
are unable to define these crucial indices due to their use of infrequent NT-proBNP measurements 
and arbitrary, predefined categories of change in NT-proBNP (tertiles(29) or deciles(32)), their sole 
focus on fatal clinical outcomes occurring long after the change in NT-proBNP concentrations or 
surrogate measures of volume, and their exclusion of peritoneal dialysis patients(34) (Table 1). 
 
METHODS/DESIGN 
The Monitoring Oscillations of NT-proBNP In guiding Therapy and predicting Outcomes in Renal 
disease (MONITOR) study was a prospective, longitudinal cohort study which sought to address the 
aforementioned limitations and advance the development of a NT-proBNP testing strategy for 
monitoring cardiovascular risk in the dialysis population. 
 
The study protocol complied with the Declaration of Helsinki and the National Statement on Ethical 
Conduct in Human Research; it received institutional ethics approval from the Metro-South Human 
Research Ethics Committee (HREC/10/QPAH/303), the University of Queensland Medical 
Research Ethics Committee (2011000484), and the Greenslopes Research and Ethics Committee 
(12/39). It was registered with the Australia and New Zealand Clinical Trials Registry 
(ACTRN12612000836831). 
 
Aims 
The aims of the MONITOR study were to estimate a magnitude of change in serial NT-proBNP 
measurements that accurately predicted non-fatal and fatal cardiovascular events in prevalent 
dialysis patients. In addition, the study sought to determine the optimal NT-proBNP monitoring 
interval and its associated time to event, and to define the pathophysiologic processes that underlie 
changes in NT-proBNP concentrations which may serve as potential interventional targets(9, 35). 
 
Study Setting and Participant Recruitment 
Participants were recruited from the in-centre and self-care hemodialysis, and the peritoneal dialysis 
units of a public, tertiary-care teaching hospital and a private, secondary-care hospital in 
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metropolitan Brisbane, Australia. Eligible participants were identified from an electronic database 
of all patients receiving dialysis therapy and were aged over 18 years, able and willing to provide 
informed consent, established on dialysis therapy for at least 90 days and maintained on the same 
dialysis prescription for at least 30 days.  
 
In addition, potential participants did not meet any of the exclusion criteria including planned living 
donor renal transplantation within 3-months of enrolment, one or more contraindications to whole 
body bioimpedance spectroscopy measurement (permanent pacemaker, implantable cardiac 
defibrillator, joint replacements, orthopaedic pins, mechanical heart valves and/or limb 
amputations), congenital heart disease (excluding haemodynamically insignificant patent foramen 
ovale), advanced malignancy, or pregnancy. 
 
Patient Assessment 
Patients were assessed at baseline and thereafter at monthly intervals for up to 24 months. 
Haemodialysis patients were assessed prior to the mid-week dialysis session, while peritoneal 
dialysis patients were assessed on a consistent weekday throughout the study. Patients were 
instructed to avoid strenuous exercise prior to assessment, and were assessed at the same time of 
day throughout the study to avoid fluctuations in NT-proBNP and hs-cTnT concentrations related to 
diurnal variation. The study schema is shown in Figure 2. 
 
Patient assessments entailed a structured clinical interview, physical examination, and review of the 
medical record to ascertain medical history, comorbidities, current treatments and dialysis 
prescription. The Canadian Cardiovascular Society Angina Grading Scale(36) was used to assess 
change in cardiac ischaemic symptoms and the Truncated Framingham Heart Failure Score(37) was  
used to assess for clinical evidence of pulmonary oedema at time of review. In addition, patients 
underwent a standard 12-lead electrocardiogram, whole body bioimpedance spectroscopy and blood 
sampling for measurement for NT-proBNP and hs-cTnT measurement on the same occasion. 
 
For haemodialysis patients, the blood pressure recorded was the median of 12 post-dialysis 
measurements taken at the end of the 12 haemodialysis treatments preceding the study assessment, 
while for peritoneal dialysis patients it was the median of 12 home blood pressure recordings 
measured thrice weekly over the 4 weeks prior to the study assessment. The median of these blood 
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pressure recordings has been shown to have the greatest agreement with 24-hour ambulatory 
measurements and therefore to be most representative of the patient’s blood pressure(38). 
 
Whole body multi-frequency bioimpedance spectroscopy 
Hydration status was assessed using whole-body, multi-frequency bioimpedance analysis with the 
Body Composition Monitor BCM® (Fresenius Medical Care, Asia-Pacific). This instrument has 
been validated in dialysis patients against radioisotope dilution methods with reported agreement 
limits (mean ± standard deviation [SD]) of -0.2±2.3L, -0.4±1.4L and 0.2±2L for total body water, 
extra- and intra-cellular water volumes, respectively(39). In addition, this instrument has been 
shown to have a detection limit for change in extra cellular volume of (mean ± SD) 0.87±0.64L(40). 
Peritoneal dialysis patients were assessed with peritoneal dialysis fluid in situ, as this has been 
previously shown to have no significant or clinically important effect on volume measurements 
compared with an empty peritoneal cavity(41). 
 
Echocardiography, pulse wave velocity and pulse wave analysis measurement 
All of the participants in the cohort study were invited to participate in a sub-study entailing annual 
echocardiography, and pulse wave analysis and velocity measurements.  These measurements were 
performed annually on a maximum of three occasions, and for haemodialysis patients they were 
performed on the non-dialysis day immediately following the mid-week dialysis treatment to ensure 
that cardiac loading conditions are representative of the patient’s usual volume state. 
Echocardiograms were performed and measured by one of two expert operators blinded to the 
patient’s NT-proBNP and hs-cTnT concentrations, hydration status and medical history.  
 
Echocardiograms were performed in the left lateral decubitus position using a 3.5MHz phased array 
transducer with harmonic imaging (Vivid7, General Electric-Vingmed Medical Systems, Horten, 
Norway).  Grayscale images from the parasternal long-axis and short axis as well as the apical 4-
chamber, 2-chamber and apical long axis views were acquired at moderate frame rate (50-70 fps) to 
allow for processing of 2D strain; apical images in the 4-chamber, 2-chamber and apical long axis 
were acquired at high frame rate (>120 fps) with a colour tissue Doppler overlay to measure colour 
tissue Doppler velocity, strain and strain rate. Doppler measurement of left ventricular (LV) inflow, 
tricuspid valve (TV) inflow and aortic and pulmonary outflow were performed using pulsed and 
continuous wave Doppler.  Colour tissue Doppler measurements were performed using pulsed wave 
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Doppler in the medial and lateral LV annulus, tricuspid annulus and for all LV segmental 
measurements. 
 
Cine loops of three cardiac cycles were acquired and the measurements were averaged.  If patients 
are in atrial fibrillation, 5-7 measurements were averaged. Left atrial and ventricular dimensions 
will be obtained by M-mode according to the American Society of Echocardiography 
Recommendations(42); endocardial borders were traced at end systole and end diastole in the apical 
4—chamber and 2-chamber views to obtain Simpson’s Rule ejection fraction; M-mode LV mass 
were calculated using the formula : LV mass =0.8 × (1.04[(LV internal dimension + septal wall 
thickness + posterior wall thickness)3 – LV internal dimension3]) + 0.6g, and these were indexed to 
the patient’s body surface area calculated using the Haycock formula (0.024265 x 
Weight(kg)0.5378 x height(cm)0.3964). 
 
For 2D strain analysis, the endocardial borders were traced at end-systole in the 4-chamber, 2-
chamber and apical long axis views; the software (EchoPac PC BTO 11, General Electric-Vingmed 
Medical Systems, Horten, Norway) divided the LV into basal, mid and apical segments and 
identifies unique “speckles” within the myocardium and tracked them frame-by-frame throughout 
the cardiac cycle to obtain strain and strain rate curves.  Segments that do not track properly were 
manually adjusted or eliminated from the analysis.  Global longitudinal strain (GLS) was expressed 
as a mean of all 18 segments. 
 
The SphygmoCor PX system (AtCor Medical, Australia) was used for measurement of pulse wave 
analysis (augmentation index) and pulse wave velocity (PWV).  Carotid-femoral PWV was the only 
method measured.  The distances between the common carotid artery and the suprasternal notch, the 
suprasternal notch and the umbilicus, and the umbilicus and the femoral artery were measured.  
Tonometery was performed in the common carotid artery as close to the aortic arch as possible and 
at the femoral artery.  The foot-to-foot times to reach the common carotid artery and the femoral 
artery were then subtracted and pulse wave velocity was expressed as metres per second (m/s).  A 
total of three measurements were taken and averaged for analysis. 
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NT-proBNP and hs-cTnT sample collection, storage and analysis 
Blood for measurement of plasma NT-proBNP concentrations was collected at each visit while 
blood for plasma hs-cTnT measurement was only collected at 3-monthly intervals. Blood samples 
for both biomarkers were collected in lithium-heparin tubes, prior to the commencement of the 
dialysis treatment for haemodialysis patients. Blood samples were centrifuged and plasma separated 
within 1 hour of collection and then stored at -80°C until assayed(43, 44).  
 
Plasma NT-proBNP concentration (pg/mL) was measured using a twin-antibody 
electrochemiluminescence assay on the Elecsys 2010 instrument (Roche Diagnostics, Australia) 
which has a reported analytical detection range of 5–35,000 pg/mL. Analytic coefficients of 
variation reported by the analysing laboratory were 2.9% and 1.8% at concentrations of 134 pg/mL 
and 4534 pg/mL respectively in keeping with desired performance of the assay(45, 46).  
 
Plasma hs-cTnT concentration (ng/L) was measured using the Cobas e170 instrument with the 
troponin-T hs kit (Roche Diagnostics, Australia); a monoclonal antibody electrochemiluminescence 
assay which has a reported detection range of 5 – 10,000 ng/L(47). Analytic coefficients of 
variation reported by the analysing laboratory were 2.8% and 1.4% at concentrations of 26.2 ng/L 
and 2210 ng/L respectively in keeping with desired performance of the assay(47). 
 
Target Conditions 
The primary target condition of interest was a composite of major adverse cardiac events including  
fatal and non-fatal heart failure, sudden cardiac death, resuscitated cardiac arrest, new onset angina 
pectoris, unstable angina pectoris, fatal and non-fatal myocardial infarction, and supraventricular 
tachycardia associated with a rapid ventricular response and compromised cardiac output.  
Secondary target conditions included all-cause mortality, all-cause hospitalisation, change  in 
extracellular body water of at least one litre assessed using whole body bioimpedance spectroscopy, 
and changes in indices of left ventricular systolic function and/or diastolic function. 
 
 
Definitions 
Heart failure was defined as new onset or worsening dyspnoea at rest and/or on exertion, 
paroxysmal nocturnal dyspnoea or orthopnoea with concurrent clinical examination findings or a 
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chest X-ray consistent with pulmonary congestion and echocardiographic evidence of left 
ventricular systolic and/or diastolic dysfunction. A diagnosis of heart failure also required an 
improvement in symptoms following diuresis, ultrafiltration, and/or systemic vasodilator 
therapy(48). 
 
Sudden cardiac death was defined as death within one hour of new cardiac symptoms or an 
unexpected, unwitnessed death in a person without any known non-cardiac illness that could be 
expected to become rapidly fatal and/or no alternative cause of death on autopsy if autopsy is 
performed(49). Resuscitated cardiac arrest was defined as sudden collapse that was witnessed, with 
either documented absent circulation or ventricular tachy- or brady-arrhythmia and where the 
patient responded to standard cardiopulmonary resuscitation procedures. 
 
New onset stable angina pectoris was defined as new onset of symptoms of angina pectoris 
occurring on moderate to severe exert ion together with either a positive non-invasive cardiac stress 
test demonstrating reversible ischaemia or coronary arteriography demonstrating at least one 50% 
stenosis in one or more epicardial coronary arteries(50). 
 
Myocardial infarction was defined as a rise and/or fall of cardiac troponin from a previous or 
baseline measurement by ≥20%, with at least one troponin concentration above the upper reference 
limit (defined as a level exceeding the 99th percentile of a reference population at which the assay 
has a coefficient of variation 10%) accompanied by symptoms of myocardial ischaemia and/or 
new significant ECG changes (comprising ST-T wave changes and/or new left bundle branch block 
and/or pathological Q-waves) and/or imaging evidence of new loss of viable myocardium or new 
regional wall abnormality and/or identification of intracoronary thrombus on coronary angiography 
or at autopsy(51). 
 
 
Sample size and statistical analysis 
It is accepted that longitudinal studies employing frequent repeated measures require a modest 
sample size to establish the presence/absence of a relationship between the biomarker and 
outcome(52, 53). Based on a similar study investigating cardiac allograft rejection monitoring using 
BNP(53), we derived a sample size calculation for a desired range of accuracy of a single baseline 
NT-proBNP level for predicting survival: assuming that the area under the curve (AUC) for 
baseline NT-proBNP discriminating between patients who live or die will be 0.7 – 0.8 and 
assuming there are 42 deaths in 150 patients over 2-years (based on an expected annual mortality 
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rate of 15 deaths per 100 person years), we estimated that we would have a more than sufficient 
sample size so that the half-width of the 95% confidence interval for the AUC is < 0.1(54). We 
therefore planned for a sample size of 150 participants comprising 60% haemo- and 40% 
peritoneal- dialysis (reflecting the proportions of dialysis modalities in current practice), knowing 
that this sample would give adequate power as the planned analysis using frequent repeated 
measures methods will require a smaller sample size than a single baseline measure. Estimates of 
event rates for morbid events were not available, but were expected to exceed fatal event rates. This 
sample size should also allow findings to be externally generalisable to the wider haemo- and 
peritoneal- dialysis populations. 
 
Time to cardiovascular event/outcome was analysed using survival analysis, with NT-proBNP 
being included as a time-varying covariate.  To determine the magnitude of change in NT-proBNP 
predictive of the outcomes, its accuracy, and the optimum monitoring interval we also analysed the 
relationship between NT-proBNP and outcomes using recently developed statistical methods that 
allow the joint modelling of time-to-event and longitudinal data(52, 55, 56). To determine whether 
NT-proBNP monitoring provides an incremental benefit over symptom monitoring, we also 
included both NT-proBNP and symptoms in our models. Other relevant clinical, biochemical and 
demographic variables were included in the model as covariates, and will also be used to 
characterise differences between groups with and without serial increments in NT-proBNP levels. 
We determined the best combination of monitoring tests (NT-proBNP, bioimpedance and/or 
symptoms) by checking the ability of our models to discriminate between patients who did or did 
not manifest the outcomes of interest. To examine the relationship between longitudinal change in 
NT-proBNP concentrations and longitudinal change in (i) bioimpedance measurements and (ii) 
echocardiographic outcomes we fitted a longitudinal model with NT-proBNP as the time-varying 
covariate outcome and the other variables (fluid state and cardiac structural changes) as outcomes. 
 
DISCUSSION 
 
The disproportionately high mortality of the dialysis population has remained largely unchanged for 
the last decade while the number of patients starting dialysis has grown, and is expected to continue 
growing exponentially(15, 57). Cardiomyopathy induced by fluid overload and hypertension is the 
leading cause of death in dialysis(3, 58). At the present time, we do not have a validated monitoring 
strategy to identify patients at increasing risk of cardiac death in order to intervene in a timely 
manner nor do we have a tool to tailor fluid targets and cardiac medication dosing for individuals. 
Our research proposal intends to fill these gaps in dialysis practice by advancing the role of NT-
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proBNP monitoring. Our study proposal is structured to deliver the key components needed to build 
a clinically useful monitoring strategy – a precise magnitude of change that accurately predicts 
adverse events, its associated time to event, and its incremental value to current practice. 
 
The results of our study will have far reaching clinical and research implications. If NT-proBNP 
monitoring is proven to be accurate in predicting adverse physiological changes and cardiac events; 
it will represent the first non-invasive, clinically validated monitoring tool that is able to accurately 
predict over-hydration, evolving cardiac dysfunction and adverse cardiac/clinical events in dialysis 
patients. This invaluable tool will be used to alert physicians to the ‘at risk’ dialysis patient prior to 
current best practice, enabling timely intervention. Furthermore, once this monitoring strategy is 
developed it will provide the framework for a treatment guidance tool that will be evaluated to 
determine if adjusting dry body weight, the dialysis prescription and cardiac medication according 
to NT-proBNP concentrations produces superior outcomes to current management. A validated 
biomarker monitoring and treatment strategy will also provide an invaluable surrogate outcome in 
many future research studies of cardiac interventions in dialysis.     
 
Some international units are already advocating monitoring of NT-proBNP(27). As detailed in this 
proposal, such adoption is premature and unproven. If this research proposal shows that NT-
proBNP monitoring is not superior to current practice then it will help avert the widespread 
implementation of an inaccurate strategy and in doing so avoid unnecessary costs and/or morbidity. 
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Table Legend 
 
Table 1. Longitudinal studies of B-type natriuretic peptides in the dialysis population. The 
table details the design, findings and limitations of published longitudinal studies measuring either  
B-type natriuretic peptide (BNP) or the amino terminal fragment of pro-B-type natriuretic peptide 
(NT-proBNP) in the dialysis population.  * , P < 0.05;  LVMI, left ventricular mass indexed to body 
surface area; RR, relative risk.
Table 1 
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Author Study population 
characteristics 
Number of 
measurements per 
subject (frequency) 
Outcome and results Limitations 
Gutierrez et al(29) 585 incident 
haemodialysis patients 
2 (3-monthly) Cardiovascular and all-cause mortality 
Largest tertile of increase in NT-proBNP 
concentrations associated with a RR of all cause 
death of 2.4* & RR of cardiovascular death of 
2.9*. 
NT-proBNP increase predicted by weight gain, 
systolic blood pressure, fall in albumin & fall in 
Hb*. 
Two NT-proBNP 
measurements only 
Haemodialysis only 
Surrogate measures of fluid 
state 
Fatal outcomes only 
Winkler et al(32) 
 
 
 
 
 
 
 
 
 
 
 
 
1203 prevalent 
haemodialysis patients 
2 (6-monthly) Cardiovascular and all-cause mortality 
RR for every unit increase in log NT-proBNP for 
(i) All-cause death = 1.23* (ii) Sudden death = 
1.45* (iii) Cardiac death, stroke or myocardial 
infarction = 1.19*. 
Patients with NT-proBNP above median at 
baseline and >10% fall at 6-months had RR of 
sudden death of 0.42* compared to patients with 
stable concentrations. 
Post-hoc analysis 
Two NT-proBNP 
measurements only 
Haemodialysis only 
Surrogate measures of fluid 
state 
Fatal outcomes only 
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Choi et al(31) 21 prevalent haemodialysis 
patients 
3 (6-monthly)  Change in LVMI on echocardiography 
Change in NT-proBNP concentrations during 
first (r=0.78)* and second (r=0.73)* 6-months of 
study directly correlated with change in LVMI 
over corresponding periods. 
Two NT-proBNP measurements 
only 
Haemodialysis only 
Small sample size 
No measure of fluid state  
No clinical outcomes 
Breidthardt et 
al(33) 
113 prevalent 
haemodialysis patients 
5 (6-monthly) Cardiac related mortality 
Non-survivors demonstrated a median increase 
in annual BNP concentrations of 175% versus 
survivors who had median fall of 14%* 
Five NT-proBNP measurements 
only 
Haemodialysis only 
No measure of fluid state 
Chazot et al(28) 46 incident haemodialysis 
patients 
2 (3-months) Percentage decline in BNP correlated 
significantly with fall in systolic and diastolic 
blood pressure. 
Percentage BNP decline independently predicted 
risk of overall mortality in patients with a cardiac 
history. 
Two BNP measurements only 
Haemodialysis only 
Small sample size 
Fatal outcomes and surrogate 
measure of fluid state   
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Figure Legends 
 
Figure 1. The essential components of a biomarker monitoring strategy. The figure depicts 
serial measurements of a hypothetical biomarker used to predict the occurrence of an adverse 
outcome (red cross). Patient symptom status and the status of the underlying pathology are depicted 
above the graph, while potential biomarker sampling time points are labelled as Tx on the x-axis. 
During asymptomatic periods when the underlying pathology is stable, biomarker measurements 
continue to fluctuate randomly around a homeostatic set-point due to biological variation. Thus the 
fluctuation between sampling points T1 and T2 is of no clinical significance. Deterioration in the 
underlying pathological process is initially subclinical with the patient remaining asymptomatic. 
This window is the ideal period during which a biomarker should alert clinicians to a change in 
pathology. Sampling at time point T3 provides a longer lead time for intervention but has the 
disadvantage of having a high false positive test detection rate as the magnitude of change in the 
biomarker level overlaps significantly with biological variation. The T4 sampling time point affords 
the same lead time advantages as sampling at T3 but with a lower false positive rate. Sampling at 
time point T5 has low utility as the patient is symptomatic and the lead time is short. 
 
Figure 2. Study schema. Target population, study schedule and target outcomes of the Monitoring 
Oscillations of NT-proBNP In guiding Therapy and predicting Outcomes in Renal disease 
(MONITOR) study. NT-proBNP, amino terminal fragment of pro-B-type natriuretic peptide; hs-
cTnT, high sensitivity cardiac troponin-T 
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Figure 2 
 
 
Monthly Measurements 
 Clinical review – History, physical 
examination & outcome 
ascertainment 
 Truncated Framingham Heart Failure 
Score 
 Multi-frequency Bioimpedance 
Analysis 
 Electrocardiogram (ECG) 
 NT-proBNP Concentration 
Study Population (n = 150) 
 Facility-based haemo- & peritoneal- dialysis patients  
(3:2) 
 Established on dialysis for ≥ 90-days 
 Single dialysis modality and stable prescription for ≥ 30 
days 
Annual Measurements 
 Transthoracic 
echocardiogram for LV 
geometry, systolic & 
diastolic functional indices 
 25-hydroxy vitamin D 
 Fasting lipids 
 Residual renal function 
3-Monthly 
Measurements 
 hs-cTnT concentration 
 Parathyroid hormone 
 C-reactive protein 
 Iron studies 
 Full blood count, 
electrolytes, albumin & 
liver enzymes 
Monthly Assessment for 24-months 
Target Conditions 
Non-fatal & fatal heart failure, resuscitated cardiac arrest & sudden cardiac death, non-fatal & fatal 
ischaemic cardiac events, arrhythmic events, deterioration in cardiac systolic & diastolic functional 
indices, progressive overhydration on bioimpedance. 
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Chapter 5 – Part B 
 
Protocol Title:  Week-Week and Month-Month Biological Variation and Reference Change Values 
of NT-proBNP and hs-cTnT in the Stable Dialysis Population 
 
Rationale:  
Cardiac disease is the leading cause of death among incident and prevalent haemo- and peritoneal- 
dialysis patients. Cohort and cross-sectional studies in the dialysis population have demonstrated 
that the amino terminal fragment of B-type natriuretic peptide (NT-proBNP) is a powerful predictor 
of cardiovascular and all cause mortality and varies directly with left ventricular mass and 
extracellular fluid excess, and inversely with left ventricular systolic function. The next step in the 
evolution of NT-proBNP as a clinically useful tool is to develop a serial monitoring model with 
both absolute value cut-offs and a magnitude of serial change that accurately predict adverse events. 
 
Acute myocardial injury is a leading cause of hospitalisation and death in the dialysis population 
(9.8-16 per 100-patient years), and cardiac troponins are among the most frequently requested tests 
in this group(1-5). A diagnosis of acute myocardial injury in dialysis patients is contingent on 
demonstrating a change in serial troponin concentrations in an appropriate clinical context(6, 7). 
However, there is currently no evidence-based guidance on how much change in serial 
measurements discriminates between biological variation and acute myocardial injury leading to 
considerable diagnostic confusion. These concerns are particularly relevant following the recent 
introduction of high sensitivity cardiac troponin T (hs-cTnT) assays which are able to detect small 
changes in circulating concentrations 
 
The use of any biological variable for serial monitoring needs to take into account variation of the 
variable within an individual over time that is not associated with an adverse event. Such variation 
is attributed to pre-analytic variation, analytic variation (precision and bias) and fluctuations of the 
variable around a homeostatic set point (intra-individual variation). By minimising pre-analytic 
variation it is possible to quantify analytic and intra-individual variation over monitoring intervals 
of interest in a stable cohort of patients. These values can then be used to calculate a bidirectional 
percentage change range – the reference change value – beyond which a value must change to 
ensure that the observed change exceeds that expected from biological variation alone. 
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Reference change values can be calculated for any given level of statistical confidence according to 
the clinical goal of serial monitoring. If the aim is to avoid missing serious adverse events and the 
action (evaluation and treatment) prompted by the test poses little risk to the patient, then it may 
appropriate to use a lower level of statistical confidence in the calculation of the reference change 
value to minimise false negatives. 
 
Study Design: Prospective observational analytic study. 
 
Hypothesis 
 
Fluctuations in serial NT-proBNP and hs-cTnT concentrations at weekly and monthly intervals 
among prevalent dialysis patients who are clinically stable and maintain a stable hydration state are 
explained by quantifiable analytic and intra-individual variation. 
 
Aims: 
 
1. Estimate the within run analytic variation of NT-proBNP and hs-cTnT measurements from a 
stable cohort of peritoneal- and haemo- dialysis patients assayed using a laboratory based 
immunoassay. 
2. Estimate the intra-individual (within-subject) variation of NT-proBNP and hs-cTnT in a stable 
cohort of peritoneal- and haemo- dialysis patients at week-week and month-month intervals. 
3. Estimate the inter-individual (between-subject) variation of NT-proBNP and hs-cTnT in a stable 
cohort of peritoneal- and haemo- dialysis patients. 
4. Calculate the bidirectional week-week and month-month reference change values of NT-
proBNP and hs-cTnT at the 95%, 90%, and 80% levels of statistical significance using estimates 
of within run and between run analytic and intra-individual variation from a stable cohort of 
peritoneal- and haemo- dialysis patients. 
 
Sample Size 
25 prevalent haemodialysis patients (1:1 M:F) 
25 prevalent peritoneal dialysis patients (1:1 M:F) 
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Selection 
Eligible participants will be selected consecutively from the in-centre haemodialysis and peritoneal 
dialysis units of a single tertiary centre (Princess Alexandra Hospital, Brisbane, Australia). 
 
Inclusion Criteria: 
1. Prevalent in-centre haemo- or peritoneal dialysis patients – established on a single dialysis 
modality for ≥ 90-days 
2. Stable dialysis prescription for at least one month 
3. Aged 18-years or older 
4. Able to provide informed consent 
5. Echocardiogram within 6-months of screening 
 
Exclusion Criteria 
1. Living renal transplantation planned within 5-months of enrolment. 
2. Home haemodialysis 
3. Patients on peritoneal dialysis not receiving continuous therapy (e.g. NIPD). 
4. Permanent pacemaker and/or implantable cardiac defibrillator. 
5. Joint replacements, orthopaedic pins, mechanical heart valves and amputations. 
6. Any of the following events / conditions in the month prior to screening:  
7. Admission to hospital for any cause. 
8. Change in dry body weight target of > 1kg. 
9. Unscheduled haemodialysis for treatment of hypertension, dyspnoea or congestive cardiac 
failure.  
10. Change in dialysis prescription. 
11. Initiation or dose alteration of angiotensin converting enzyme inhibitor, angiotensin receptor 
blocker, beta-blocker, or aldosterone receptor antagonist. 
12. If has ischaemic heart disease – change in severity of angina – increased frequency and/or 
occurrence with lesser degrees of exertion and/or alteration in dose of anti-anginal agent(s). 
13. If has arrhythmia – change in dose of anti-arrhythmic agent or initiation of new anti-arrhythmic 
agent.  
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14. Systemic infection. 
15. Congenital heart disease (excluding haemodynamically insignificant patent foramen ovale). 
16. Documented severe left ventricular systolic dysfunction defined as an ejection fraction less than 
30% by Simpson’s rule. 
17. Severe valvular heart disease including: 
a. Severe aortic stenosis or regurgitation.  
b. Severe mitral stenosis or regurgitation.  
18. Severe pulmonary hypertension (RVSP > [60 mmHg > RA]) due to any cause. 
19. ST or non-ST segment myocardial infarction (defined as a combination of serial elevation in 
Troponin T and any one of new ST/T wave changes on ECG and/or symptoms of cardiac 
ischaemia) in the 6-months prior to screening. 
20. Cardiac surgery and/or coronary angioplasty in the 6-months prior to screening. 
21. Pulmonary embolism in the preceding 6-months. 
22. Advanced malignancy. 
23. Pregnancy. 
24. Current immunosuppressive pharmacotherapy for any indication. 
25. Patients will also be eliminated from the analysis if during the study or in the interval (7- or 30- 
days) following completion of the study, the patient: 
a. Undergoes an unscheduled haemodialysis for treatment of hypertension, dyspnoea or 
congestive cardiac failure. 
b. Has an alteration in their extracellular body volume of ≥ 1l as assessed by bioimpedance 
analysis or a change in their dry body weight target ≥ 1kg.  
c. Has an alteration of their dialysis prescription. 
d. Has clinical evidence of congestive cardiac failure on the heart failure assessment scale 
(score ≥ 2).  
e. Undergoes initiation or dose alteration of angiotensin converting enzyme inhibitor, 
angiotensin receptor blocker, beta-blocker, or aldosterone receptor antagonist. 
f. Is admitted to hospital for any cause. 
g. Develops systemic infection. 
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h. If has ischaemic heart disease – change in severity of angina – increased frequency 
and/or occurrence with lesser degrees of exertion and/or alteration in dose of anti-
anginal agent(s). 
i. If has arrhythmia – change in cardiac rate or rhythm on ECG and/or change in dose of 
anti-arrhythmic agent or initiation of new anti-arrhythmic agent. 
j. Dies. 
k. Has a renal transplant 
 
Intervals to be Assessed 
Week – week – 4 intervals 
Month – month – 4 intervals 
 
Method 
 Informed consent. 
 Baseline data collection (see appendix 1). 
 Patients will be instructed to avoid strenuous exercise prior to attending the assessment and 
baseline visits. 
 All assessment visits will be performed on the same day of the week between 0800 and 1000: 
 Mid-week, pre-dialysis for haemodialysis patients. 
 Mid-week for peritoneal dialysis patients. 
 Clinical assessments, bioimpedance analysis, and blood draws will be conducted at: 
o Day 0 (Baseline) 
o Day 7 (Week 1) 
o Day 14 (Week 2) 
o Day 21 (Week 3) 
o Day 28 (Week 4 and Month 1) 
o Day 60 (Month 2) 
o Day 90 (Month 3) 
o Day 120 ( Month 4) 
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Clinical assessments and bioimpedance analysis will also be performed on Day 35 and Day 150 to 
confirm clinical and physiological stability. 
 
Assessment visit procedure 
 Medication review – type and doses. 
 Enquiry regarding hospital admission for any cause and/or unscheduled dialysis and/or systemic 
infection since previous assessment. 
 Enquiry about change in dry body weight target and/or change in dialysis regimen since 
previous assessment. 
 Enquiry about change in angina frequency and/or severity if applicable. 
 Manual blood pressure. 
 Weight using same scales as baseline weight. 
 Patient to lie supine for 15-minutes. 
 Heart failure assessment scale. 
 ECG 
 Bioimpedance analysis. 
 NT-proBNP and hs-cTnT blood draw and analysis 
 Patient supine for 15-minutes 
 Haemodialysis - Blood drawn via AV-fistula / graft / permacath following cannulation, and 
prior to heparinization 
 Peritoneal dialysis – Blood drawn from antecubital vein with tourniquet time not exceeding 1-
minute 
 2 blood samples (10 ml) will be drawn into Lithium-heparin tubes from the same lot number for 
all patients across the entire study.  
 Collected specimens will be labelled with a unique patient and interval number identifier and 
stored at 4°C for no more than 1-hour prior to centrifugation. 
Samples will be centrifuged at 20°C for 10 minutes at 3000g (5600 rpm) consistently for the entire 
study. Plasma then will be separated in aliquots of 1 ml and stored at -80°C in a monitored freezer.  
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Samples from all time points belonging to one individual will be analysed in random duplicate by a 
single operator in a single run using a single batch of reagent on calibrated Elecsys 2010® and 
Cobas e170 analysers (Roche Diagnostics). 
Remaining plasma will be stored to allow for re-analysis in the future. This information will be 
included in the consent form. 
 
Assessment schedule 
Task D 0 D 7 D 
14 
D 
21 
D 
28 
M 1 
D 
35 
D 
60 
M 2 
Day 
90 
M 3 
D 
120 
M 4 
D 
150 
M 5 
Baseline Data X - - - - - - - - - 
Medication Review X X X X X X X X X X 
Unscheduled dialysis 
review 
X X X X X X X X X X 
Any admissions or 
systemic infections 
since last review?  
X X X X X X X X X X 
Change in angina 
severity 
X X X X X X X X X X 
Dry weight or dialysis 
prescription change 
review 
X X X X X X X X X X 
Manual BP X X X X X X X X X X 
Weight X X X X X X X X X X 
ECG X X X X X X X X X X 
Heart Failure 
Assessment Scale 
X X X X X X X X X X 
Bioimpedance 
Analysis 
X X X X X X X X X X 
NT-proBNP and hs-
cTnT Blood Draw 
X X X X X - X X X - 
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Analysis 
We will transform NT-proBNP and hs-cTnT values using an appropriate transformation if required 
(eg log transformation) so that the data are approximately normally distributed. Variance 
homogeneity will be analysed at the within run, within person, and between person levels and 
outliers excluded. We will estimate the within and between run analytic variation, within-person 
biological variability and between person-variability using a mixed model (Rabe-Hesketh, S. and 
Skrondal, A. (2008). analysed Multilevel and Longitudinal Modelling Using Stata. (Second 
Edition). College Station, TX: Stata Press).  From this, we will be able to calculate reference change 
values using standard methods (Changes in serial results; Fraser C. (2009). Biological Variation: 
From Principles to Practice. AACC Press.)  . 
 
Adverse Event Reporting 
An adverse event is classified as SERIOUS (SAE) if it meets any one of the following criteria: 
DEATH 
LIFE-THREATENING:  The subject was at substantial risk of dying at the time of the adverse 
event or it is suspected that the use or continued use of the product would result in the subject’s 
death. 
HOSPITALISATION (initial or prolonged):  Required admission to the hospital or prolongation of 
a hospital stay. 
DISABILITY:  Resulted in a significant, persistent, or permanent change, impairment, damage or 
disruption in the subject’s body function/structure, physical activities or quality of life. 
CONGENITAL ANOMALY/BIRTH DEFECT 
IMPORTANT MEDICAL EVENT:  Other medically important events that, in the opinion of the 
investigator, may jeopardise the subject or may require intervention to prevent on of the other 
outcomes listed above. 
 
This study is purely observational with no investigational drugs or interventions and no deviations 
from current standard practice.  Thus we will seek an exemption from reporting Serious Adverse 
Events unless they are ‘unexpected’ or deemed ‘clinically significant’ by the Principal 
Investigator/s. 
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Principal Investigator 
 
Dr Magid Fahim 
PhD Candidate and Nephrologist  
University of Queensland at The Princess Alexandra Hospital, Brisbane, Australia 
 
Associate Investigators and Collaborators 
 
Associate Professor Carmel Hawley 
Consultant Nephrologist, The Princess Alexandra Hospital, Brisbane, Australia 
Associate Professor, School of Population Health, University of Queensland 
 
Dr Scott Campbell 
Consultant Nephrologist, The Princess Alexandra Hospital, Brisbane, Australia 
 
Professor Jonathan Craig 
Consultant Nephrologist, The Children’s Hospital at Westmead, Sydney 
Professor (Personal Chair), Clinical Epidemiology, School of Public Health, University of Sydney, 
Australia 
 
Professor David Johnson 
Consultant Nephrologist, Clinical Director, Professor of Medicine (University of Queensland), 
Professor of Population Health (University of Queensland) 
Princess Alexandra Hospital, Brisbane, Australia 
 
Dr Andrew Hayen 
Biostatistician and Senior Lecturer, Screening and Test Evaluation Program, School of Public 
Health, University of Sydney, Sydney 
 
Mr Goce Demiski 
Supervising scientist, Chemical Pathology Princess Alexandra Hospital, Brisbane, Australia 
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Professor Andrea Rita Horvath 
Clinical director SEALS Department of Clinical Chemistry, Prince of Wales Hospital in Sydney. 
Honorary Professor, University of Sydney. Conjoint Professor, School of Medical Sciences, 
University of New South Wales. 
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Appendix 1 
 
Baseline Data Items 
Age 
Gender 
Ethnicity 
Renal diagnosis 
Date of dialysis commencement 
History of transplantation 
Current dialysis prescription 
Haemodialysis – frequency, duration of session, dialysis membrane ultrafiltration coefficient, blood 
flow rate, dialysate flow rate, dialysate composition, last single-pool Kt/V, average inter-dialytic 
weight gain as a percentage of estimated dry body weight in the week prior to assessment ( [Total 
weight gain across entire week /  number of haemodialysis sessions] / estimated dry body weight) x 
100.  
Peritoneal dialysis – CAPD vs CCPD, total volume of exchanges per 24-hours, transporter status, last 
recorded weekly Kt/V 
Current vascular access 
AV fistula / graft flow rate if applicable 
Residual renal function (measured within 3-months of enrolment) 
Medications - current and changes within last month (commencement / cessation / dose change) 
ESA dose – type and dose as mcg or mg/kg per g/l Hb 
Last recorded haemoglobin, CRP, calcium, phosphate, PTH, albumin 
Co-morbidities 
Cardiac 
Ischaemic heart disease  
Angina - severity, and therapy (medical, PTCA, and/or coronary surgery) 
 115 
 
Myocardial infarction – ST-elevation MI, or Non-ST elevation MI (defined as a serial increase in 
troponin concentration associated with either ischaemic symptoms and/or serial change in ECG) 
Document results of previous / most recent: 
Coronary angiogram 
Non-invasive cardiac stress test 
History of left ventricular systolic dysfunction and/or dilated cardiomyopathy, and/or hypertrophic 
obstructive cardiomyopathy 
Document measures of most recent Echocardiogram 
Valvular heart disease – document valve involved, type of dysfunction, and severity from most recent 
echocardiogram. Valve surgery. 
Arrhythmia – type, rate, and therapy 
Peripheral vascular disease and therapy 
Cerebrovascular disease – thrombotic or haemorrhagic stroke, subarachnoid haemorrhage, or 
transient ischaemic attack 
Pulmonary disease – restrictive or obstructive 
Dyslipidaemia 
Diabetes 
Hypertension 
Smoking history 
Other 
Hepatic – viral hepatitis, alcoholic or non-alcoholic steatohepatitis, cirrhosis 
Peptic ulcer disease 
Endocrine 
Neurological 
Weight 
Height 
Waist circumference 
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BMI 
Body temperature (tympanic reading) 
Heart failure assessment scale 
ECG 
Bioimpedance analysis 
NT-proBNP and hs-cTnT blood draw 
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Appendix 2 
 
Heart Failure Assessment Scale – Truncated Framingham Heart Failure Assessment Score 
 
Symptom / Sign Value Patient Score 
Orthopnoea 0.5  
Paroxysmal nocturnal dyspnoea 1.0  
Reduction in exercise tolerance 0.5  
Resting sinus tachycardia ( > 100 / min) 0.5  
Jugular venous pressure > 4 cm 0.5  
Hepatojugular reflex positive 1.0  
Third heart sound 1.0  
Bibasal crackles 1.0  
Hepatomegaly 0.5  
Peripheral Oedema 0.5  
Total 
 
From Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham 
Study. J Am Coll Cardiol 1993; 22: 6A-13A 
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Chpater 6 
 
 
N-Terminal pro-B-type Natriuretic Peptide (NT-proBNP) Variability in Stable Dialysis 
Patients 
 
The following chapter presents the findings of the biological variation study performed to 
estimate the within- and between-person coefficients of variation of plasma NT-proBNP in a 
cohort of stable dialysis patients. The within-person coefficients of variation estimated in this 
study will be key to the interpretation of serial measurements in any future clinical monitoring 
strategy, as well as for adjusting for any regression-to-mean effects in research practice. In 
addition, they provide important insights into the ideal strategy for applying NT-proBNP testing 
in the dialysis population.  
 
 The following chapter was published as peer reviewed original research: 
 
Fahim MA, Hayen A, Horvath AR, Dimeski G, Coburn A, Johnson DW, Hawley CM, 
Campbell SB, Craig JC: N-Terminal Pro-B-Type Natriuretic Peptide Variability in Stable 
Dialysis Patients. Clin J Am Soc Nephrol, 2015 DOI:10.2215/CJN.09060914 
 
The following chapter was also presented by the candidate at the finalist session of Young 
Investigator Award, Australia and New Zealand Society of Nephrology Annual Scientific 
Meeting, Brisbane, Australia (2013). Short and Long Term Biological Variation of high 
sensitivity Troponin T (hs-cTnT) and N-Terminal B-type Natriuretic Peptide (NT-proBNP) in 
The Stable Dialysis Population. Fahim M, Hayen A, Coburn A, Dimeski G, Johnson D, Craig J, 
Horvath A, Campbell S, Hawley C.   
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ABSTRACT 
 
BACKGROUND AND OBJECTIVES: Monitoring N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) may be useful for assessing cardiovascular risk in dialysis patients. However its 
biological variation is unknown, hindering the accurate interpretation of serial concentrations. The 
aims of this prospective cohort study were to estimate the within- and between-person coefficients 
of variation of NT-proBNP in stable dialysis patients, and derive the critical difference between 
measurements needed to exclude biological and analytic variation. 
 
DESIGN, SETTING, PARTICIPANTS AND MEASUREMENTS: 55 prevalent hemo- and 
peritoneal-dialysis patients attending two hospitals were assessed weekly for 5-weeks then 
monthly for 4-months between October 2010 and April 2012. Assessments were conducted at the 
same time in the dialysis cycle and entailed NT-proBNP testing, clinical review, 
electrocardiography, and bioimpedance spectroscopy. Patients were excluded if they became 
unstable.  
 
RESULTS: 136 weekly and 113 monthly NT-proBNP measurements from 40 and 41 stable 
patients respectively were analysed. 22% had ischemic heart disease; 9% and 87% had left 
ventricular systolic and diastolic dysfunction respectively. Median NT-proBNP concentration was 
Respective between- and within-person coefficients of variation were 153% and 27% for weekly 
measurements, and 148% and 35% for monthly measurements. Within-person variation was 
unaffected by dialysis modality, hydration status, inflammation or cardiac co-morbidity. NT-
proBNP concentrations measured at weekly intervals needed to increase by at least 46% or fall by 
84% to exclude change due to biological and analytic variation alone with 90% certainty, while 
monthly measurements need to increase by at least 119% or fall by 54%. 
 
CONCLUSIONS: The between-person variation of NT-proBNP was large and markedly greater 
than within-person variation indicating that NT-proBNP testing might better be applied in the 
dialysis population using a relative change strategy. Serial NT-proBNP concentrations need to 
double or halve to confidently exclude change due to analytic and biological variation alone. 
 
KEYWORDS 
Renal Dialysis, N-terminal pro-B-type natriuretic peptide, B-type natriuretic peptide, Variability
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INTRODUCTION 
 
The N-terminal fragment of the pro-B-type natriuretic peptide (NT-proBNP) is an inactive peptide 
secreted from the myocardium in response to stretch, strain, ischemia, inflammation and 
sympathetic overactivity(1). Cohort studies in the dialysis population have demonstrated a direct 
association between NT-proBNP concentrations and the risk of cardiovascular and all-cause 
mortality(2-5); prompting calls to incorporate NT-proBNP testing into dialysis practice as a means 
of monitoring individual patient’s cardiovascular risk(6-8). 
 
However, before these findings can be translated into clinical practice, the biological variation of 
NT-proBNP in dialysis patients needs to be determined in order to avoid misinterpreting serial 
measurements. Biological or within-person variation is the random fluctuation of a biomarker 
around a homeostatic set-point in healthy individuals or those with stable disease(9), resulting in 
potentially large numerical changes in serial biomarker concentrations which are of no clinical 
significance. Failure to account for biological variation can result in false reassurance or alarm, and 
unnecessary changes to therapy with their associated morbidity and costs(10). 
 
The aims of this study were to estimate the within- and between-person variation of NT-proBNP 
measured at weekly and monthly intervals in stable dialysis patients and to use these estimates to 
calculate the percentage change between serial NT-proBNP measurements needed to exclude 
change due to biological and analytic variation alone. We also sought to determine if the within-
person variation of NT-proBNP differed according to cardiac co-morbidity, hydration or 
inflammatory status or between dialysis modalities. 
 
 
MATERIALS AND METHODS 
 
Study Design and Patient Recruitment 
A prospective cohort study was conducted between October 2010 and April 2012 according to 
methods described by Fraser and Harris(11). The study complied with the declaration of Helsinki 
and received ethics approval from the Metro-South Human Research Ethics Committee 
(HREC/10/QPAH/131). 
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Participants were recruited from the in-centre hemodialysis and peritoneal dialysis units of a 
tertiary-care teaching hospital in Brisbane, and a secondary-care hospital in Logan, Australia. 
Eligible participants identified from an electronic database of all patients receiving dialysis therapy 
were adults (aged ≥18-years) on maintenance dialysis for ≥90-days who had a stable dialysis 
prescription for ≥30-days and a transthoracic echocardiogram ≤12-months prior to screening.  
 
Eligibility criteria were chosen to ensure that the study cohort were physiologically and clinically 
stable at enrolment, and likely to remain stable for the duration of the study while still being 
representative of the dialysis population. Patients were excluded if they had undergone coronary 
and/or valvular intervention or suffered a myocardial infarction or pulmonary embolism in the 6-
months prior to screening; had echocardiographic evidence of severe pulmonary hypertension, 
severe functional aortic and/or mitral valvular disease, or a left ventricular ejection fraction <30%; 
had been hospitalised for any indication or undergone an unscheduled dialysis for the treatment of 
hypertension, heart failure or dyspnoea in the 30-days prior to screening; had been commenced on 
or undergone a dose change of a diuretic, beta-blocker, aldosterone receptor antagonist, angiotensin 
converting enzyme inhibitor or angiotensin receptor type-1 blocker in the 30-days prior to 
screening; had experienced worsening angina, a new cardiac arrhythmia or undergone change in 
associated therapies in the 30-days prior to screening; had a contraindication to bioimpedance 
measurement including a pacemaker, joint replacements, or mechanical heart valve; were pregnant; 
had advanced malignancy; or were unable to provide informed consent. 
 
Patient Assessment 
Patients were assessed on 10 consecutive occasions - weekly for 5 weeks then monthly for another 
4 months. All assessments were conducted between 6–8 AM, prior to the mid-week dialysis session 
for hemodialysis patients, and between 8–10 AM on the same weekday for peritoneal dialysis 
patients. Patients avoided strenuous exercise prior to assessment. 
 
Several factors affect NT-proBNP concentrations including extracellular volume(12), cardiac 
rhythm(13), myocardial ischemia(14, 15), the dialysis prescription(16) and cardiac 
pharmacotherapy(17-19). These influences were assessed at every visit using a structured clinical 
interview, physical examination and medical records review to ascertain interim hospitalisation, 
changes to medication and/or the dialysis prescription. The Canadian Cardiovascular Society 
Angina Grading Scale(20) was used to assess change in cardiac ischemic symptoms and the 
Truncated Framingham Heart Failure Score(21) was used to assess for pulmonary edema. Patients 
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underwent a standard 12-lead electrocardiogram and whole-body, multi-frequency bioimpedance 
analysis using the Body Composition Monitor BCM® (Fresenius Medical Care, Asia-Pacific) at 
each visit to measure extracellular volume. This instrument has a detection limit for change in 
extracellular volume of 0.87L ±0.64L(22, 23). 
 
Specimen Collection, Storage and Analysis 
NT-proBNP concentrations were measured at 8 of 10 visits - baseline then at weeks 1-4 and months 
2-4, providing data for 4 weekly and monthly intervals. To ensure that changes in NT-proBNP 
concentrations during the final measurement interval did not reflect changes in subclinical risk, 
patients were assessed for stability at week 5 and month 5 without measurement of NT-proBNP. 
Blood collected in lithium-heparin tubes was centrifuged and plasma separated within 1-hour of 
collection. Plasma was stored at -80C until assayed (24). 
 
Samples were batched and analysed together in a single analytic-run in random duplicate by a 
single expert operator using a single instrument and a single batch of reagent, control, and 
calibrators. Plasma NT-proBNP concentration (pg/mL) was measured using a twin-antibody 
electrochemiluminescence assay on the Elecsys 2010 instrument (Roche Diagnostics, Australia) 
which has a reported analytical detection range of 5–35,000 pg/mL(25). NT-proBNP was chosen in 
preference to BNP due to its superior stability which minimises preanalytic variation(26), and due 
to the greater agreement between NT-proBNP assays from different manufacturers(27), allowing 
the study’s findings to be more widely generalizable. 
 
C-reactive protein (mg/L) was measured pre-dialysis at the baseline visit and analysed using a 
turbidimetric method on the Beckman DxC800 analyser (Beckman Coulter, CA, USA). This 
method has a lower limit of detection of 2.0 mg/L, and analytic coefficients of variation of  6.3% 
and 3.1% at concentrations of 6.0 and 85.0 mg/L respectively. 
 
Statistical Analysis 
Based on a ratio of analytic to within-person variation of <0.5 for NT-proBNP, we estimated that a 
study sample of 40 patients undergoing NT- proBNP testing on 8 occasions over 4 weekly and 
monthly intervals would have power >0.99 to estimate the within-person coefficient of variation 
with a 95% confidence interval of ±3.6%(28). A sample size of 55 patients was chosen to allow for 
dropouts as a result of instability. 
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The principal assumption of biological variation studies is that the cohort is stable with respect to 
physiological, pathological and extrinsic factors that influence the concentration of the biomarker of 
interest. In the study presented here, patients were deemed to be unstable if they experienced a 
change in dose of diuretic, beta-blocker, aldosterone receptor antagonist, angiotensin converting 
enzyme inhibitor or angiotensin receptor blocker; a change in severity of cardiac ischemic 
symptoms, dose of anti-anginal agents, or cardiac intervention; a change in anti-arrhythmic agent or 
new cardiac arrhythmia; a change in extracellular volume >1L on bioimpedance analysis; a change 
in dialysis modality or prescription; hospitalisation for any reason or exhibited pulmonary edema 
defined as a score ≥2 on the Truncated Framingham Heart Failure Score. If a study participant was 
deemed to be unstable, the NT-proBNP concentrations from the intervals preceding and following 
the event were excluded from the statistical analysis.  
 
Normally distributed variables are presented as mean ± standard deviation, and non-normally 
distributed variables as median and interquartile range. NT-proBNP concentrations were 
logarithmically transformed for the variation analyses. We fitted mixed effects models with random 
intercepts to calculate the between-person coefficient of variation across the cohort (CVG), the 
within-person coefficient of variation at weekly and monthly intervals (CVI) and the within-run 
analytic co-efficient variation (CVA). Outlying variances were excluded using the Reed and 
Cochran tests. Linear regression was used to identify and exclude participants who demonstrated a 
consistent increase or decrease in log NT-proBNP concentrations throughout the study as such a 
trend may represent a change in future risk that may not have manifest clinically during the study. 
 
The cohort was also divided into eight subgroups according to dialysis modality, hydration status, 
ischemic heart disease status, severity of left ventricular diastolic dysfunction, presence or absence 
of left ventricular systolic dysfunction and left ventricular hypertrophy, tertiles of C-reactive protein 
concentrations, and quartiles of NT-proBNP concentrations at enrolment. CVI was estimated for 
each subgroup and compared using Bartlett’s test. Overhydration was assessed using the ratio of 
absolute overhydration volume to total extracellular volume measured using bioimpedance and 
categorised as absent (<6.8%), moderate (6.8–15%), or severe (>15%)(29). Ischemic heart disease 
was defined as any of inducible ischaemia on non-invasive cardiac stress testing and/or ≥50% 
stenosis in ≥1 epicardial coronary artery on coronary angiography and/or a history of myocardial 
infarction. Left ventricular diastolic dysfunction(30) and left ventricular hypertrophy(31) were 
graded as absent, mild, moderate or severe according to established algorithms using 
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echocardiographic measurements. Left ventricular systolic dysfunction was defined as a left 
ventricular ejection fraction ≤50% using Simpson’s rule(30).  
 
The index of individuality (IOI) was calculated as CVI/CVG. This ratio gives an indication of 
whether a biomarker is best used within a relative-change monitoring strategy (IOI <0.6) or a 
reference interval strategy (IOI >0.6). The bidirectional reference change value (RCV) was 
calculated according to the method described by Fokkema et al(32) for logarithmically transformed 
data as = exp(–Z×√2×σ) to exp(+Z×√2×σ); where σ = √ln(CVi2+1) and Z is the Z-score of a 
standard normal distribution corresponding to a given probability. 
 
RESULTS 
 
Patient Characteristics 
Details of the number of patients assessed, enrolled and included in the final analysis are shown in 
Figure 1. Fifty five patients were recruited from the hemodialysis (n=28) and peritoneal dialysis 
units (n=27) of the participating institutions and their baseline characteristics are summarised in 
Table 1. Cardiovascular risk factors, including hypertension (100%), diabetes mellitus (40%), and 
current or former smoking (51%) were highly prevalent. A substantial proportion of the cohort also 
had evidence of established cardiovascular disease including ischemic heart disease (22%), left 
ventricular hypertrophy (44%), diastolic (87%) and/or systolic (9%) dysfunction, and peripheral- 
and/or cerebro-vascular disease (9%). Baseline NT-proBNP concentrations demonstrated a right 
skewed frequency distribution with a median of 1698 (interquartile range 718–3742) pg/mL. 93% 
of the study cohort had a NT-proBNP concentration above 300 pg/mL; the threshold used to 
exclude acute decompensated heart failure in the general population(33). 
 
Weekly and Monthly Variation of NT-proBNP 
Seven patients and their corresponding NT-proBNP measurements were excluded due to hospital 
admission (n=3), paroxysmal atrial fibrillation (n=3), and escalating anginal symptoms (n=1). In 
addition, 36-weekly and 51-monthly NT-proBNP sample pairs were excluded due to a change in 
extracellular volume of  >1L between consecutive visits. None of the participants were excluded on 
the basis of outlying variances or the linear regression analysis. NT-proBNP measurements made 
over 136-weekly intervals from 40 patients and 113-monthly intervals from 41 patients were 
included in the final analysis. These data are shown in Figure 2 with excluded measurements 
represented by gaps. 
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The respective analytic, within-person, and between-person coefficients of variation of NT-proBNP 
were 1.9%, 27%, and 153% for weekly intervals, and 1.6%, 35%, and 148% for monthly intervals 
(Table 2). Between person variation was much greater than within-person variation (Figure 3), 
yielding low indices of individuality of 0.18 and 0.24 for the weekly and monthly intervals 
respectively (Table 2). 
 
Weekly and monthly reference change values for the 70%, 80%, and 90% degrees of statistical 
confidence are shown in Table 2. Thus, NT-proBNP concentrations measured at weekly intervals 
needed to increase by 84% or fall by 46% to ensure with 90% confidence that the observed change 
exceeded analytic and biological variation alone. Monthly reference change values were slightly 
larger than weekly values for a given degree of statistical confidence. 
The within-person co-efficient of variation did not differ significantly between dialysis modalities, 
by ischemic heart disease, hydration or inflammatory status, by severity of diastolic dysfunction, by 
presence or absence of left ventricular hypertrophy or across quartiles of NT-proBNP concentration 
(Table 3). The effect of left ventricular systolic dysfunction on within-person variation was unable 
to be meaningfully analysed as only one such patient was retained in the final analysis after the 
exclusion of unstable patients. 
 
DISCUSSION 
 
This study demonstrated that NT-proBNP concentrations vary considerably across the dialysis 
population with a between-person coefficient of variation of 158%; markedly greater than that 
reported for healthy individuals (36-70%)(34, 35). This marked variability likely reflects the broad 
range of hydration status, residual renal function, dialysis regimens, pharmacotherapies, and the 
numerous types and severities of cardiac pathologies present in the dialysis population. In contrast, 
the within-person coefficient of variation of NT-proBNP among stable dialysis patients in this study 
was markedly smaller, equating to 27% and 35% for the weekly and monthly measurement 
intervals respectively.  
 
The large discrepancy between the within- and between-person coefficients of variation has 
important implications for how NT-proBNP is interpreted in the dialysis population. The ratio of 
within- to between-person variation is termed the index of individuality, and in this study equated to 
0.18 and 0.24 for the weekly and monthly measurement intervals respectively. Ratios less than 0.6 
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indicate a high degree of individuality and imply that NT-proBNP testing is better applied in the 
dialysis population using a relative change strategy wherein serial measurements from the same 
patient are compared to each other rather than comparing single values to a reference interval or a 
threshold value(36). This finding represents an important departure from the majority of 
contemporary studies in this area have sought to derive an absolute NT-proBNP concentration 
below which cardiac dysfunction and/or over-hydration can be confidently excluded in a manner 
analogous to which a NT-proBNP concentration less than 300 pg/mL is used to exclude acute 
decompensated heart failure in the non-dialysis population(33, 37-41). Our findings suggest that 
such a strategy would be inaccurate for predicting cardiovascular risk in the dialysis population, 
resulting in unacceptably high false negative or false positive rates depending on the threshold value 
chosen while also missing the majority of important changes in serial NT-proBNP concentrations 
measured from an individual dialysis patient(36). Instead, we suggest that a relative change strategy 
would be of greater clinical value by accurately detecting significant changes in serial NT-proBNP 
concentrations irrespective of the absolute values. Significant changes in NT-proBNP 
concentrations would likely reflect important changes in composite cardiovascular risk caused by 
one or more pathophysiological processes including volume overload, ventricular dysfunction, 
and/or cardiac ischemia. This hypothesis is supported by longitudinal studies that have 
demonstrated a direct correlation between change in NT-proBNP concentrations and the risk of 
fatal cardiovascular events(2-5), change in left ventricular mass(42), and change in surrogate 
measures of volume status(4, 7).  
 
However, not all changes in serial NT-proBNP concentrations are of clinical significance and may 
instead be attributed to analytic and/or biological variation. The within-person coefficients of 
variation estimated in this study will play a crucial role in making this distinction in both the 
clinical and research settings(10, 43, 44). Using these estimates we calculated a bidirectional 
magnitude of change between serial NT-proBNP measurements which excludes change due to 
biological and analytic variation alone for a pre-specified degree of statistical confidence – the 
reference change value(32, 43). The 90% reference change value for NT-proBNP measured at 
weekly intervals was -46% and +84%, implying that serial NT-proBNP concentrations must 
increase by at least 84% or fall by at least 46% to exclude change due to biological and analytic 
variation alone with 90% certainty. Reducing the degree of statistical confidence reduces the 
magnitude of change required in either direction and increases the sensitivity but reduces the 
specificity for detecting a clinically important change. The degree of statistical confidence used is 
dictated by whether a change in biomarker levels is intended to rule in a given medical condition 
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(high specificity required) or rule it out (high sensitivity required). While the precise role of NT-
proBNP monitoring in the dialysis population has yet to be absolutely defined, we hypothesize that 
it will primarily be used to identify patients at risk of major adverse cardiac events who require 
further evaluation to determine which pathophysiologic process(s) is/are responsible. A lower 
degree of statistical confidence would be suitable for such a strategy as neither diagnosis nor 
therapy would be solely predicated on changing NT-proBNP concentrations alone. Finally, we 
found that the within-person coefficient of variation of NT-proBNP was not significantly different 
between dialysis modalities, by ischemic heart disease, inflammatory or hydration status, by 
severity of diastolic dysfunction, by presence or absence of left ventricular hypertrophy or across 
quartiles of baseline NT-proBNP concentrations implying that a single decision limit can be applied 
across the entire dialysis population. 
 
Our estimates of within-person variation are supported by the findings of Aakre et al(35), who 
recently reported a within-person coefficient of variation of 26% for NT-proBNP measured at 
weekly intervals from a cohort of 17 hemodialysis patients. This study was limited by its small 
sample size, the exclusion of peritoneal dialysis patients and a lack of rigour in ensuring patient 
stability, wherein the investigators relied either on patient report or a history of hospitalization alone 
to determine stability and did not measure volume status. As previously described, NT-proBNP 
concentrations may be affected by volume status, cardiac arrhythmias, the dialysis prescription and 
changes in angina class that may not necessarily warrant admission. Ensuring stability of all of 
these parameters is essential to deriving accurate estimates of within-person variation.  
 
Our study has a number of strengths that address these limitations including the use of a rigorous 
approach to ensure the stability of all factors that influence NT-proBNP concentrations, the 
enrolment of both peritoneal- and hemo-dialysis patients, measurement of NT-proBNP over both 
weekly and monthly intervals, and a larger sample size. Nevertheless, the present study has several 
potential limitations. Firstly, patients with the most severe cardiovascular co-morbidities were 
excluded to maximise the likelihood that patients would remain stable for the duration of follow-up. 
Although this potentially limits the generalizability of the study’s findings, the baseline 
characteristics of our study cohort were similar to those reported for prevalent Australasian dialysis 
patients in the Australian and New Zealand Dialysis and Transplant Registry(45). Secondly, mean 
hemodialysis session duration in this study was considerably longer than that reported by most 
North American centres(46), whether hemodialysis session length affects the within-person 
variation of NT-proBNP could not be investigated in this study due to the homogeneity of dialysis 
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prescriptions and should be investigated by future studies before these results are applied to 
populations receiving shorter hemodialysis sessions. Thirdly, it was unable to be determined if the 
within-person coefficient of variation of NT-proBNP was affected by left ventricular systolic 
impairment as only one such patient remained stable during the study. Finally, reference change 
values only exclude biological and analytic variation, and changes in biomarker concentrations 
exceeding the reference change value are not automatically of clinical significance. 
 
NT-proBNP holds much promise as a biomarker of cardiovascular risk in the dialysis population, 
however much remains to be established before it can be adopted into clinical practice. This study 
represents an important step in that direction. Based on its findings we suggest that NT-proBNP 
testing may be better applied in the dialysis population using a relative change strategy rather than 
by comparing absolute values to a reference interval or threshold value, and that large changes in 
NT-proBNP concentrations are needed to confidently exclude change due to biological variation 
alone. Moving forward, longitudinal cohort studies are needed to determine the accuracy of serial 
NT-proBNP testing for predicting adverse cardiovascular events in the dialysis population and 
potential targets for therapeutic intervention. 
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FIGURE LEGENDS 
Figure 1. Flow diagram of patients assessed for eligibility, enrolled and analysed in the study. 
 
Figure 2. Variation of N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations 
measured from each of the stable participants over the (A) weekly and (B) monthly follow-up phases. 
Gaps represent measurements excluded due to a change in extracellular volume > 1L between 
consecutive visits. 
 
Figure 3. Box-plot of NT-proBNP concentrations for stable participants during the weekly follow-
up phase plotted in ascending order of median NT-proBNP concentrations. Each box plot depicts five 
logarithmically transformed NT-proBNP concentrations taken from a single stable participant over 
the first 5 weeks of the study. The whiskers delimit the range and the middle, lower and upper lines 
of the box represent the median, upper and lower quartiles respectively. Between-person variation is 
reflected in the variation between median NT-proBNP concentrations across the entire cohort and 
was large. By comparison, within-person variation depicted by the box plots was much smaller and 
largely uniform between patients. 
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Table 1. Baseline characteristics of the study cohort. 
Characteristic Value (n=55) 
Male gender (%) 45 
Age  
Mean ± SD (years)  
Age distribution (%) 
18 – 49  
50 – 69  
70 – 79  
80 – 90 
 
59±15 
 
33 
40 
22 
5 
Hemodialysis (%) 
Dialysis sessions per week (n) 
Duration of dialysis session (hours) 
Single pool Kt/V 
Interdialytic weight gain (Kg) 
Interdialytic weight gain relative to estimated  
dry weight (%) 
51 
3 
5.1±0.7 
1.73±0.38 
1.7 (1.5 – 2.3) 
2.3±1 
Peritoneal dialysis (%) 
Volume of peritoneal dialysis solution exchanged 
per 24 hours (L) 
Four hour D/P creatinine 
Weekly Kt/V 
49 
8 (8 – 10) 
 
0.72±0.52 
2.21 (1.95 – 2.49) 
Time on dialysis (months) 35 (16 – 58) 
Body Mass Index (Kg/m2) 30.2 (28.5 – 34.6) 
Systolic blood pressure (mmHg) 130±15 
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Diastolic blood pressure (mmHg) 74±12 
Diabetes mellitus (%) 40 
Current or former smoker (%) 51 
Ischemic heart disease (%) 22 
Peripheral- and/or cerebro-vascular disease (%) 9 
Hydration status 
Ratio of extracellular to total body water 
Overhydration volume relative to extracellular volume (%) 
Normohydrated (%) 
Moderately overhydrated (%) 
Severely overhydrated (%) 
 
0.48±0.04 
3±9 
69 
21 
10 
Left ventricular structure and function 
Left ventricular hypertrophy (%) 
Nil 
Mild 
Moderate 
Ejection fraction (%) 
Left ventricular systolic dysfunction (%) 
Diastolic dysfunction (%) 
Nil 
Mild  
Moderate  
Severe  
 
 
56 
33 
11 
60±7 
9 
 
13 
24 
45 
18 
Antihypertensive agents 
Median number of anti-hypertensive agents 
 
1(1-2) 
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Proportion on beta-blocker (%) 
Proportion on ACE-I or ARB (%) 
42 
38 
C-reactive protein (mg/L) 5.0 (2.1 – 12) 
NT-proBNP (pg/mL) 
Median (IQR) 
Distribution (%) 
< 300 pg/mL 
300 – 899 pg /mL 
900 – 4999 pg/mL 
5000 – 19,999 pg/mL 
≥ 20,000 pg/mL 
 
1698 (718 – 3742) 
 
7% 
20% 
51% 
11% 
11% 
 
Abbreviations: D/P creatinine, ratio of creatinine concentration in dialysate to plasma; Kt/V, 
dialysis urea clearance; ACE-I, Angiotensin converting enzyme inhibitor; ARB, Angiotensin 
type-1 receptor blocker; NT-proBNP, N-terminal pro-B-type natriuretic peptide. 
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Table 2. Estimates of variance components of NT-proBNP, bidirectional reference change values for stated degrees of statistical confidence and 
index of individuality over weekly and monthly intervals for stable study participants. 
 
 
 
 
Coefficient of variation (%) 
 
Reference change value 
 
Index of 
individuality 
 Analytic 
(CVA) 
Between-person 
(CVG) 
Within-person 
(CVI) 
 
90% 80% 70% 
 
CVI:CVG 
Weekly 1.9 153 27  -46% and +84% -38% and +61% -32% and +47%  0.18 
Monthly 1.6 148 35  -54% and +119% -46% and +84% -39% and +64%  0.24 
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Sub-group Weekly Within-person Coefficient  
of  Variation CVI % (95% CI) 
p-value 
Dialysis modality 
Peritoneal dialysis 
Hemodialysis 
 
24.5 (20.5 – 29.2) 
29.3 (24.5 – 35.2) 
 
0.45 
Coronary artery disease 
Absent 
Present 
 
29.3 (25.3 – 34.0) 
18.8 (14.7 – 24.1) 
 
0.15 
Left ventricular hypertrophy 
Absent 
Present 
 
28.6 (24.3 – 33.7) 
24.3 (19,9 – 29.7) 
 
0.52 
Diastolic dysfunction 
Nil / Mild 
Moderate / Severe 
 
27.3 (22.8 – 32.8) 
27.1 (22.7 – 32.5) 
 
0.98 
 
Hydration status 
Normohydration 
Moderate / Severe overhydration 
 
28.4 (24.7 – 32.7) 
22.3 (15.9 – 31.3) 
 
0.28 
CRP concentration (mg/L) 
1st tertile (2 - 4) 
2nd tertile (5 - 13) 
3rd tertile (14 - 59) 
 
29.6 (23.9 – 36.7) 
28.8 (23.3 – 35.7) 
20.6 (16.3 – 26.0) 
 
0.43 
NT-proBNP concentration (pg/mL) 
1st  quartile (180 - 718) 
2nd quartile (719 - 1698) 
 
29.4 (22.6 – 38.5) 
29.7 (22.6 – 39.0) 
 
0.89 
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Table 3. Within-person coefficients of variation of N-terminal pro-B-type natriuretic peptide 
(mean and 95% confidence intervals) by subgroups of dialysis modality, ischemic heart disease 
status, left ventricular hypertrophy, cardiac diastolic function, hydration status, tertiles of C-
reactive protein (CRP) concentration, and quartiles of N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) concentration. 
 
 
 
 
 
 
 
 
 
3rd quartile (1699 - 3742) 
4th quartile (3743 - 44091) 
25.1 (19.6 – 32.1) 
23.9 (19.0 – 30.2) 
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Chapter 7 
 
Biological Variation of High Sensitivity Cardiac Troponin-T in Stable Dialysis Patients: 
Implications For Clinical Practice 
 
The following chapter presents the findings of the biological variation study performed to 
estimate the within- and between-person coefficients of variation of plasma hs-cTnT in stable 
dialysis patients. The week-week estimates derived in this study aid the interpretation of 
serial hs-cTnT concentrations measured clinically for the diagnosis or exclusion of acute 
myocardial injury. The month-month estimates derived in this study will be key to the 
interpretation of serial measurements in any future clinical monitoring strategy, as well as for 
adjusting for any regression-to-mean effects in research practice. 
 
 The following chapter was published as peer reviewed original research: 
 
Fahim MA, Hayen AD, Horvath AR, Dimeski G, Coburn A, Tan KS, Johnson DW, Craig 
JC, Campbell SB, Hawley CM: Biological variation of high sensitivity cardiac troponin-T in 
stable dialysis patients: implications for clinical practice. Clin Chem Lab Med, 2014 
DOI:10.1515/cclm-2014-0838 
 
The following chapter was also presented by the candidate at the finalist session of Young 
Investigator Award, Australia and New Zealand Society of Nephrology Annual Scientific 
Meeting, Brisbane, Australia (2013). Short and Long Term Biological Variation of high 
sensitivity Troponin T (hs-cTnT) and N-Terminal B-type Natriuretic Peptide (NT-proBNP) in 
The Stable Dialysis Population. Fahim M, Hayen A, Coburn A, Dimeski G, Johnson D, Craig 
J, Horvath A, Campbell S, Hawley C. 
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ABSTRACT 
 
BACKGROUND Changes in high sensitivity cardiac troponin-T (hs-cTnT) concentrations may 
reflect either acute myocardial injury or biological variation. Distinguishing between these 
entities is essential to accurate diagnosis, however the biological variation of hs-cTnT in dialysis 
population is currently unknown. We sought to estimate the within- and between-person 
coefficients of variation of hs-cTnT in stable dialysis patients, and derive the critical difference 
between measurements needed to exclude biological variation with 99% confidence. 
 
METHODS Fifty five prevalent haemo- and peritoneal-dialysis patients attending two 
metropolitan hospitals were assessed on 10 consecutive occasions; weekly for 5-weeks then 
monthly for 4-months. Assessments were conducted at the same dialysis cycle time-point and 
entailed hs-cTnT testing, clinical review, electrocardiography, and bioimpedance spectroscopy. 
Patients were excluded if they developed clinical or physiological instability. 
 
RESULTS 137 weekly and 114 monthly hs-cTnT measurements from 42 stable patients were 
analysed. Respective between- and within-person coefficients of variation were 83% and 7.9% 
for weekly measurements, and 79% and 12.6% for monthly measurements. Within-person 
variation was unaffected by dialysis modality or cardiac co-morbidity. The bidirectional 99% 
reference change value was -25% and +33% for weekly measurements, and -37% and +58% for 
monthly measurements.  
 
CONCLUSIONS The between-person variation of hs-cTnT in the dialysis population is 
markedly greater than within-person variation indicating that hs-cTnT testing is best applied in 
this population using a relative change strategy. An increase of 33% or a reduction of 25% in 
serial hs-cTnT concentrations measured at weekly intervals excludes change due to analytical 
and biological variation alone with 99% confidence. 
 
KEYWORDS 
Renal Dialysis 
Troponin T 
Variability
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INTRODUCTION 
 
Acute myocardial injury is a leading cause of hospitalisation and death in the dialysis population 
(9.8-16 per 100-patient years), and cardiac troponins are among the most frequently requested tests 
in this group(1-5). A diagnosis of acute myocardial injury in dialysis patients is contingent on 
demonstrating a change in serial troponin concentrations in an appropriate clinical context(6, 7). 
However, there is currently no evidence-based guidance on how much change in serial 
measurements discriminates between biological variation and acute myocardial injury leading to 
considerable diagnostic confusion(8). 
 
Biological or within-person variation describes the random fluctuation of biomarker levels around a 
homeostatic set-point in healthy individuals or those with stable disease, and is of no clinical 
significance(9). Failure to accurately discriminate between changes in troponin concentrations 
caused by biological variation versus acute myocardial injury can result in unnecessary alarm, 
inappropriate management, and patient harm(10). These concerns are particularly relevant 
following the recent introduction of high sensitivity cardiac troponin T (hs-cTnT) assays which are 
able to detect small changes in circulating concentrations(11). Current guidelines either do not 
specify a magnitude of change in hs-cTnT concentrations that excludes biological variation in 
dialysis patients(6, 8) or have developed theoretical recommendations based on the analytic 
performance of assays(7).  
 
The aims of our study were to estimate the within- and between-person variation of hs-cTnT 
measured at weekly and monthly intervals from a cohort of stable dialysis patients and to use these 
estimates to calculate the percentage change between serial hs-cTnT measurements needed to 
exclude biological and analytic variation. We also sought to determine if the within-person variation 
of hs-cTnT differed according to cardiac co-morbidity or between dialysis modalities.  
 
 
SUBJECTS AND METHODS 
 
Study Design and Patient Recruitment 
A prospective cohort study was conducted between October 2010 and April 2012 according to 
methods described by Fraser and Harris(12). The study complied with the declaration of Helsinki 
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and received ethics approval from the Metro-South Human Research Ethics Committee 
(HREC/10/QPAH/131). 
 
Participants were recruited from the in-centre haemodialysis and peritoneal dialysis units of a 
tertiary-care teaching hospital in Brisbane, and a secondary-care hospital in Logan, Australia. 
Eligible participants identified from an electronic database of all patients receiving dialysis therapy 
were adults (aged ≥ 18-years) on maintenance dialysis for ≥ 90-days who had a stable dialysis 
prescription for ≥ 30-days and a transthoracic echocardiogram ≤ 12-months prior to screening.  
Eligibility criteria were chosen to ensure that the study cohort were physiologically and clinically 
stable at enrolment, and likely to remain stable for the duration of the study while still being 
representative of the dialysis population.  
 
Patients were excluded if they had undergone coronary and/or valvular intervention or suffered a 
myocardial infarction or pulmonary embolism in the 6-months prior to screening; had 
echocardiographic evidence of severe pulmonary hypertension, severe functional aortic and/or 
mitral valvular disease, or a left ventricular ejection fraction < 30%; had been hospitalised for any 
indication in the 30-days prior to screening; had been commenced on or undergone a dose change of 
a diuretic, beta-blocker, aldosterone receptor antagonist, angiotensin converting enzyme inhibitor or 
angiotensin type-1 receptor blocker in the 30-days prior to screening; had experienced worsening 
angina, a new cardiac arrhythmia or undergone a dose change of associated therapies in the 30-days 
prior to screening; had a contraindication to bioimpedance measurement including a pacemaker, 
implantable cardiac defibrillator, joint replacements, or mechanical heart valve; were pregnant; had 
advanced malignancy; or were unable to provide informed consent. 
 
Patient Assessment 
Patients were assessed on 10 consecutive occasions - weekly for 5 weeks then monthly for another 
4 months. All assessments were conducted between 6–8 AM, prior to the mid-week dialysis session 
for haemodialysis patients, and between 8–10 AM on the same weekday for peritoneal dialysis 
patients. Patients avoided strenuous exercise prior to assessment. 
 
Several factors affect hs-cTnT concentrations including extracellular volume(13), cardiac 
rhythm(14), myocardial ischaemia(15), and the dialysis prescription(16, 17). These influences were 
assessed using a structured clinical interview, physical examination and medical records review to 
ascertain interim hospitalisation, changes to medication and/or the dialysis prescription. The 
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Canadian Cardiovascular Society Angina Grading Scale(18) was used to assess change in cardiac 
ischaemic symptoms and the Truncated Framingham Heart Failure Score(19) was used to assess for 
evidence of pulmonary oedema at time of review. Patients also underwent a standard 12-lead 
electrocardiogram and whole body, multi-frequency bioimpedance analysis using the Body 
Composition Monitor BCM® (Fresenius Medical Care, Asia-Pacific) at each visit to measure intra- 
and extra-cellular volume. This instrument has a detection limit for change in extracellular volume 
of 0.87L ± 0.64L(20, 21). 
 
Specimen Collection, Storage and Analysis 
hs-cTnT concentrations were measured at baseline then at weeks 1-4 and months 2-4, providing 
data for 4 consecutive weekly and monthly intervals. To ensure that changes in hs-cTnT 
concentrations during the final measurement interval did not reflect changes in subclinical risk, 
patients were also assessed for stability at week 5 and month 5. 
Blood collected in lithium-heparin tubes was centrifuged and plasma separated within 1-hour of 
collection. Plasma was stored at -80C until assayed. hs-cTnT has been shown to be stable under 
these conditions(22). 
 
All samples were batched and analysed together in a single analytic-run in random duplicate by a 
single expert operator using a single instrument, and a single batch of reagent, control, and 
calibrators. Plasma hs-cTnT concentrations (nanograms per litre) were measured on the Cobas e170 
instrument using the troponin-T hs kit (Roche Diagnostics, Australia); a monoclonal antibody 
electrochemiluminescence assay which has a reported detection range of 5 – 10,000 ng/L. The 
population 99th centile reference limit for the assay is 14 ng/L(11). 
 
Statistical Analysis 
Based on a ratio of analytic to within-person variation of < 0.5 for hs-cTnT, we estimated that a 
study sample of 40 patients undergoing hs-cTnT testing on 8 occasions over 4 weekly and monthly 
intervals would have power = 1.0 to estimate the within-person coefficient of variation with a 95% 
confidence interval of ± 1.9%(23). A sample size of 55 was chosen to allow for dropouts and 
exclusions due to instability. 
 
Patients were deemed to be unstable if between study visits they underwent a change in dose of 
diuretic, beta-blocker, aldosterone receptor antagonist, angiotensin converting enzyme inhibitor or 
angiotensin type-1 receptor blocker; a change in severity of cardiac ischaemic symptoms, dose of 
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anti-anginal agents, or cardiac intervention; a change in anti-arrhythmic agent or new cardiac 
arrhythmia; a change in extracellular volume > 1L on bioimpedance analysis; a change in dialysis 
modality or prescription; hospitalisation for any reason or exhibited pulmonary oedema defined as a 
score ≥ 2 on the Truncated Framingham Heart Failure Score(19). If a study participant was deemed 
to be unstable, the hs-cTnT concentrations from the intervals preceding and following the event 
were excluded from the statistical analysis.  
 
Normally distributed variables are summarised as mean ± standard deviation, and non-normally 
distributed variables as median and interquartile range. hs-cTnT concentrations were 
logarithmically transformed for the variation analyses. We fitted mixed-effects models with random 
intercepts to calculate the between-person coefficient of variation (CVG), the within-person 
coefficient of variation at weekly and monthly intervals (CVI) and the within-run analytic 
coefficient variation (CVA). Outlying variances were excluded using the Reed and Cochran tests, 
and linear regression analysis was used to exclude participants who demonstrated a consistent trend 
in hs-cTnT concentrations in either direction which may reflect a change in subclinical risk. 
The cohort was also divided into subgroups according to ischaemic heart disease status, severity of 
left ventricular diastolic dysfunction, presence or absence of left ventricular systolic dysfunction, 
quartiles of hs-cTnT concentrations at enrolment, and by dialysis modality. CVI was estimated for 
each subgroup and compared using Bartlett’s test. Ischaemic heart disease was defined as one or 
more of inducible ischaemia on non-invasive cardiac testing and/or ≥ 50% stenosis in ≥ 1 epicardial 
coronary artery on coronary angiography and/or a history of myocardial infarction. Left ventricular 
diastolic dysfunction was graded as absent, mild, moderate or severe according to an established 
algorithm using echocardiographic measurements(24). Left ventricular systolic dysfunction was 
defined as a left ventricular ejection fraction ≤ 50% using Simpson’s rule(24).  
 
The index of individuality (IOI) was calculated as CVI/CVG. This ratio gives an indication of 
whether a biomarker is best used within a relative-change monitoring strategy (IOI < 0.6) or a 
reference interval strategy (IOI > 0.6). The bidirectional reference change value (RCV) was 
calculated according to the method described by Fokkema et al(25) for logarithmically transformed 
data as = exp(–Z × √2 × σ) and exp(+Z × √2 × σ); where σ = √ln(CVI2 + 1) and Z is the Z-score of a 
standard normal distribution corresponding to a given probability. 
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RESULTS 
 
Patient Characteristics 
Details of the number of patients assessed, enrolled and included in the final analysis are shown in 
Figure 1. Fifty five patients were recruited from the haemodialysis (n=28) and peritoneal dialysis 
units (n=27) of the participating institutions and their baseline characteristics are summarised in 
Table 1. Cardiovascular risk factors, including hypertension (100%), diabetes mellitus (40%), and 
current or former smoking (51%) were highly prevalent. A substantial proportion of the cohort also 
had evidence of established cardiovascular disease including ischaemic heart disease (22%), left 
ventricular diastolic (87%) and/or systolic (9%) dysfunction, and peripheral- and/or cerebro- 
vascular disease (9%). Baseline hs-cTnT concentrations demonstrated a right skewed frequency 
distribution with a median of 34 (interquartile range 24 – 54) ng/L. 90% of the study cohort had a 
hs-cTnT concentration exceeding the 99th centile upper reference limit of the hs-cTnT assay(11).  
 
Weekly and Monthly Variation of hs-cTnT 
Seven patients and their corresponding hs-cTnT measurements were excluded due to hospital 
admission (n=3), paroxysmal atrial fibrillation (n=3), and escalating anginal symptoms (n=1). In 
addition, 36 weekly and 51 monthly hs-cTnT sample-pairs were excluded due to a change in 
extracellular volume of  > 1L between consecutive visits. hs-cTnT measurements performed over 
136 weekly intervals from 42 patients and 113 monthly intervals from 39 patients were included in 
the final analysis. These data are shown in Figure 2 with excluded measurements represented by 
gaps.  
 
The respective analytic, within-person, and between-person coefficients of variation of hs-cTnT 
were 3.1%, 7.9%, and 83% for weekly intervals, and 2.4%, 12.6%, 79% for monthly intervals 
(Table 2). Between person variation was much greater than within-person variation (Figure 3), 
yielding low indices of individuality of 0.10 and 0.16 for the weekly and monthly intervals 
respectively (Table 2). 
 
Weekly and monthly reference change values for the 80%, 90%, and 99% degrees of statistical 
confidence are shown in Table 2. Thus, hs-cTnT concentrations measured at weekly intervals 
needed to increase by 33% or fall by 25% to ensure with 99% confidence that the observed change 
exceeded analytic and biological variation alone. Monthly reference change values were larger than 
weekly values for a given degree of statistical confidence. 
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The within-person co-efficient of variation did not differ significantly between dialysis modalities, 
by ischaemic heart disease status, by severity of diastolic dysfunction or across quartiles of hs-cTnT 
concentration (Table 3). The effect of left ventricular systolic dysfunction on within-person 
variation was unable to be meaningfully analysed as only one such patient was retained in the final 
analysis after the exclusion of unstable patients. 
 
DISCUSSION 
 
This study demonstrated that the between-person variation of hs-cTnT across the dialysis 
population was large and markedly greater than within-person variation for both the weekly and 
monthly measurement intervals (83% vs. 7.9%, and 79% vs. 12.6% respectively). This was 
reflected in the low index of individuality and indicates that hs-cTnT measurements from dialysis 
patients are best interpreted by comparing serial measurements to each other rather than by 
comparing single values to a reference interval or a threshold value(26). These findings support 
current recommendations on interpreting troponin concentrations measured from dialysis patients(6, 
7). 
 
Interpreting serial hs-cTnT concentrations in dialysis patients 
 
We found that the within-person coefficients of variation of hs-cTnT in stable dialysis patients were 
7.9% and 12.6% for the weekly and monthly measurement intervals respectively. Using these 
values we calculated bidirectional reference change values for pre-specified degrees of statistical 
confidence (table 2)(25). The weekly 99% reference change value was +33% and -25%, indicating 
that hs-cTnT concentrations must increase by at least 33% or fall by 25% in the short-term to 
exclude change due to biological and analytic variation alone with 99% certainty. We suggest that 
this short term reference change value has the greatest relevance to clinical practice where troponin 
is measured over hours or days to diagnose acute myocardial injury. In addition, we suggest using 
the 99% level of statistical confidence as therapies that may be instituted after excluding biological 
variation carry risks of serious adverse events necessitating a high degree of certainty. It is also 
important to highlight that acute myocardial injury may result from either coronary or non-coronary 
aetiologies(6) and that careful clinical assessment remains imperative to determining the underlying 
cause of acute myocardial injury and to guide its management. We recommend using a relative (e.g. 
33%) rather than absolute (e.g. 5-7 ng/L) change criterion as the former has been shown to be 
diagnostically superior in populations where the majority of individuals have a baseline hs-cTnT 
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concentration exceeding the upper reference limit of the assay used and where the between-person 
variation of hs-cTnT is large, both of which have been demonstrated in this study(27). 
 
Explicit guidance on the interpretation of serial troponins measured from dialysis patients is 
necessary as the distinction between troponin fluctuations resulting from biological variation versus 
those occurring during acute coronary syndromes, particularly non-ST elevation myocardial 
infarction, is frequently unclear(28, 29). To date, consensus guidelines on the interpretation of serial 
troponin measurements in dialysis patients have either provided no guidance on this issue(6, 8) or 
have based their guidance on the analytic performance of troponin assays, recommending the use of 
a 20% magnitude of change on the basis that such a delta equates to 3 standard deviations of the 
troponin assay’s analytic variation(7). Based on the within-person coefficient of variation estimated 
in our study, a 20% change in serial troponin concentrations would only have a 90% degree of 
statistical confidence for excluding biological and analytic variation, and would therefore not be 
sufficiently specific for excluding biological variation. 
 
Impact of dialysis therapy and cardiac co-morbidity on biological variation 
The weekly and monthly within-person variation of hs-cTnT estimated from dialysis patients in this 
study was markedly smaller than corresponding values reported for healthy individuals (15% and 
31% respectively)(30), but similar to those reported for non-dialysis dependent individuals with 
coronary artery disease (7.3% at 4-hourly intervals and 10.7% at 3-weekly intervals)(31). These 
findings are likely explained by the fact that both dialysis patients and non-dialysis dependent 
patients with coronary artery disease have baseline troponin-T concentrations around or exceeding 
the 99th centile upper reference limit of the hs-cTnT assay(16, 31) whereas healthy individuals have 
much lower baseline values(11). Accordingly, any fluctuations in troponin concentrations caused by 
biological variation in the former groups represent a smaller proportion of the baseline 
concentration resulting in a smaller within-person coefficient of variation. 
 
In our study the within-person coefficient of variation of hs-cTnT was not significantly different 
between dialysis modalities, by ischaemic heart disease status, by severity of diastolic dysfunction, 
or across quartiles of baseline hs-cTnT concentrations implying that the reference change values 
described previously can be applied to dialysis patients regardless of their cardiac comorbidity 
status or dialysis modality. Furthermore, the analytic variation in our study was consistent with that 
reported from a multi-centre evaluation of the same analytic method using standard laboratory 
protocols(11). It is therefore unlikely that the reference change values reported in this study would 
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be appreciably affected by analytic differences related to ‘real world’ performance of the hs-cTnT 
assay. 
 
Strengths and limitations 
Our estimates of the within-person variation of hs-cTnT in the dialysis population are supported by 
the findings of  Aakre et al(32), Pianta et al(16) and Jacobs et al(33) who reported a within-person 
coefficient of variation of 8.3%, 9.7% and 13% for hs-cTnT measured weekly, fortnightly and 
monthly respectively in haemodialysis patients. However, these studies were limited by the 
exclusion of peritoneal dialysis patients(16, 32, 33), a paucity of repeated measures(16, 33) and 
most importantly by a lack of rigour in ensuring patient stability, wherein they relied either on 
patient report(16) or a history of hospitalization(32, 33) alone to determine stability. The latter 
introduces the possibility that unstable patients may have been included in the analyses of these 
studies and impacted the accuracy of  their findings. Indeed, Aakre et al reported that hs-cTnT 
concentrations measured over 90-minute intervals in their study demonstrated a consistent 
decreasing trend; this may reflect recovering acute myocardial injury due to haemodialysis induced 
cardiac stunning(34) which was not considered by the authors(32). 
 
Our study has a number of important strengths that address these limitations, including the 
enrolment of both peritoneal- and haemo-dialysis patients, multiple measurements of hs-cTnT, and 
a rigorous approach towards ensuring stability of all factors affecting hs-cTnT concentrations. 
Nevertheless, the present study has several limitations. Firstly, patients with the most severe 
cardiovascular co-morbidities were excluded to maximise the likelihood that enrolled patients 
would remain stable for the duration of follow-up. Although this potentially limits the 
generalizability of the study’s findings, it is noteworthy that the baseline characteristics of our study 
cohort were similar to those reported for prevalent Australasian dialysis patients in the Australian 
and New Zealand Dialysis and Transplant Registry(35). Secondly, the biological variation of hs-
cTnT over 3-hourly intervals was not investigated. While this would have most closely 
approximated the interval over which hs-cTnT is measured in clinical practice, such a study design 
would have imposed substantial inconvenience on participants, necessitating a 15 hour visit and 5 
venepunctures on a non-dialysis day and would likely have limited participation. Finally, our study 
could not determine if the within-person coefficient of variation of hs-cTnT was affected by left 
ventricular systolic impairment as only one such patient remained stable during the study. 
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Conclusions 
Based on the findings of this study, it is recommended that hs-cTnT concentrations measured in 
dialysis patients for the diagnosis of acute myocardial injury be interpreted using a relative change 
strategy rather than by comparing absolute concentrations to a reference interval. An increase of 
over 33% or a reduction of 25% in serial hs-cTnT concentrations measured at weekly intervals from 
dialysis patients excludes change due to biological and analytic variation alone with 99% certainty 
and should prompt investigation for coronary and/or non-coronary causes of acute myocardial 
injury; concurrent clinical assessment remains essential to establishing the underlying cause of 
acute myocardial injury and to guide therapy accordingly. Using the change limits identified in this 
study, future randomised studies should investigate if early intervention for  minor, but significant, 
changes in cardiac troponin concentrations improves patient outcomes in the dialysis population as 
has been demonstrated in the non-dialysis population(36). 
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FIGURE LEGENDS 
 
Figure 1. Flow diagram of patients assessed for eligibility, enrolled and analysed in the study. 
 
Figure 2. Variation of high sensitivity cardiac troponin T (hs-cTnT) concentrations measured from 
each of the stable participants over the weekly and monthly follow-up phases.  
 
Figure 3. Box-plot of median (horizontal line), upper and lower quartiles (large rectangle), and 
range (whiskers) of high sensitivity cardiac Troponin T (hs-cTnT) concentrations for each of the 
stable participants during the weekly follow-up phase. 
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Table 1. Baseline characteristics of the study cohort. 
Characteristic Value (n=55) 
Male gender (%) 45 
Age  
Mean ± sd (years)  
Age distribution (%) 
18 – 49 years 
50 – 69 years 
70 – 79 years 
80 – 90 years 
 
59±15 
 
33 
40 
22 
5 
Haemodialysis (%) 51 
Time on dialysis (months) 35 (16 – 58) 
Body mass index (Kg/m2) 30.2 (28.5 – 34.6) 
Ratio of extracellular to total body water 0.48±0.04 
Systolic blood pressure (mmHg) 130±15 
Diastolic blood pressure (mmHg) 74±12 
Diabetes mellitus (%) 40 
Current or former smoker (%) 51 
Ischaemic heart disease (%) 22 
Peripheral- and/or cerebro-vascular disease (%) 9 
Left ventricular ejection fraction 
Mean±sd (%) 
Left ventricular systolic dysfunction (%) 
 
60±7 
9 
Diastolic dysfunction (%) 
Nil 
 
13 
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Mild  
Moderate  
Severe  
24 
45 
18 
Antihypertensive agents 
Median number of anti-hypertensive agents 
Proportion on beta-blocker (%) 
Proportion on ACE-I or ARB (%) 
 
1(1-2) 
42 
38 
hs-cTnT (ng/L) 
Median (IQR) 
Minimum 
Maximum 
Proportion  of sample (%) with baseline hs-cTnT concentration > 14 ng/L 
 
34 (24 – 150) 
8 
241 
90% 
 
Abbreviations: ACE-I, Angiotensin converting enzyme inhibitor; ARB, Angiotensin type-1 receptor 
blocker
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Table 2. Estimates of variance components of high sensitivity troponin-T, bidirectional reference change values for stated degrees of statistical 
confidence and index of individuality over weekly and monthly intervals for stable study participants. 
 
 
 
Coefficient of variation (%) 
 
Reference change value  
 Index of 
Individuality 
 Analytic  
(CVA) 
Between-person 
(CVG) 
Within-person 
(CVI) 
 
99% 90% 80% 
 
CVI:CVG 
Weekly 3.1 83 7.9  -25% and +33% -17% and +20% -13% and +15%  0.10 
Monthly 2.4 79 12.6  -37% and +58% -25% and +34% -20% and +25%  0.16 
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Table 3. Within-person coefficients of variation of high sensitivity cardiac troponin-T (mean and 
95% confidence intervals) by subgroups of dialysis modality, ischaemic heart disease status, 
cardiac diastolic function and quartiles of high sensitivity cardiac troponin-T concentration (hs-
cTnT). 
 
Sub-group Weekly Within-person Coefficient of 
Variation CVI % (95% CI) 
p-value 
Dialysis modality 
Peritoneal dialysis 
Haemodialysis 
 
7.5 (6.2 – 9.0) 
8.2 (6.8 – 10.0) 
 
0.68 
Ischaemic heart disease 
Absent 
Present 
 
5.7 (4.5 – 7.3) 
8.5 (7.3 – 9.9) 
0.90 
Diastolic dysfunction 
Nil / Mild 
Moderate / Severe 
 
8.2 (6.8 – 9.9) 
7.7 (6.4 – 9.3) 
0.78 
hs-cTnT concentration (ng/L) 
1st  quartile (8 - 24) 
2nd quartile (25 - 34) 
3rd quartile (35 - 54) 
4th quartile (55 - 241) 
 
10.3 (7.8 – 13.4) 
8.3 (6.5 – 10.7) 
6.3 (4.6 – 8.8) 
5.6 (4.5 – 7.1) 
0.31 
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Chapter 8 
 
Pathophysiologic Associations of the N-terminal Fragment of Pro-B-type Natriuretic 
Peptide (NT-proBNP) in the Dialysis Population. 
 
The following chapter investigates the associations between plasma NT-proBNP 
concentrations and objective measures of hydration state, vascular function, left ventricular 
mass and function, and comorbid conditions in a cohort of prevalent haemodialysis and 
peritoneal dialysis patients. It provides insights into the pathophysiological factors mediating 
abnormal NT-proBNP concentrations in the dialysis population, and consequently how levels 
should be interpreted and what interventions might be considered in any future monitoring 
strategies. 
 
This chapter is in the process of being submitted for publication.  
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Chapter 8 
 
Pathophysiologic Associations of the N-terminal Fragment of Pro-B-type Natriuretic 
Peptide (NT-proBNP) in the Dialysis Population 
 
 
INTRODUCTION 
 
Patients on maintenance dialysis have a 10-60 times increased risk of cardiovascular 
mortality compared to their non-dialysis counterparts, and this risk has not improved 
substantively over the past decade(1-4). A key factor underpinning this poor progress is our 
inability to identify dialysis patients at an increased risk of cardiac morbidity and/or mortality 
in a timely manner or to monitor the efficacy of cardiac interventions(5). 
 
The N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) is an inactive 
peptide secreted principally from the ventricular myocardium in response to stretch, strain, 
ischemia, inflammation and sympathetic overactivity(6). NT-proBNP concentrations have 
been shown in cohort studies to be independently associated with the risk of cardiovascular 
and all-cause mortality among the dialysis population(7-9) positioning it as a candidate 
biomarker for monitoring cardiac risk.  
 
However, the translation of NT-proBNP testing into clinical dialysis practice has been 
hampered by uncertainty regarding the pathophysiological factors mediating abnormal NT-
proBNP concentrations in this population, and consequently how levels should be interpreted 
and what interventions might be used to modify this heightened risk(10, 11). Studies 
examining the association between NT-proBNP concentrations and volume status, 
cardiomyopathy, and vascular stiffness in the dialysis population have yielded conflicting 
conclusions; suggesting it is either a marker of cardiomyopathy alone(12-22) or hydration 
status alone(23-28). These contradictory findings can be attributed, at least in part, to 
inadequate adjustment for confounding variables(17-19, 24-26, 28), small sample sizes(22, 
24, 25), use of surrogate measures of volume(16-21), and insensitive measures of myocardial 
contractility(20, 22-26, 28).  
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The aim of this study was to determine the associations between NT-proBNP concentrations 
and objective measures of hydration state, vascular function, left ventricular mass and 
function, and comorbid conditions in a cohort of prevalent haemodialysis and peritoneal 
dialysis patients. 
 
METHODS 
 
Study Design and Patient Recruitment 
A cross-sectional study was conducted between June 2011 and August 2013. The study 
complied with the declaration of Helsinki and received ethics approval from the Metro-South 
Human Research Ethics Committee (HREC/10/QPAH/131), the Greenslopes Research and 
Ethics Committee (Protocol 12/39), and the University of Queensland Medical Research 
Ethics Committee (2011000484). 
 
Participants were recruited from the in-centre haemodialysis and peritoneal dialysis units of a 
public, tertiary-care teaching hospital and a private, secondary-care hospital in metropolitan 
Brisbane, Australia. Eligible participants identified from an electronic database of all patients 
receiving dialysis were adults (aged ≥18-years) established on maintenance dialysis for ≥90-
days who had a stable dialysis prescription for ≥30-days, and were able and willing to 
provide informed consent. 
 
Patients were excluded if they were planned for living donor renal transplantation within 3-
months of enrolment, had advanced malignancy, were pregnant, were unable to provide 
informed consent or had a contraindication to whole body bioimpedance spectroscopy 
measurement (including a permanent pacemaker, implantable cardiac defibrillator, joint 
replacements, orthopaedic pins, mechanical heart valves and/or limb amputations). 
 
Patient Assessment 
Haemodialysis patients were assessed between 6–8 AM, prior to the mid-week dialysis 
session, and peritoneal dialysis patients were assessed between 8–10 AM on a consistent 
weekday. Patients were instructed to avoid strenuous exercise prior to assessment. 
Assessments entailed a structured clinical interview, physical examination, and review of the 
medical record to ascertain medical history, comorbidities, current treatments and dialysis 
prescription. In addition, patients underwent a standard 12-lead electrocardiogram, whole 
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body bioimpedance spectroscopy and blood sampling for measurement of NT-proBNP on the 
same occasion. 
 
For haemodialysis patients, the blood pressure recorded was the median of 12 post-dialysis 
measurements taken at the end of the 12 haemodialysis treatments that preceded the study 
assessment, while for peritoneal dialysis patients it was the median of 12 home blood 
pressure recordings measured thrice weekly over the 4 weeks prior to the study assessment. 
The median of these blood pressure recordings has been shown to have the greatest 
agreement with 24-hour ambulatory measurements and therefore to be most representative of 
the patient’s blood pressure(29). 
 
Hydration status was assessed using whole-body, multi-frequency bioimpedance analysis 
with the Body Composition Monitor BCM® (Fresenius Medical Care, Asia-Pacific). This 
instrument has been validated in dialysis patients against radioisotope dilution methods with 
reported agreement limits (mean ± standard deviation [SD]) of -0.2±2.3L, -0.4±1.4L and 
0.2±2L for total body water, extra- and intra-cellular water volumes, respectively(30). 
Peritoneal dialysis patients were assessed with peritoneal dialysis fluid in situ, which has 
been previously shown to have no significant or clinically important effect on volume 
measurements compared with an empty peritoneal cavity(31). 
 
Echocardiography and pulse wave velocity measurement 
Echocardiograms and pulse wave velocity measurements were performed within one week of 
NT-proBNP sampling, and for haemodialysis patients they were performed on the non-
dialysis day immediately following the mid-week dialysis treatment to ensure that cardiac 
loading conditions were representative of the patient’s usual volume state. Echocardiograms 
were performed and measured by one of two expert operators blinded to patient’s NT-
proBNP concentrations and medical history.  
 
Echocardiograms were performed in the left lateral decubitus position using a 3.5MHz 
phased array transducer with harmonic imaging (Vivid7, General Electric-Vingmed Medical 
Systems, Horten, Norway).  Grayscale images from the parasternal long-axis and short axis 
as well as the apical 4-chamber, 2-chamber and apical long axis views were acquired at 
moderate frame rate (50-70 fps) to allow for processing of 2D strain; apical images in the 4-
chamber, 2-chamber and apical long axis were acquired at high frame rate (>120 fps) with a 
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colour tissue Doppler overlay to measure colour tissue Doppler velocity, strain and strain 
rate. Doppler measurement of LV inflow, TV inflow and aortic and pulmonary outflow were 
performed using pulsed and continuous wave Doppler.  Colour tissue Doppler measurements 
were performed using pulsed wave Doppler in the medial and lateral LV annulus, tricuspid 
annulus and for all LV segmental measurements. 
 
Cine loops of three cardiac cycles were acquired and the measurements averaged.  If patients 
were in atrial fibrillation, 5-7 measurements were averaged.    Left atrial and ventricular 
dimensions were obtained by M-mode according to the American Society of 
Echocardiography Recommendations(32); endocardial borders were traced at end systole and 
end diastole in the apical 4—chamber and 2-chamber views to obtain Simpson’s Rule 
ejection fraction; M-mode LV mass  was calculated using the formula : LV mass =0.8 × 
(1.04[(LV internal dimension + septal wall thickness + posterior wall thickness)3 – LV 
internal dimension3]) + 0.6g, and these were indexed to the patient’s body surface area 
calculated using the Haycock formula (0.024265 x Weight(kg)0.5378 x height(cm)0.3964). 
 
For 2D strain analysis, the endocardial borders were traced at end-systole in the 4-chamber, 
2-chamber and apical long axis views; the software (EchoPac PC BTO 11, General Electric-
Vingmed Medical Systems, Horten, Norway) divided the LV into basal, mid and apical 
segments, and identified unique “speckles” within the myocardium and tracked them frame-
by-frame throughout the cardiac cycle to obtain strain and strain rate curves.  Segments that 
did not track properly were manually adjusted or eliminated from the analysis.  Global 
longitudinal strain (GLS) was expressed as a mean of all 18 segments. 
 
The SphygmoCor PX system (AtCor Medical, Australia) was used for measurement of pulse 
wave analysis (augmentation index) and pulse wave velocity (PWV).  Carotid-femoral PWV 
was the only method measured.  The distances between the common carotid artery and the 
suprasternal notch, the suprasternal notch and the umbilicus, and the umbilicus and the 
femoral artery were measured.  Tonometery was performed in the common carotid artery as 
close to the aortic arch as possible and at the femoral artery.  The foot-to-foot times to reach 
the common carotid artery and the femoral artery were then subtracted and pulse wave 
velocity was expressed as metres per second (m/s).  A total of three measurements were taken 
and averaged for analysis. 
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NT-proBNP sample collection, storage and analysis 
Blood for measurement of NT-proBNP concentrations was collected in lithium-heparin tubes, 
prior to the commencement of the dialysis treatment for haemodialysis patients. Blood 
samples were centrifuged and plasma separated within 1 hour of collection and then stored at 
-80°C until assayed(33). 
Plasma NT-proBNP concentration (pg/mL) was measured using a twin-antibody 
electrochemiluminescence assay on the Elecsys 2010 instrument (Roche Diagnostics, 
Australia) which has a reported analytical detection range of 5–35,000 pg/mL. Analytic 
coefficients of variation reported by the analysing laboratory were 2.9% and 1.8% at 
concentrations of 134 pg/mL and 4534 pg/mL respectively in keeping with desired 
performance of the assay(34, 35). 
 
Definitions 
Ischemic heart disease was defined as any of inducible ischaemia on non-invasive cardiac 
stress testing and/or ≥50% stenosis in ≥1 epicardial coronary artery on coronary angiography 
and/or a history of myocardial infarction and/or a history of coronary artery angioplasty, 
stenting or coronary artery bypass grafting. 
 
Systolic dysfunction was classified either as an ejection fraction ≤ 50% measured using 
Simpson’s rule(36) or a global longitudinal strain > -15% which has been associated with 
increased risk of mortality in both the general and dialysis populations(37-39). Diastolic 
dysfunction was graded as absent (normal diastolic function) or assigned a grade from one to 
three reflecting worsening diastolic dysfunction according to a consensus guidelines(40). 
Gender specific limits from consensus guidelines were used to classify left ventricular 
hypertrophy as absent, mild, moderate or severe according to left ventricular mass indexed to 
body surface area(32). 
 
Hydration status was expressed as the ratio of extracellular to total body water volumes, and 
overhydration defined as a ratio two standard deviations above the mean age and gender 
matched ratio in the normal population(11, 31). 
 
Statistical analysis 
Categorical variables are presented as frequencies and percentages, and continuous variables 
as mean ± standard deviation if normally distributed and as median and interquartile range if 
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non-normally distributed. NT-proBNP concentrations were logarithmically transformed for 
correlation, univariable and multivariable linear regression analyses. Bivariate correlation 
between log transformed NT-proBNP concentrations and independent variables were 
analysed using pairwise correlation.  
 
Thirteen participants had at least one missing measurement for either global longitudinal 
strain (n=1), left ventricular mass (n=7), and/or pulse wave velocity (n=12) which could not 
be measured due to body habitus or arrhythmia. Examination of the missing data 
demonstrated an arbitrary pattern and missing values were assumed to be missing at random. 
Multiple imputation was used to impute missing values using a multivariable normal model 
with 20 imputations(41). Univariable and multivariable linear regression analyses were 
performed using imputed data as the primary analyses, and repeated using non-imputed data 
as a sensitivity analysis (supplement). The latter did not alter the results in a clinically 
meaningful manner. 
 
Independent variables for inclusion in the linear regression models were chosen based on 
published associations with NT-proBNP. Independent variables identified as being significant 
at the 5% level (P <0.05) from the univariable analyses were analysed in the multivariable 
linear regression model. Variable selection was not performed. Global longitudinal strain and 
ejection fraction are both measures of left ventricular contractility with differing sensitivity, 
thus they were used individually as independent variables in two separate multivariable linear 
regression analyses. Regression diagnostics were performed for both multivariable models 
and were satisfactory. Semi-partial correlations were calculated for independent variables to 
determine increment to R2. All analyses were performed using Stata/MP 12.1 (College 
Station, Tx, USA). 
 
 
RESULTS 
 
Participant characteristics 
Seventy eight prevalent patients were recruited between June 2011 and January 2014 from 
the haemodialysis (n=47) and peritoneal dialysis (n=31) units of the participating institutions 
and their baseline characteristics are shown in Table 1. Cardiovascular risk factors and 
established cardiovascular disease were highly prevalent among the study cohort, including 
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diabetes mellitus (45%), hypertension (100%), current or former smoking (61%), ischaemic 
heart disease (41%) and peripheral and/or cerebrovascular disease (16%). In addition, a 
substantial proportion of participants had evidence of cardiomyopathy on echocardiography 
including left ventricular hypertrophy (67%) and/or diastolic dysfunction (84%). The 
prevalence of systolic dysfunction differed according to the measure of left ventricular 
systolic function used with 32% of the cohort having an ejection fraction under 50%,  while 
56% of the cohort had a global longitudinal strain measurement > -15%. Fifty seven percent 
of males and seventy one percent of females in the study cohort were overhydrated on 
bioimpedance analysis. Baseline NT-proBNP concentrations demonstrated a right skewed 
frequency distribution with a median of 3344 (interquartile range 1080-9786) pg/mL. Ninety 
five percent of the study cohort had a NT-proBNP concentration above 300 pg/mL, the 
threshold used to exclude acute decompensated heart failure in the general population. 
 
Bivariate correlation and univariable linear regression analyses are shown in Table 2 and 
Figure 1. These analyses demonstrated significant direct correlations between NT-proBNP 
concentrations and age, female gender, hydration status, global longitudinal strain, increasing 
grade of diastolic dysfunction, ischaemic heart disease and left ventricular mass indexed to 
body surface area. In addition, significant inverse correlations were demonstrated between 
NT-proBNP concentrations and left ventricular ejection fraction and residual renal function. 
 
 Multivariable linear regression 
Two multivariable linear regression models were used to analyse associations between NT-
proBNP concentrations and significant independent variables identified from the univariable 
analyses. The models differed in terms of the measure of left ventricular systolic function 
used, with model 1 using global longitudinal strain and model 2 using left ventricular ejection 
fraction (table 3). Both models demonstrated significant associations between NT-proBNP 
concentrations and hydration status and left ventricular mass. However a significant 
association with left ventricular systolic function was only demonstrated in model 1 using 
global longitudinal strain, which also resulted in a significant increment to R2 of 0.06 
(p=0.003) as shown in Figure 2. In the multivariable model, hydration status explained the 
greatest proportion of the variation in NT-proBNP concentrations (standardised β = 0.313, 
p<0.01) followed by left ventricular mass (standardised β = 0.238, p<0.01), global 
longitudinal strain (standardised β = 0.233, p<0.01) and residual renal function (standardised 
β = -0.182, p=0.05). 
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DISCUSSION 
 
This study demonstrated an independent association between NT-proBNP concentrations and 
hydration status, left ventricular systolic function and left ventricular mass, and furthers 
understanding of the pathophysiological mechanisms underlying the association between NT-
proBNP concentrations and the heightened risk of mortality in dialysis patients. 
 
Overhydration, impaired myocardial contractility and left ventricular hypertrophy each result 
in cardiac volume and/or pressure overload and stretch/strain of cardiac myocytes, which in 
turn secrete BNP and NT-proBNP in equimolar amounts(42). It is noteworthy that ventricular 
pressure overload can occur in overhydrated dialysis patients, even in the absence of 
structural or functional cardiomyopathy, accounting for the independent association of 
plasma NT-proBNP concentrations with hydration status observed in this study(43).  
 
Cross-sectional studies have previously reported a significant association between NT-
proBNP concentrations and either hydration status(23-28) or left ventricular systolic 
function(12-22) on multivariable analysis, but not with both independent variables 
concurrently. The discrepancy between these findings and those of the present study might be 
explained the limitations of the previous studies, including small sample sizes(22, 24, 25), 
inadequate control for confounding variables(17-19, 22, 24-26, 28) and the use of surrogate 
measures of hydration(16-21) and/or ejection fraction as the measure of systolic function(20, 
22, 23, 25, 26, 28) and the measurement error introduced as a consequence. In the present 
study, whole body, multi-frequency bioimpedance spectroscopy was used as an objective, 
validated measure of hydration status(11, 30) and global longitudinal strain as a sensitive 
measure of ventricular contractility(37, 39). The importance of the latter is highlighted by the 
finding in this study that NT-proBNP concentrations were significantly associated with 
global longitudinal strain but not ejection fraction. Global longitudinal strain measures 
deformation of the ventricular myocardium by frame-by-frame tracking of natural acoustic 
markers generated from the interaction between ultrasound and the myocardium, and is less 
prone to errors caused by variation in heart rate and cardiac loading(44). It has been 
independently associated with mortality in dialysis patients and compared with ejection 
fraction, has been shown to be a more sensitive and objective measure of myocardial 
contractility(37). 
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Overhydration(45, 46), systolic dysfunction and left ventricular hypertrophy(47, 48) have all 
been independently associated with the risk of cardiovascular morbidity and mortality in the 
dialysis population, although strategies for monitoring them remain suboptimal. Clinical 
assessment of hydration status is inaccurate and subject to high interobserver variability(49), 
while bioimpedance, lung ultrasound(50), and echocardiography are likely to entail 
substantial financial and personnel costs, which may prohibit their universal and/or on a 
regular application(51). Echocardiography and technological volume assessment are also 
limited by the fact that they each measure a single risk factor without quantifying its effect on 
composite cardiac risk in the individual being evaluated. NT-proBNP has the potential to 
address these limitations, however the ideal strategy for implementing this biomarker in 
practice remains unclear. 
 
Efforts at translating NT-proBNP testing into clinical usage have so far focused on 
establishing a threshold concentration below which cardiomyopathy or overhydration(13, 16, 
21, 52) can be confidently excluded in a manner akin to which a NT-proBNP concentration 
less than 300 pg/mL is used to exclude acute decompensated heart failure in the non-dialysis 
population(53). The finding in this study that NT-proBNP concentrations are independently 
associated with three important pathophysiologies makes it unlikely that any single threshold 
concentration will have the sensitivity or specificity required to exclude systolic dysfunction, 
ventricular hypertrophy and overhydration concurrently. In addition, recent studies have 
demonstrated that the between-person variation of NT-proBNP in the dialysis population is 
large and much greater than its within-person variation implying that a relative change 
strategy may be more appropriate(54, 55) to monitor cardiovascular risk related to hydration 
status and cardiomyopathy. 
 
This study also demonstrated a significant, inverse correlation between NT-proBNP 
concentrations and residual renal function, which can be attributed to the fact that NT-
proBNP has a fractional renal extraction of approximately 20%(56). However, as 
demonstrated in this study, impaired renal clearance only accounts for a small proportion of 
the elevation and variation in NT-proBNP concentrations among dialysis patients which is 
principally explained by hydration state and cardiomyopathy. Significant associations 
demonstrated between NT-proBNP and age, gender, diastolic dysfunction and ischaemic 
heart disease on univariable linear regression analyses were not borne out on multivariable 
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linear regression analyses suggesting that univariable associations were confounded by other 
independent variables. 
 
This study has several strengths including the standardisation of NT-proBNP sampling, 
handling and storage to minimise pre-analytic variation, its use of sensitive and objective 
measures of myocardial contractility (global longitudinal strain) and volume (whole body 
bioimpedance spectroscopy), and its inclusion of both haemodialysis and peritoneal-dialysis 
patients thereby broadening the generalizability of its findings. Nevertheless, this study had 
two principal limitations including its sample size, which restricted the number of 
independent variables that could be explored in the multivariable linear regression models, 
and the lack of measurement of inflammatory markers which have been associated with NT-
proBNP concentrations in the dialysis population in previous reports(23). 
 
 
Conclusion 
This study demonstrated that NT-proBNP concentrations in prevalent haemodialysis and 
peritoneal dialysis patients were independently associated with hydration status, left 
ventricular mass, left ventricular systolic function (assessed using global longitudinal strain) 
and residual renal function. Coupled with the established association between NT-proBNP 
concentrations and mortality, these findings suggest that NT-proBNP testing may have a role 
in monitoring the risk of adverse cardiac events related to hydration state and 
cardiomyopathy in the dialysis population. Longitudinal studies are needed to determine the 
accuracy of such a strategy before it can be adopted into clinical practice. 
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Figure Legends 
 
Figure 1. Bivariate correlation between NT-proBNP concentrations and hydration status, left 
ventricular mass and systolic function. Scatter plots, regression line and 95% confidence interval 
(grey area). a, P = < 0.001; BSA = body surface area; ECW = extracellular water volume; LV = left 
ventricular; r = correlation coefficient; TBW = total body water. 
 
Figure 2. Proportion of variation in NT-proBNP concentrations explained by hydration 
status, residual renal function, and left ventricular mass and systolic function. Increment to the 
coefficient of determination (R2) due to residual renal function (semi-partial correlation = 0.025, P 
= 0.049), hydration status (semi-partial correlation 0.067, P = 0.001),  left ventricular mass indexed 
to body surface area (semi-partial correlation 0.087, P < 0.001) and global longitudinal strain (semi-
partial correlation 0.060, P = 0.003). IHD = ischaemic heart disease; GLS = global longitudinal 
strain; LVMI = left ventricular mass indexed to body surface area; RRF = residual renal function.
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Figure 1
r = 0.563 a r = 0.510 a 
r = 0.474 a r = -0.413 a 
  
 
189 
 
Figure 2 
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Table 1. Baseline characteristics of the study cohort. Abbreviations: ACE-I = Angiotensin 
converting enzyme inhibitor; ARB = Angiotensin type-1 receptor blocker; D/P creatinine = ratio of 
creatinine concentration in dialysate to plasma; Kt/V = dialysis urea clearance; NT-proBNP = N-
terminal pro-B-type natriuretic peptide. 
Characteristic Value (n=78) 
Male gender n (%) 50 (64) 
Age  
Mean ± SD (years)  
Age distribution n (%) 
18 – 49  
50 – 69  
70 – 79  
80 – 90 
 
64±13 
 
12 (15) 
35 (45) 
20 (26) 
11 (14) 
Hemodialysis n (%) 
Dialysis sessions per week (n) 
Duration of dialysis session (hours) 
Single pool Kt/V 
Interdialytic weight gain (kg) 
Interdialytic weight gain relative to estimated  
dry weight (%) 
48 (61) 
3 
4.7±0.7 
1.58±0.3 
1.83 (1.40 – 2.23) 
2.4±1.1 
 
Peritoneal dialysis n (%) 
Volume of peritoneal dialysis solution exchanged 
per 24 hours (L) 
Four hour D/P creatinine 
Weekly Kt/V 
30 (39) 
8 (8 – 8.9) 
 
0.72±0.1 
1.93 (1.76 – 2.25) 
Time on dialysis (years) 6 (4-9.5) 
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Body Mass Index (kg/m2) 29.3±6.4 
Systolic blood pressure (mmHg) 128±20 
Diastolic blood pressure (mmHg) 70±13 
Diabetes mellitus n (%) 35 (45) 
Current or former smoker n (%) 48 (61) 
Ischemic heart disease n (%) 32 (41) 
Peripheral- and/or cerebro-vascular disease n (%) 13 (16) 
Hydration status 
Ratio of extracellular to total body water 
Proportion overhydrated n (%) 
Male 
Female 
 
0.49±0.03 
 
29 (57) 
20 (71) 
Residual renal function (mL/min) 0 (0-3) 
Left ventricular structure and function 
Left ventricular mass indexed to BSA (g/m2) 
Left ventricular hypertrophy n (%) 
Nil 
Mild 
Moderate 
Moderate 
Ejection fraction (%) 
Global longitudinal strain (%) 
Left ventricular systolic dysfunction n (%) 
Ejection fraction 
Global longitudinal strain 
Diastolic dysfunction n (%) 
 
119 (97-146) 
 
26 (33) 
10 (13) 
15 (19) 
27 (35) 
54 (49-62) 
-14±3.2 
 
25 (32) 
44 (56) 
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Nil 
Grade 1 
Grade 2 
Grade 3 
12 (16) 
33 (42) 
26 (33) 
7 (9) 
Pulse wave velocity (m/s) 9.4 (8.2-11.8) 
Antihypertensive agents 
Median number of anti-hypertensive agents 
Proportion on beta-blocker n (%) 
Proportion on ACE-I or ARB n (%) 
 
1(1-2) 
45 (58) 
27 (34) 
NT-proBNP (pg/mL) 
Median (IQR) 
Distribution n (%) 
< 300 pg/mL 
300 – 899 pg /mL 
900 – 4999 pg/mL 
5000 – 19,999 pg/mL 
≥ 20,000 pg/mL 
 
3344 (1080-9786) 
 
4 (5) 
9 (12) 
34 (44) 
20 (27) 
11 (12) 
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Table 2. Univariable associations of NT-proBNP. Linear regression coefficients (β) and 
bivariate correlation coefficients (r) of NT-proBNP and dependent variables. ACE-I = 
Angiotensin converting enzyme inhibitor; ARB = Angiotensin type-1 receptor blocker; BSA 
= body surface area; ECW = extracellular water volume; LV = left ventricular; TBW = total 
body water. 
 
  r β  (95% CI) P value 
Age (years) 0.328 0.039 (0.013 – 0.065) 0.004 
Gender (female) 0.237 0.754 (0.044 – 1.465) 0.038 
Hydration status (ECW:TBW) 0.563 26.476 (17.537 – 35.414) <0.001 
Diabetes -0.080 -0.246 (-0.950 – 0.458) 0.489 
Ischaemic heart disease (absence) -0.367 -1.139 (-1.803 – -0.475) 0.001 
Left ventricular ejection fraction (%) -0.413 -0.067 (-0.102 – -0.033) <0.001 
Global longitudinal strain (%) 0.474 0.220 (0.128 – 0.320) < 0.001 
Diastolic Dysfunction 
Grade 1 
Grade 2 
Grade 3 
0.492 0.883 
0.682 
1.092 
3.419 
(0.523 – 1.243) 
(-0.197 – 1.560) 
(0.187 – 1.998) 
(2.185 – 4.653) 
<0.001 
0.126 
0.019 
<0.001 
Left ventricular mass indexed to BSA 
(g/m2) 
0.510 0.020 (0.012 – 0.028) <0.001 
Pulse wave velocity (m/s) 0.205 0.085 (-0.013 – 0.183) 0.09 
Mean arterial pressure (mmHg) 0.019 0.002 (-0.025 – 0.029) 0.864 
Residual renal function (mL/min) -0.268 -0.141 (-0.260 – -0.021) 0.022 
Beta-blocker use 0.056 0.173 (-0.539 – 0.886) 0.629 
ACE-I or ARB use 0.084 0.270 (-0.471 – 1.011) 0.470 
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Table 3. Multivariable associations of NT-proBNP. Multivariable linear regression models with NT-proBNP as the dependent variable. Model 1 uses 
global longitudinal strain as the measure of left ventricular systolic function while model 2 uses left ventricular ejection fraction as the measure of left 
ventricular systolic function. Unstandardized (β) and standardised (Std β) linear regression coefficients; 95% CI = 95% confidence intervals. BSA = body 
surface area; ECW = extracellular water volume; TBW = total body water. 
 
  Model 1 – Global longitudinal strain as the measure of 
systolic function 
 Model 2 – Left ventricular ejection fraction as the 
measure of systolic function 
β (95% CI) Std β P value R2 β (95% CI) Std β P value R2 
Age (years)  0.019 (-0.002 – 0.040) 0.160 0.08 0.631  0.020 (-0.002 – 0.042) 0.170 0.08 0.597 
Gender (female)  0.430 (-0.092 – 0.957) 0.136 0.10 0.406 (-0.138 – 0.951) 0.128 0.14 
Hydration status (ECW:TBW)  14.726 (5.132 – 24.319) 0.313 <0.01 15.514 (5.476 – 25.552) 0.330 <0.01 
Ischaemic heart disease  -0.081 (-0.647 – 0.485) -0.026 0.78 -0.088 (-0.693 – 0.515) -0.028 0.77 
Global longitudinal strain (%)  0.111 (0.028 – 0.193) 0.233 <0.01 -------- ------------------- -------- ------- 
Left ventricular ejection fraction (%)  ------- ------------------- -------- -------- -0.006 (-0.039 – 0.027) -0.038 0.71 
Diastolic dysfunction 
Grade 1 
Grade 2 
Grade 3 
 0.073 
-0.295 
-0.251 
-0.558 
(-0.291 – 0.436) 
(-1.068 – 0.479) 
(-1.094 – 0.591) 
(-0.737 – 1.853) 
0.040 
-0.095 
-0.078 
0.105 
0.69 
0.45 
0.55 
0.39 
0.052 
-0.268 
-0.289 
0.819 
(-0.290 – 0.477) 
(-1.089 – 0.553) 
(-1.181 – 0.604) 
(-0.540 – 2.178) 
0.05 
-0.086 
-0.089 
0.154 
0.62 
0.51 
0.52 
0.23 
Left ventricular mass indexed to BSA (g/m2)  0.011 (0.003 – 0.019) 0.238 <0.01 0.013 (0.005 – 0.021) 0.339 <0.01 
Residual renal function (mL/min)  -0.086 (-0.173 – 0.000) -0.182 0.05 -0.084 (-0.175 – 0.006) -0.159 0.07 
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Supplement 
Table 1. Multivariable associations of NT-proBNP using non-imputed data. Multivariable linear regression models with NT-proBNP as the 
dependent variable. Model 1 uses global longitudinal strain as the measure of left ventricular systolic function while model 2 uses left ventricular 
ejection fraction as the measure of left ventricular systolic function. Unstandardized (β) and standardised (Std β) linear regression coefficients; 95% CI 
= 95% confidence intervals. BSA = body surface area; ECW = extracellular water volume; TBW = total body water. 
  Model 1 – Global longitudinal strain as the measure of 
systolic function 
 Model 2 – Left ventricular ejection fraction as the 
measure of systolic function 
β (95% CI) Std β P value R2 β (95% CI) Std β P value R2 
Age (years)  0.018 (-0.005 - 0.041) 0.146 0.13 0.653  0.017 (-0.007 - 0.041) 0.141 0.17 0.609 
Gender (female)  0.564 (0.013 - 1.115) 0.172 0.045 0.512 (-0.072 - 1.097) 0.157 0.09 
Hydration status (ECW/TBW)  15.605 (5.431 - 25.779) 0.328 <0.01 16.573 (5.811 - 27.335) 0.349 <0.01 
Ischaemic heart disease  -0.053 (-0.659 - 0.551) -0.017 0.86 -0.064 (-0.713 - 0.585) -0.020 0.84 
Global longitudinal strain (%)  0.119 (0.031 - 0.208) 0.244 <0.01 ------- ------------------- -------- -------- 
Left ventricular ejection fraction (%)  ------- ------------------- -------- -------- -0.008 (-0.046 - 0.030) -0.046 0.68 
Diastolic dysfunction 
Grade 1 
Grade 2 
Grade 3 
 0.028 
-0.492 
-0.458 
0.279 
(-0.358 - 0.414) 
(-1.393 - 0.410) 
(-1.401 - 0.485) 
(-1.111 - 1.668) 
0.014 
-0.152 
-0. 39 
0.053 
0.89 
0.28 
0.34 
0.69 
0.055 
-0.329 
-0.392 
0.669 
( -0.362 - 0.473) 
(-1.276 - 0.618) 
(-1.390 - 0.607) 
(-0.818 - 2.156) 
0.029 
-0.102 
-0.119 
0.128 
0.79 
0.49 
0.44 
0.37 
Left ventricular mass indexed to BSA (g/m2)  0.012 (0.004 - 0.020) 0.294 <0.01 0.014 (0.005 - 0.022) 0.331 <0.01 
Residual renal function (mL/min)  -0.099 (-0.197 - -0.001) -0.167 0.045 -0.098 (-0.201 - 0.005) -0.165 0.06 
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Chapter 9 
 
Pathophysiologic Associations of High Sensitivity Cardiac Troponin-T (hs-cTnT) in the 
Dialysis Population 
 
The following chapter investigates the associations between plasma hs-cTnT concentrations 
and objective measures of hydration state, vascular function, left ventricular mass and 
function, and comorbid conditions in a cohort of prevalent haemodialysis and peritoneal 
dialysis patients. It provides insights into the pathophysiological factors mediating abnormal 
hs-cTnT concentrations in the dialysis population, and consequently how levels should be 
interpreted and what interventions might be considered in any future monitoring strategies. 
 
This chapter is in the process of being submitted for publication. 
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Chapter 9 
 
Pathophysiologic Associations of High Sensitivity Cardiac Troponin-T (hs-cTnT) in the 
Dialysis Population 
 
 
 
INTRODUCTION 
 
Cardiac troponin measurements have an established role in the diagnosis of myocardial injury 
in acute care settings(1), however they may also have a role in risk stratifying dialysis 
patients in the chronic care setting. Up to 94% of physiologically stable and asymptomatic 
dialysis patients have a persistently elevated cardiac troponin concentration(2-4), which has 
been independently associated with the risk of morbidity and mortality in this group(4, 5). 
These findings have spurred calls to use cardiac troponin testing as means of risk stratifying 
dialysis patients(6, 7), and has led to the licensing of cardiac troponins by the United States 
Food and Drug Administration (FDA) for this indication(8). 
 
However, there remains considerable uncertainty regarding the pathophysiological factors 
mediating abnormal troponin concentrations in this population, and consequently what 
interventions might be used to modify this heightened risk. The majority of studies examining 
the associations of cardiac troponins in the dialysis population have reported associations 
with left ventricular hypertrophy(3, 9-13) and/or systolic dysfunction(10, 14, 15), while 
others have reported associations with hydration status(16) and surrogate measures of 
vascular stiffness(15). These contradictory findings can be attributed, at least in part, to 
inadequate adjustment for confounding variables, small sample sizes, use of surrogate 
measures of volume, and insensitive measures of myocardial contractility. 
 
The aim of this study was to determine the associations between high sensitivity cardiac 
troponin-T (plasma hs-cTnT) concentrations and objective measures of hydration state, 
vascular function, left ventricular mass and function, and comorbid conditions in a cohort of 
prevalent haemodialysis and peritoneal dialysis patients. 
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METHODS 
 
Study Design and Patient Recruitment 
A cross-sectional study was conducted between June 2011 and August 2013. The study 
complied with the declaration of Helsinki and received ethics approval from the Metro-South 
Human Research Ethics Committee (HREC/10/QPAH/131), the Greenslopes Research and 
Ethics Committee (Protocol 12/39), and the University of Queensland Medical Research 
Ethics Committee (2011000484). 
 
Participants were recruited from the in-centre haemodialysis and peritoneal dialysis units of a 
public, tertiary care teaching hospital and a private, secondary care hospital in metropolitan 
Brisbane, Australia. Eligible participants identified from an electronic database of all patients 
receiving dialysis were adults (aged ≥18-years) established on maintenance dialysis for ≥90-
days who had a stable dialysis prescription for ≥30-days, and were able and willing to 
provide informed consent. 
 
Patients were excluded if they were planned for living donor renal transplantation within 3-
months of enrolment, had advanced malignancy, were pregnant, were unable to provide 
informed consent or had a contraindication to whole body bioimpedance spectroscopy 
measurement (including a permanent pacemaker, implantable cardiac defibrillator, joint 
replacements, orthopaedic pins, mechanical heart valves and/or limb amputations). 
 
Patient Assessment 
Haemodialysis patients were assessed between 6–8 AM, prior to the mid-week dialysis 
session, and peritoneal dialysis patients were assessed between 8–10 AM on a consistent 
weekday. Patients were instructed to avoid strenuous exercise prior to assessment. 
Assessments entailed a structured clinical interview, physical examination, and review of the 
medical record to ascertain medical history, comorbidities, current treatments and dialysis 
prescription. In addition, patients underwent a standard 12-lead electrocardiogram, whole 
body bioimpedance spectroscopy and blood sampling for measurement of plasma hs-cTnT on 
the same occasion. 
 
For haemodialysis patients, the blood pressure recorded was the median of 12 post-dialysis 
measurements taken at the end of the 12 haemodialysis treatments that preceded the study 
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assessment, while for peritoneal dialysis patients it was the median of 12 home blood 
pressure recordings measured thrice weekly over the 4 weeks prior to the study assessment. 
The median of these blood pressure recordings has been shown to have the greatest 
agreement with 24-hour ambulatory measurements and therefore to be most representative of 
the patient’s blood pressure(17). 
 
Hydration status was assessed using whole-body, multi-frequency bioimpedance analysis 
with the Body Composition Monitor BCM® (Fresenius Medical Care, Asia-Pacific). This 
instrument has been validated in dialysis patients against radioisotope dilution methods with 
reported agreement limits (mean ± standard deviation [SD]) of -0.2±2.3L, -0.4±1.4L and 
0.2±2L for total body water, extra- and intra-cellular water volumes, respectively(18). 
Peritoneal dialysis patients were assessed with peritoneal dialysis fluid in situ, which has 
been previously shown to have no significant or clinically important effect on volume 
measurements compared with an empty peritoneal cavity(19). 
 
Echocardiography and pulse wave velocity measurement 
Echocardiograms and pulse wave velocity measurements were performed within one week of 
plasma hs-cTnT sampling, and for haemodialysis patients they were performed on the non-
dialysis day immediately following the mid-week dialysis treatment to ensure that cardiac 
loading conditions were representative of the patient’s usual volume state. All 
echocardiograms were performed and measured by one of two expert operators blinded to 
patient’s plasma hs-cTnT concentrations and medical history.  
 
Echocardiograms were performed in the left lateral decubitus position using a 3.5MHz 
phased array transducer with harmonic imaging (Vivid7, General Electric-Vingmed Medical 
Systems, Horten, Norway).  Grayscale images from the parasternal long-axis and short axis 
as well as the apical 4-chamber, 2-chamber and apical long axis views were acquired at 
moderate frame rate (50-70 fps) to allow for processing of 2D strain; apical images in the 4-
chamber, 2-chamber and apical long axis were acquired at high frame rate (>120 fps) with a 
colour tissue Doppler overlay to measure colour tissue Doppler velocity, strain and strain 
rate. Doppler measurement of LV inflow, TV inflow and aortic and pulmonary outflow were 
performed using pulsed and continuous wave Doppler.  Colour tissue Doppler measurements 
were performed using pulsed wave Doppler in the medial and lateral LV annulus, tricuspid 
annulus and for all LV segmental measurements. 
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Cine loops of three cardiac cycles were acquired and the measurements averaged.  If patients 
were in atrial fibrillation, 5-7 measurements were averaged.    Left atrial and ventricular 
dimensions were obtained by M-mode according to the American Society of 
Echocardiography Recommendations(20); endocardial borders were traced at end systole and 
end diastole in the apical 4—chamber and 2-chamber views to obtain Simpson’s Rule 
ejection fraction; M-mode LV mass  was calculated using the formula : LV mass =0.8 × 
(1.04[(LV internal dimension + septal wall thickness + posterior wall thickness)3 – LV 
internal dimension3]) + 0.6g, and these were indexed to the patient’s body surface area 
calculated using the Haycock formula (0.024265 x Weight(kg)0.5378 x height(cm)0.3964). 
 
For 2D strain analysis, the endocardial borders were traced at end-systole in the 4-chamber, 
2-chamber and apical long axis views; the software (EchoPac PC BTO 11, General Electric-
Vingmed Medical Systems, Horten, Norway) divided the LV into basal, mid and apical 
segments, and identified unique “speckles” within the myocardium and tracked them frame-
by-frame throughout the cardiac cycle to obtain strain and strain rate curves. Segments that 
did not track properly were manually adjusted or eliminated from the analysis.  Global 
longitudinal strain (GLS) was expressed as a mean of all 18 segments. 
 
The SphygmoCor PX system (AtCor Medical, Australia) was used for measurement of pulse 
wave analysis (augmentation index) and pulse wave velocity (PWV).  Carotid-femoral PWV 
was the only method measured.  The distances between the common carotid artery and the 
suprasternal notch, the suprasternal notch and the umbilicus, and the umbilicus and the 
femoral artery were measured.  Tonometery was performed in the common carotid artery as 
close to the aortic arch as possible and at the femoral artery.  The foot-to-foot times to reach 
the common carotid artery and the femoral artery were then subtracted and pulse wave 
velocity was expressed as metres per second (m/s).  A total of three measurements were taken 
and averaged for analysis. 
 
Plasma hs-cTnT sample collection, storage and analysis 
Blood for measurement of plasma hs-cTnT concentrations was collected in lithium-heparin 
tubes, prior to the commencement of the dialysis treatment for haemodialysis patients. Blood 
samples were centrifuged and plasma separated within 1 hour of collection and then stored at 
-80°C until assayed(21). 
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Plasma hs-cTnT concentration (ng/L) was measured using the Cobas e170 instrument with 
the troponin-T hs kit (Roche Diagnostics, Australia); a monoclonal antibody 
electrochemiluminescence assay which has a reported detection range of 5 – 10,000 ng/L(22). 
Analytic coefficients of variation reported by the analysing laboratory were 2.8% and 1.4% at 
concentrations of 26.2 ng/L and 2210 ng/L respectively in keeping with desired performance 
of the assay(22). 
 
Definitions 
Ischemic heart disease was defined as any of inducible ischaemia on non-invasive cardiac 
stress testing and/or ≥50% stenosis in ≥1 epicardial coronary artery on coronary angiography 
and/or a history of myocardial infarction and/or a history of coronary artery angioplasty, 
stenting or coronary artery bypass grafting. 
 
Systolic dysfunction was classified either as an ejection fraction ≤ 50% measured using 
Simpson’s rule(23) or a global longitudinal strain > -15% which has been associated with 
increased risk of mortality in both the general and dialysis populations(24-26). Diastolic 
dysfunction was graded as absent (normal diastolic function) or assigned a grade from one to 
three reflecting worsening diastolic dysfunction according to a consensus guideline(27). 
Gender specific limits from consensus guidelines were used to classify left ventricular 
hypertrophy as absent, mild, moderate or severe according to left ventricular mass indexed to 
body surface area(20). 
 
Hydration status was expressed as the ratio of extracellular to total body water volumes, and 
overhydration defined as a ratio two standard deviations above the mean age- and gender- 
matched ratio in the normal population(19, 28). 
 
 
Statistical analysis 
Categorical variables are presented as frequencies and percentages, and continuous variables 
as either mean ± standard deviation if normally distributed or as median and interquartile 
range if non-normally distributed. Plasma hs-cTnT concentrations were logarithmically 
transformed for correlation, univariable and multivariable linear regression analyses. 
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Bivariate correlation between log transformed plasma hs-cTnT concentrations and 
independent variables were analysed using pairwise correlation. 
 
Thirteen participants had at least one missing measurement for either global longitudinal 
strain (n=1), left ventricular mass (n=7), and/or pulse wave velocity (n=12) which could not 
be measured due to body habitus or arrhythmia. Examination of the missing data 
demonstrated an arbitrary pattern and missing values were assumed to be missing at random. 
Multiple imputation was used to impute missing values using a multivariable normal model 
with 20 imputations(29). Univariable and multivariable linear regression analyses were 
performed using imputed data as the primary analyses, and repeated using non-imputed data 
as a sensitivity analysis (supplement). Differences between the results of the two analyses are 
presented and discussed below.  
 
Independent variables for inclusion in the linear regression models were chosen based on 
published associations with plasma hs-cTnT. Independent variables identified as being 
significant at the 5% level (P <0.05) from the univariable analyses were analysed in the 
multivariable linear regression model. Global longitudinal strain and ejection fraction are 
both measures of left ventricular contractility with differing sensitivity, thus they were used 
individually as independent variables in two separate multivariable linear regression analyses. 
Regression diagnostics were performed for both multivariable models and were satisfactory. 
Semi-partial correlations were calculated for independent variables to determine increment to 
coefficient of determination (R2). All analyses were performed using Stata/MP 12.1 (College 
Station, TX, USA). 
 
RESULTS 
 
Participant characteristics 
Seventy eight prevalent patients were recruited between June 2011 and January 2014 from 
the haemodialysis (n=47) and peritoneal dialysis (n=31) units of the participating institutions. 
Their baseline characteristics are shown in Table 1. Cardiovascular risk factors and 
established cardiovascular disease were highly prevalent among the study cohort, including 
diabetes mellitus (45%), hypertension (100%), current or former smoking (61%), ischaemic 
heart disease (41%) and peripheral and/or cerebrovascular disease (16%). In addition, a 
substantial proportion of participants had evidence of cardiomyopathy on echocardiography 
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including left ventricular hypertrophy (67%) and/or diastolic dysfunction (84%). The 
prevalence of systolic dysfunction differed according to the measure of left ventricular 
systolic function used with 32% of the cohort having an ejection fraction under 50%,  while 
56% of the cohort had an abnormal global longitudinal strain measurement of > -15%. Fifty 
seven percent of males and 71% of females in the study cohort were overhydrated on 
bioimpedance analysis. Baseline plasma hs-cTnT concentrations demonstrated a right skewed 
frequency distribution with a median of 51 ng/L (interquartile range 32-91 ng/L). Ninety six 
percent of the study cohort had a plasma hs-cTnT concentration above the currently accepted 
assay upper reference limit of 14 ng/L(22), and 84% of males and 100% of women (91% of 
the cohort) had a plasma hs-cTnT exceeding recently proposed age and gender based upper 
reference limits(30). 
 
Bivariate correlation and univariable linear regression analyses are shown in Table 2 and 
Figure 1. These analyses demonstrated significant direct correlations between plasma hs-
cTnT concentrations and age, hydration status, a history of either diabetes mellitus or 
ischaemic heart disease, global longitudinal strain and pulse wave velocity. In addition, a 
significant inverse correlation was demonstrated between plasma hs-cTnT concentrations and 
left ventricular ejection fraction. There were no significant associations between plasma hs-
cTnT concentrations and either left ventricular mass indexed to body surface area nor with 
central or peripheral augmentation indices.  
  
Multivariable linear regression 
Two multivariable linear regression models were used to analyse associations between 
plasma hs-cTnT concentrations, significant independent variables identified from the 
univariable analyses, and left ventricular mass indexed to body surface area which was 
included in the multivariable models a priori as numerous published studies have suggested it 
is significantly associated with plasma hs-cTnT concentrations. The two multivariable 
models differed in terms of the measure of left ventricular systolic function used, with model 
1 using global longitudinal strain and model 2 using left ventricular ejection fraction (table 
3). Plasma hs-cTnT concentrations were significantly associated with both hydration status 
and pulse wave velocity in both models, although a significant association with pulse wave 
velocity was only demonstrated in the analysis using imputed data. Neither multivariable 
model demonstrated a significant association with left ventricular systolic function. 
Hydration status explained the greatest proportion of the variation in plasma hs-cTnT 
  
 
204 
 
concentrations (standardised β = 0.379, p<0.01), and led to a significant improvement in the 
coefficient of determination of the multivariable model with an increment to R2 of 0.109, P < 
0.01 (Figure 2). 
 
DISCUSSION 
 
This study demonstrated an independent association between plasma hs-cTnT concentrations 
and hydration status, as well as a possible independent association with vascular stiffness 
assessed using pulse wave velocity in prevalent dialysis patients. These findings improve our 
understanding of potential pathophysiological mechanisms underpinning chronically elevated 
plasma hs-cTnT concentrations and their associated adverse outcomes in the dialysis 
population. 
 
Several mechanisms have been posited to explain the release of cardiac troponins in 
overhydrated states including the stimulation of stretch sensitive integrins in viable 
myocardial fibrils(31), stretch- and/or strain-induced cardiomyocyte apoptosis(32), and 
volume overload-induced sub-endocardial ischaemia(33). Overhydration in dialysis patients  
has been shown to result in cardiac pressure overload even in the absence of established 
cardiomyopathy(34), and may stimulate cardiac troponin release by some or all of the 
aforementioned mechanisms.  
 
An independent association between plasma troponin T and hydration status in dialysis 
patients has only been reported in one previous investigation. In their study of 74 
haemodialysis patients, Park and colleagues reported an independent association between 
troponin T measured using a third generation assay and hydration status assessed using 
bioimpedance spectroscopy (β = 0.37, P < 0.01)(16). However, this study was significantly 
limited by the fact that participants did not undergo echocardiography, with the only 
independent cardiac variable included in the multivariable analysis being left ventricular 
hypertrophy assessed using electrocardiography. The insensitivity of the latter measure, and 
the lack of inclusion of echocardiographic measures of systolic and/or diastolic function cast 
doubt on the significance of this study’s findings. The study presented here addresses these 
limitations through its use of standardised echocardiography with measurement of both 
established and novel cardiac structural and functional indices. 
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Overhydration is as an independent predictor of mortality in the dialysis population(35) and 
provides a partial explanation for the adverse prognosis portended by elevated plasma hs-
cTnT concentrations in this group. Hydration status in dialysis patients is currently assessed 
using either clinical examination or devices, such as bioimpedance or lung ultrasound, which 
are variously limited by their inaccuracy, subjectivity and/or cost(36). The association 
between plasma hs-cTnT and hydration status reported in this study raises the prospect that 
plasma hs-cTnT testing could be used to monitor hydration status in dialysis populations, 
although the accuracy of such a strategy and its impact on patient outcomes need to be 
established before it can be routinely adopted in clinical practice(37). 
 
This study also demonstrated an independent association between plasma hs-cTnT 
concentrations and pulse wave velocity in analyses using imputed data. This is a novel and 
plausible association. Pulse wave velocity measures the velocity of the propagated cardiac 
pulse wave which is a function of vascular compliance(38). Vascular calcification in the 
dialysis population increases vascular stiffness(39) resulting in an increase in pulse wave 
velocity which has in turn been independently associated with the risk of mortality in this 
group(40). This heightened mortality risk is thought to be related to an increase in cardiac 
afterload leading to ventricular hypertrophy, and from an earlier reflection of the cardiac 
pulse wave which impairs coronary diastolic flow(41, 42). Both of these physiological 
alterations may result in myocardial ischaemia and release of cardiac troponins. The 
association between cardiac troponin and vascular stiffness in the dialysis population has not 
been previously reported, but is lent support the findings of Artunc et al(15) who reported an 
independent association between high sensitivity troponin I and pulse pressure in dialysis 
patients. 
 
However, it is important to view the association with pulse wave velocity reported in this 
study with caution as a significant association could not be demonstrated between plasma hs-
cTnT and other measures of vascular dysfunction, including central and peripheral 
augmentation indices, and because the association with pulse wave velocity was only 
demonstrated on multivariable analysis using imputed data. As such, the association between 
plasma hs-cTnT and vascular stiffness should be considered preliminary until it is either 
confirmed or refuted in future studies. 
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The majority of published studies investigating the pathophysiologic associations of cardiac 
troponin in the dialysis population have reported an independent association with left 
ventricular hypertrophy(3, 9-13) and/or left ventricular systolic dysfunction(10, 14, 15). 
However, these studies were limited by their lack of control for confounding variables, 
particularly hydration status which was not measured in most of these studies. In this study, 
significant associations between plasma hs-cTnT and cardiac structural and functional indices 
were only demonstrated in univariable linear regression analyses and multivariable analyses 
that did not include hydration status. The inclusion of hydration status as independent 
variable in the multivariable models resulted in cardiomyopathic indices losing their 
significance and led to a significant improvement in the coefficient of determination of the 
multivariable model. 
 
This study has several strengths including the its use of the latest generation high sensitivity 
troponin assays to minimise measurement error, standardisation of plasma hs-cTnT sampling, 
handling and storage to minimise pre-analytic variation, its use of sensitive and objective 
measures of myocardial contractility (global longitudinal strain) and volume (whole body 
bioimpedance spectroscopy), and its inclusion of both haemodialysis and peritoneal-dialysis 
patients thereby broadening the generalizability of its findings. Nevertheless, this study had 
two principal limitations including its sample size, which restricted the number of 
independent variables that could be explored in the multivariable linear regression models, 
and the lack of measurement of inflammatory markers which have been associated with 
plasma hs-cTnT concentrations in previous dialysis population studies. 
 
Conclusion 
This study demonstrated that plasma hs-cTnT concentrations in prevalent haemodialysis and 
peritoneal dialysis patients were independently associated with hydration status, and possibly 
pulse wave velocity. These findings raise the possibility that plasma hs-cTnT testing could be 
used to monitor hydration status in dialysis patients, however longitudinal studies are needed 
to determine the accuracy of such a strategy and its impact on patient outcomes before it can 
be routinely implemented in clinical practice. In addition, further studies are needed to either 
confirm or refute an association between plasma hs-cTnT and vascular stiffness in the 
dialysis population. 
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Figure Legends 
 
Figure 1. Bivariate correlation between plasma hs-cTnT concentrations and hydration 
status, pulse wave velocity, and left ventricular mass and systolic function. Scatter plots, 
regression line and 95% confidence interval (grey area). BSA = body surface area; ECW = 
extracellular water volume; LV = left ventricular; r = correlation coefficient; TBW = total 
body water. 
 
Figure 2. Proportion of variation in plasma hs-cTnT concentrations explained by 
hydration status, and pulse wave velocity. Increment to the coefficient of determination 
(R2) due to pulse wave velocity (semi-partial correlation = 0.032, P < 0.01) and hydration 
status (semi-partial correlation = 0.109, P < 0.01). DM = diabetes mellitus, IHD = ischaemic 
heart disease; GLS = global longitudinal strain; LVMI = left ventricular mass indexed to 
body surface area.
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Figure 1
r = 0.494  
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Table 1. Baseline characteristics of the study cohort. Abbreviations: ACE-I = Angiotensin 
converting enzyme inhibitor; ARB = Angiotensin type-1 receptor blocker; D/P creatinine = ratio of 
creatinine concentration in dialysate to plasma; Kt/V = dialysis urea clearance; plasma hs-cTnT = 
high sensitivity cardiac troponin-T; URL = upper reference limit. 
Characteristic Value (n=78) 
Male gender n (%) 50 (64) 
Age  
Mean ± SD (years)  
Age distribution n (%) 
18 – 49  
50 – 69  
70 – 79  
80 – 90 
 
64±13 
 
12 (15) 
35 (45) 
20 (26) 
11 (14) 
Haemodialysis n (%) 
Dialysis sessions per week (n) 
Duration of dialysis session (hours) 
Single pool Kt/V 
Interdialytic weight gain (kg) 
Interdialytic weight gain relative to estimated  
dry weight (%) 
48 (61) 
3 
4.7±0.7 
1.58±0.3 
1.83 (1.40 – 2.23) 
2.4±1.1 
 
Peritoneal dialysis n (%) 
Volume of peritoneal dialysis solution exchanged 
per 24 hours (L) 
Four hour D/P creatinine 
Weekly Kt/V 
30 (39) 
8 (8 – 8.9) 
 
0.72±0.1 
1.93 (1.76 – 2.25) 
Time on dialysis (years) 6 (4-9.5) 
  
 
216 
 
Body Mass Index (kg/m2) 29.3±6.4 
Systolic blood pressure (mmHg) 128±20 
Diastolic blood pressure (mmHg) 70±13 
Diabetes mellitus n (%) 35 (45) 
Current or former smoker n (%) 48 (61) 
Ischemic heart disease n (%) 32 (41) 
Peripheral- and/or cerebro-vascular disease n (%) 13 (16) 
Hydration status 
Ratio of extracellular to total body water 
Proportion overhydrated n (%) 
Male 
Female 
 
0.49±0.03 
 
29 (57) 
20 (71) 
Residual renal function (mL/min) 0 (0-3) 
Left ventricular structure and function 
Left ventricular mass indexed to BSA (g/m2) 
Left ventricular hypertrophy n (%) 
Nil 
Mild 
Moderate 
Moderate 
Ejection fraction (%) 
Global longitudinal strain (%) 
Left ventricular systolic dysfunction n (%) 
Ejection fraction 
Global longitudinal strain 
Diastolic dysfunction (%) 
 
119 (97-146) 
 
26 (33) 
10 (13) 
15 (19) 
27 (35) 
54 (49-62) 
-14±3.2 
 
25 (32) 
44 (56) 
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Nil 
Grade 1 
Grade 2 
Grade 3 
12 (16) 
33 (42) 
26 (33) 
7 (9) 
Pulse wave velocity (m/s) 9.4 (8.2-11.8) 
Antihypertensive agents 
Median number of anti-hypertensive agents 
Proportion on beta-blocker (%) 
Proportion on ACE-I or ARB (%) 
 
1(1-2) 
45 (58) 
27 (34) 
Plasma hs-cTnT (ng/L) 
Median (IQR) 
Distribution by age and gender specific URL n (%) 
Plasma hs-cTnT > 14 ng/L 
Males < 50 years 
Females < 65 years  
Plasma hs-cTnT > 17 ng/L 
Males 50 – 64 years 
Females ≥ 65 years 
Plasma hs-cTnT > 31 ng/L 
Males ≥ 65 years 
 
51 (32-91) 
 
 
7 (78%) 
14 (100%) 
 
13 (100%) 
14 (100%) 
 
22 (79%) 
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Table 2. Univariable associations of plasma hs-cTnT. Linear regression coefficients (β) and 
bivariate correlation coefficients (r) of plasma hs-cTnT and dependent variables. ACE-I = 
Angiotensin converting enzyme inhibitor; ARB = Angiotensin type-1 receptor blocker; BSA = 
body surface area; ECW = extracellular water volume; TBW = total body water. 
 
Variable r β   (95% CI) P value 
Age (years) 0.293 0.015 (0.004 – 0.028) 0.01 
Gender (female) -0.081 -0.119 (-0.453 – 0.215) 0.48 
Hydration status (ECW/TBW) 0.494 10.64
3 
(6.341 – 14.945) <0.001 
Diabetes mellitus (absence) -0.334 -0.470 (-0.775 – -0.166) 0.003 
Ischaemic heart disease status (absence) -0.290 -0.411 (-0.725 – -0.099) 0.01 
Left ventricular ejection fraction (%) -0.233 -0.017 (-0.034 – -0.001) 0.04 
Global longitudinal strain (%) 0.359 0.070 (0.028 – 0.111) 0.001 
Diastolic Dysfunction 
Grade 1 
Grade 2 
Grade 3 
0.191 0.157 
0.310 
0.327 
0.608 
(-0.029 – 0.342) 
(-0.163 – 0.783) 
(-0.161 – 0.815) 
(-0.057 – 1.273) 
0.10 
0.20 
0.19 
0.07 
Left ventricular mass indexed to BSA 
(g/m2) 
0.231 0.004 (-0.004 – 0.008) 0.08 
Pulse wave velocity (m/s) 0.368 0.068 (0.025 – 0.111) 0.003 
Central augmentation index 0.034 0.001 (-0.006 – -0.008) 0.78 
Peripheral augmentation index 0.140 0.006 (-0.004 – 0.016) 0.27 
Mean arterial pressure (mmHg) -0.061 -0.003 (-0.015 – 0.009) 0.59 
Residual renal function (mL/min) -0.086 -0.021 (-0.077 – 0.035) 0.46 
Beta-blocker use 0.143 0.204 (-0.119 – 0.527) 0.52 
ACEI / ARB use 0.012 0.017 (-0.323 – 0.357) 0.92 
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Table 3. Multivariable associations of plasma hs-cTnT. Multivariable linear regression models with plasma hs-cTnT as the dependent variable. Model 1 
uses global longitudinal strain as the measure of left ventricular systolic function while model 2 uses left ventricular ejection fraction as the measure of left 
ventricular systolic function. Unstandardized (β) and standardised (Std β) linear regression coefficients; 95% CI = 95% confidence intervals. BSA = body 
surface area; ECW = extracellular water volume; TBW = total body water. 
 
 
 
 
 
 
 
 
 
  Model 1 – Global longitudinal strain as the measure of 
systolic function 
 Model 2 – Left ventricular ejection fraction as the 
measure of systolic function 
β (95% CI) Std β P value R2 β (95% CI) Std β P value R2 
Age (years)  -0.001 (-0.013 - 0.012) -0.010 0.93 0.407  -0.001 (-0.013 - 0.013) -0.001 0.99 0.379 
Hydration status (ECW/TBW)  8.156 (2.930 - 13.381) 0.379 <0.01 8.045 (2.680 - 13.409) 0.374 <0.01 
Ischaemic heart disease  0.048 (-0.268 - 0.363) 0.034 0.77 0.069 (-0.263 - 0.400) 0.048 0.68 
Global longitudinal strain (%)  0.038 (-0.005 - 0.080) 0.192 0.09 ------- ------------------- -------- ------- 
Left ventricular ejection fraction (%)  ------- -------------------- --------- --------  -0.005 (-0.023 - 0.012) -0.068 0.56 
Diabetes mellitus  -0.173 (-0.466 - 0.120) -0.123 0.24  -0.199 (-0.500 - 0.100) -0.142 0.19 
Pulse wave velocity (m/s)  0.045 (0.002 - 0.087) 0.250 0.04  0.052 (0.009 - 0.095) 0.290 0.02 
Left ventricular mass indexed to BSA (g/m2)  0.002 (-0.002 - 0.006) 0.099 0.37  0.002 (-0.002 - 0.007) 0.130 0.75 
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SUPPLEMENT 
Table 1. Multivariable associations of plasma hs-cTnT using non-imputed data. Multivariable linear regression models with plasma hs-cTnT as the dependent 
variable. Model 1 uses global longitudinal strain as the measure of left ventricular systolic function while model 2 uses left ventricular ejection fraction as the measure of 
left ventricular systolic function. Unstandardized (β) and standardised (Std β) linear regression coefficients; 95% CI = 95% confidence intervals. BSA = body surface 
area; ECW = extracellular water volume; TBW = total body water. 
 
 
 
 
 
  Model 1 – Global longitudinal strain as the measure of 
systolic function 
 Model 2 – Left ventricular ejection fraction as the 
measure of systolic function 
β (95% CI) Std β P value R2 β (95% CI) Std β P value R2 
Age (years)  0.002 (-0.011 - 0.016) 0.049 0.72 0.368  0.002 (-0.011 - 0.015) 0.048 0.73 0.366 
Hydration status (ECW/TBW)  8.835 (2.925 - 14.747) 0.445 <0.01 8.998 (3.048 - 14.948) 0.453 <0.01 
Ischaemic heart disease  0.038 (-0.325 - 0.402) 0.028 0.83 0.034 (-0.333 - 0.400) 0.025 0.85 
Global longitudinal strain (%)  0.012 (-0.041 - 0.064) 0.053 0.66 ------- ------------------- -------- ------- 
Left ventricular ejection fraction (%)  ------- -------------------- --------- --------   0.001 (-0.018 - 0.020) 0.015 0.91  
Diabetes mellitus  -0.079 (-0.426 - 0.267) -0.058 0.65   -0.083 (-0.429 - 0.263) -0.061 0.63  
Pulse wave velocity (m/s)  0.038 (-0.009 - 0.086) 0.208 0.11   0.040 (-0.006 - 0.086) 0.218 0.09  
Left ventricular mass indexed to BSA (g/m2)  0.001 (-0.003 - 0.006) 0.63 0.63   0.001 (-0.003 - 0.006) 0.080 0.55  
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Chapter 10 
 
 
Longitudinal correlation of the amino terminal fragment of pro-B-type natriuretic peptide (NT-
proBNP) and hydration status in dialysis patients. 
 
This chapter investigates whether NT-proBNP and hydration status assessed using bioimpedance 
analysis are independently correlated over time and consequently whether NT-proBNP testing can be 
used to monitor hydration status in dialysis patients. This chapter provides important insights into 
potential interventional targets for future monitoring strategies. 
 
The following chapter is in the process of being finalised for publication. 
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Chapter 10 - Longitudinal correlation of the amino terminal fragment of the pro-B-type 
natriuretic peptide (NT-proBNP) and hydration status in dialysis patients. 
 
Word count: 2909 
 
INTRODUCTION 
Overhydration is common among patients on maintenance dialysis therapy(1), contributes to 
the genesis and progression of cardiomyopathy(2) and has been independently associated 
with the risks of morbidity and mortality in this group(1, 3). However, current methods for 
the assessment of hydration status are suboptimal and rely principally on clinical examination 
which is inaccurate and has high interobserver variability(4). The introduction of 
technologies such as bioimpedance(5) and lung ultrasound(6), have improved the accuracy of 
hydration assessment, although these devices incur significant personnel and equipment costs 
thereby limiting their universal and/or regular application. 
 
The amino terminal fragment of the pro-B-type natriuretic peptide (NT-proBNP) is an 
inactive peptide secreted from the myocardium in response to cardiac stretch and/or strain(7) 
such as occur during volume overload(8). Furthermore, plasma NT-proBNP has been 
independently associated with risks of incident heart failure(9) and cardiovascular death in 
dialysis patients(10), raising the possibility that NT-proBNP testing may have a role in the 
monitoring of hydration status of dialysis patients. However, the studies investigating the 
correlation of NT-proBNP and volume status in dialysis patients have so far yielded 
conflicting results(11). The majority of these studies have been cross-sectional in design(12-
17) with limited applicability to clinical longitudinal monitoring, whereas preliminary 
longitudinal studies have been limited by their use of surrogate measures of volume 
status(18-24), small sample sizes(19-23), limited numbers of repeated measures(22-25) and 
short-term follow-up(22-24). 
 
The aim of this study was to investigate the longitudinal correlation of plasma NT-proBNP 
and hydration status assessed using bioimpedance spectroscopy in a cohort of prevalent 
haemodialysis and peritoneal dialysis patients and to determine whether this correlation was 
affected by dialysis modality and/or cardiac functional or structural abnormalities. 
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METHODS 
 
Study Design and Patient Recruitment 
A prospective, longitudinal cohort study was conducted between June 2011 and January 
2015. The study complied with the declaration of Helsinki and received ethics approval from 
the Metro-South Human Research Ethics Committee (HREC/10/QPAH/131), the 
Greenslopes Research and Ethics Committee (Protocol 12/39), and the University of 
Queensland Medical Research Ethics Committee (2011000484). 
 
Participants were recruited from the in-centre haemodialysis and peritoneal dialysis units of a 
public, tertiary-care teaching hospital and a private, secondary-care hospital in metropolitan 
Brisbane, Australia. Eligible participants identified from an electronic database of all patients 
receiving dialysis were adults (aged ≥18 years) established on maintenance dialysis for ≥90 
days who had a stable dialysis prescription for ≥30 days, and were able and willing to provide 
informed consent. 
Patients were excluded if they were planned for living donor renal transplantation within 3 
months of enrolment, had advanced malignancy, were pregnant, were unable to provide 
informed consent or had a contraindication to whole-body bioimpedance spectroscopy 
measurement (including a permanent pacemaker, implantable cardiac defibrillator, joint 
replacements, orthopaedic pins, mechanical heart valves and/or limb amputations). 
 
Patient Assessment 
Patients were assessed at baseline and thereafter at monthly intervals for up to 24 months. 
Haemodialysis patients were assessed prior to the mid-week dialysis session, while peritoneal 
dialysis patients were assessed on a consistent weekday throughout the study. Patients were 
instructed to avoid strenuous exercise prior to assessment, and were assessed at the same time 
of day throughout the study to avoid fluctuations in NT-proBNP concentrations related to 
diurnal variation. Patient assessments entailed a structured clinical interview, physical 
examination, and review of the medical record to ascertain medical history, comorbidities, 
current treatments and dialysis prescription. In addition, patients underwent a standard 12-
lead electrocardiogram, whole body bioimpedance spectroscopy and blood sampling for 
measurement of NT-proBNP on the same occasion. 
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For haemodialysis patients, the blood pressure recorded was the median of 12 post-dialysis 
measurements taken at the end of the 12 haemodialysis treatments that preceded the study 
assessment, while for peritoneal dialysis patients it was the median of 12 home blood 
pressure recordings measured thrice weekly over the 4 weeks prior to the study assessment. 
The median values of these blood pressure recordings have been shown to have the greatest 
agreement with 24-hour ambulatory measurements and therefore to be most representative of 
the patients’ blood pressures(26). 
 
Whole body multi-frequency bioimpedance spectroscopy 
Hydration status was assessed using whole-body, multi-frequency bioimpedance analysis 
with the Body Composition Monitor BCM® (Fresenius Medical Care, Asia-Pacific). This 
instrument has been validated in dialysis patients against radioisotope dilution methods with 
reported agreement limits (mean ± standard deviation [SD]) of -0.2±2.3L, -0.4±1.4L and 
0.2±2L for total body water, extra- and intra-cellular water volumes, respectively(5). In 
addition, this instrument has been shown to have a detection limit for change in extracellular 
volume (mean ± SD) of 0.87±0.64L(27). Peritoneal dialysis patients were assessed with 
peritoneal dialysis fluid in situ, as this has been previously shown to have no significant or 
clinically important effect on volume measurements compared with an empty peritoneal 
cavity(28). 
 
NT-proBNP sample collection, storage and analysis 
Blood for measurement of NT-proBNP concentrations was collected in lithium-heparin tubes 
prior to the commencement of the dialysis treatment for haemodialysis patients. Blood 
samples were centrifuged and plasma separated within 1 hour of collection and then stored at 
-80°C until assayed(29). Plasma NT-proBNP concentration (pg/mL) was measured using a 
twin-antibody electrochemiluminescence assay on the Elecsys 2010 instrument (Roche 
Diagnostics, Australia), which has a reported analytical detection range of 5–35,000 pg/mL. 
Analytic coefficients of variation reported by the analysing laboratory were 2.9% and 1.8% at 
concentrations of 134 pg/mL and 4534 pg/mL, respectively in keeping with desired 
performance of the assay(30, 31). 
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Echocardiography 
All of the participants in the cohort study were invited to participate in an echocardiographic 
sub-study.  Echocardiograms were performed within one week of baseline NT-proBNP 
sampling, and for haemodialysis patients they were performed on the non-dialysis day 
immediately following the mid-week dialysis treatment to ensure that cardiac loading 
conditions were representative of the patient’s usual volume state. Echocardiograms were 
performed and measured by one of two expert operators blinded to the patient’s NT-proBNP 
concentrations, hydration status and medical history.  
 
Echocardiograms were performed in the left lateral decubitus position using a 3.5MHz 
phased array transducer with harmonic imaging (Vivid7, General Electric-Vingmed Medical 
Systems, Horten, Norway).  Grayscale images from the parasternal long-axis and short axis 
as well as the apical 4-chamber, 2-chamber and apical long axis views were acquired at 
moderate frame rate (50-70 fps) to allow for processing of 2D strain. Apical images in the 4-
chamber, 2-chamber and apical long axis were acquired at high frame rate (>120 fps) with a 
colour tissue Doppler overlay to measure colour tissue Doppler velocity, strain and strain 
rate. Doppler measurement of left ventricular (LV) inflow, tricuspid valve (TV) inflow and 
aortic and pulmonary outflow were performed using pulsed and continuous wave Doppler.  
Colour tissue Doppler measurements were performed using pulsed wave Doppler in the 
medial and lateral LV annulus, tricuspid annulus and for all LV segmental measurements. 
 
Cine loops of three cardiac cycles were acquired and the measurements averaged.  If patients 
were in atrial fibrillation, 5-7 measurements were averaged. Left atrial and ventricular 
dimensions were obtained by M-mode according to the American Society of 
Echocardiography Recommendations(32). Endocardial boarders were traced at end systole 
and end diastole in the apical 4-chamber and 2-chamber views to obtain Simpson’s Rule 
ejection fraction. M-mode LV mass was calculated using the formula : LV mass =0.8 × 
(1.04[(LV internal dimension + septal wall thickness + posterior wall thickness)3 – LV 
internal dimension3]) + 0.6g, and was indexed to the patient’s body surface area calculated 
using the Haycock formula (0.024265 x Weight(kg)0.5378 x height(cm)0.3964). 
 
For 2D strain analysis, the endocardial boarders were traced at end-systole in the 4-chamber, 
2-chamber and apical long axis views; the software (EchoPac PC BTO 11, General Electric-
Vingmed Medical Systems, Horten, Norway) divided the LV into basal, mid and apical 
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segments, and identified unique “speckles” within the myocardium and tracked them frame-
by-frame throughout the cardiac cycle to obtain strain and strain rate curves.  Segments that 
did not track properly were manually adjusted or eliminated from the analysis.  Global 
longitudinal strain (GLS) was expressed as a mean of all 18 segments. 
 
Definitions 
Ischemic heart disease was defined as any of inducible ischaemia on non-invasive cardiac 
stress testing and/or ≥50% stenosis in ≥1 epicardial coronary artery on coronary angiography 
and/or a history of myocardial infarction and/or a history of coronary artery angioplasty, 
stenting or coronary artery bypass grafting. 
 
Systolic dysfunction was classified either as a global longitudinal strain > -15% which has 
been associated with increased risk of mortality in both the general and dialysis 
populations(33-35). Diastolic dysfunction was graded as absent (normal diastolic function) or 
assigned a grade from one to three reflecting worsening diastolic dysfunction according to a 
consensus guidelines(36). Gender-specific limits from consensus guidelines were used to 
classify left ventricular hypertrophy as absent, mild, moderate or severe according to left 
ventricular mass indexed to body surface area(32). 
Hydration status was expressed as the ratio of extracellular to total body water volumes, and 
overhydration defined as a ratio two standard deviations above the mean age- and gender-
matched ratio in the normal population(28, 37). 
 
Statistical analysis 
Categorical variables were presented as frequencies and percentages, and continuous 
variables as mean ± standard deviation if normally distributed and as median and interquartile 
range if non-normally distributed. NT-proBNP concentrations demonstrated a right skewed 
distribution and were logarithmically transformed. 
 
Participants with less than three paired NT-proBNP and hydration status measurements were 
excluded from the correlation analysis as they skewed the correlation. The correlation 
between the logarithm of NT-proBNP and hydration status (expressed as the ratio of 
extracellular water to total body water [ECW:TBW]) for each participant was calculated 
using Pearson’s correlation at each time point. The correlation coefficient and associated 
standard error for each participant were then transformed using the Fisher’s transformation. A 
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random effects meta-analysis was then conducted on the Fisher’s transformed correlation 
coefficients across all participants, and the resulting combined estimate was then back-
transformed to determine the combined correlation coefficient and its 95% confidence 
interval(38, 39). 
 
To investigate if the correlation between NT-proBNP and hydration status differed according 
to dialysis modality, left ventricular hypertrophy, systolic and/or diastolic function, the entire 
cohort was divided according to dialysis modality and the echocardiographic study subgroup 
was divided according to the presence or absence of systolic dysfunction measured using 
global longitudinal strain, grade of diastolic dysfunction and severity of left ventricular 
hypertrophy. The correlation coefficients in the subgroups were compared to the referent 
subgroup category using meta-regression. 
 
RESULTS 
 
Participant and echocardiographic characteristics 
One hundred and three patients comprising 68 haemodialysis and 35 peritoneal dialysis 
patients were enrolled in the study and 78 of these patients also participated in the 
echocardiographic sub-study. The baseline characteristics of the whole cohort and the 
echocardiographic sub-study cohort were comparable and are shown in Table 1. 
Cardiovascular risk factors and established cardiovascular disease were highly prevalent 
among the study cohort, including diabetes mellitus (43%), hypertension (96%), current or 
former smoking (57%), ischaemic heart disease (39%) and peripheral and/or cerebrovascular 
disease (15%). A substantial proportion of the cohort was prescribed a beta-blocker (54%) 
and/or a angiotensin converting enzyme inhibitor / angiotensin type-1 receptor blocker 
(31%). 
 
Echocardiographic abnormalities were common among the sub-study cohort including left 
ventricular hypertrophy (67%) and diastolic dysfunction (84%). The prevalence of systolic 
dysfunction differed according to the measure of left ventricular systolic function used with 
32% of the cohort having an ejection fraction ≤ 50%,  while 56% of the cohort had a global 
longitudinal strain measurement > -15%. 
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Correlation between plasma NT-proBNP and hydration status 
At baseline, the median plasma NT-proBNP concentration was 2299 pg/mL (IQR 956-
11697), the mean (±SD) ratio of extracellular water volume to total body water volume was 
0.49±0.04, and 48% of males and 53% of females were overhydrated. Participants were each 
reviewed for a median of 14 months (IQR 9-22) providing a total of 1431 paired 
bioimpedance and plasma NT-proBNP measurements. Ten participants with 14 
corresponding paired measurements were excluded from the analysis as these participants 
each had less than 3 measurements performed. Meta-analysis of the correlation coefficients 
calculated for each analysed participant yielded a significant correlation coefficient of 0.273 
(95% CI 0.200-0.342,  I2 = 48.3%) between plasma NT-proBNP concentration and 
ECW:TBW. Time series plots of plasma NT-proBNP concentration and ECW:TBW ratio for 
three study participants are shown in Figure 1. 
 
Meta-regression was used to compare the correlation coefficients of plasma NT-proBNP and 
hydration status between subgroups of dialysis modality, left ventricular function, grade of 
diastolic dysfunction and severity of left ventricular hypertrophy. The correlation coefficients 
remained significant for all subgroups and did not differ between categories within a 
subgroup. 
 
DISCUSSION 
 
The present study is the largest and most comprehensive examination to date of the 
longitudinal correlation between plasma NT-proBNP and hydration status in prevalent 
haemodialysis and peritoneal dialysis patients. This study demonstrated that NT-proBNP 
concentrations measured at monthly intervals were significantly and directly correlated with 
changes in hydration status assessed using bioimpedance spectroscopy and were independent 
of dialysis modality, and cardiac structural and functional abnormalities. 
 
The physiological basis for this correlation lies in the fact that overhydration in dialysis 
patients is able to cause ventricular pressure overload which in turn results in stretch and/or 
strain of myocardial fibrils thereby stimulating the secretion of B-type natriuretic peptide 
(BNP) and NT-proBNP in equimolar amounts(8, 40). Of note, ventricular pressure overload 
can occur in the absence of established cardiomyopathy and improves with ultrafiltration 
during the dialysis procedure(8). The findings of this study suggest that monthly NT-proBNP 
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testing may have roles in identifying and risk stratifying dialysis patients with worsening 
overhydration who might benefit from further specific assessment  and management, and in 
monitoring their response to optimization treatment. Compared to a bioimpedance / lung 
ultrasound monitoring strategy alone, NT-proBNP testing would have the added advantage of 
not only identifying overhydration but also quantifying its impact on the risk of adverse 
cardiac events(10, 41, 42). 
 
To date, the relationship between plasma NT-proBNP and hydration status in dialysis patients 
has been controversial(11) with studies yielding conflicting findings(12-16, 19, 20, 25, 43, 
44). However, the vast majority of these investigations have been cross-sectional in 
design(12-14, 16, 43, 44) and therefore of limited direct relevance to clinical monitoring 
which requires demonstration of a longitudinal correlation between NT-proBNP and 
hydration status. A small number of longitudinal studies have also examined the association 
between NT-proBNP concentrations and surrogate measures of volume over the short- and 
medium- terms. Cohort studies examining the correlation between changes in NT-proBNP 
concentrations and either ultrafiltration volume or weight over a single haemodialysis 
session(22, 45) or across three haemodialysis treatments(22, 23) did not demonstrate a 
significant association between the two variables suggesting that it is not a short-term marker 
of hydration status. These findings are not surprising given that B-type natriuretic peptides 
are not stored in intracellular secretory granules, but are instead are regulated through 
changes in gene expression and are thus unlikely to change significantly over a short time 
frame(7). Conversely, cohort studies(19, 20) examining the associations between plasma B-
type natriuretic peptides and surrogate measures of hydration such as serum albumin 
concentration, weight, and blood pressure over monthly or quarterly intervals have 
demonstrated significant correlations between these two variables. The findings of these 
studies lend support to an association between volume status and plasma B-type natriuretic 
peptide concentrations in dialysis patients, although they have significant limitations 
attributable to their use of surrogate measures of volume, infrequent repeated measures and 
small sample sizes. Finally, a recent cohort study by Davenport et al demonstrated a 
significant correlation between change in plasma NT-proBNP and hydration status assessed 
using bioimpedance measured on two occasions over 6-months(25). However, the paucity of 
repeated measures in this study introduced the risk that the correlation between the two 
variables may have been overestimated. The study presented here confirmed a significant 
correlation between NT-proBNP and hydrations status in the dialysis population while 
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addressing the limitations of previous studies through its use of a large inclusive sample, 
objective measures of volume status, and frequent repeated measurements. 
 
A cross sectional study by David et al(46) has previously reported that plasma NT-proBNP 
concentration and hydration status were only correlated in dialysis patients with systolic 
dysfunction. To investigate whether the correlation between plasma NT-proBNP 
concentration and hydration status differed according to cardiomyopathy and/or dialysis 
modality, patients were divided into four subgroups based on dialysis modality, and left 
ventricular hypertrophy, and systolic and diastolic function. Correlation coefficients were 
then compared within subgroups using meta-regression. This analysis found that the 
correlation coefficients of plasma NT-proBNP and hydration status were of similar 
magnitudes, and remained statistically significant irrespective of subgroup implying that if 
NT-proBNP testing was to be used for monitoring hydration status in the dialysis population, 
then the same decision limits could be used regardless of dialysis modality or 
cardiomyopathy. 
 
This study has several strengths including its large sample size and the large number of 
repeated measures per participant, its use of multi-frequency bioimpedance spectroscopy as 
an objective measure of hydration status, its standardisation of plasma NT-proBNP sampling, 
handling and storage to minimise pre-analytic variation, and its inclusion of both 
haemodialysis and peritoneal dialysis patients to extend the generalizability of its findings. 
Nevertheless, the study was limited by the fact that not all participants underwent 
echocardiography potentially impacting the findings of the subgroup analysis. 
 
Conclusion 
This study demonstrated that plasma NT-proBNP concentrations were significantly and 
directly correlated with hydration status measured longitudinally in both haemodialysis and 
peritoneal dialysis patients irrespective of dialysis modality. These findings raise the 
possibility that NT-proBNP could be used to identify patients with worsening overhydration 
and to monitor their response to adjustment of the dialysis prescription. However, further 
longitudinal studies are needed to determine the accuracy and impact of such a monitoring 
strategy on patient outcomes before it can be routinely adopted into clinical practice.  
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Figure Legends 
 
Figure 1. Time series plot of plasma NT-proBNP concentrations and hydration status. 
Time series plot of plasma NT-proBNP concentrations (pg/mL, red line) and ratio of 
extracellular water (ECW) volume to total body water (TBW) volume (blue line) for three 
study participants.
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Table 1. Baseline characteristics of the entire study and echocardiographic sub-study cohorts. 
Abbreviations: ACE-I = Angiotensin converting enzyme inhibitor; ARB = Angiotensin type-1 receptor 
blocker; D/P creatinine = ratio of creatinine concentration in dialysate to plasma; Kt/V = dialysis urea 
clearance; NT-proBNP = N-terminal pro-B-type natriuretic peptide. 
Characteristic 
Entire study cohort 
 (n=103) 
Echocardiographic  
sub-study  (n=78) 
Male gender n (%) 64 (62) 50 (64) 
Age  
Mean ± SD (years)  
Age distribution n (%) 
18 – 49  
50 – 69  
70 – 79  
80 – 90 
 
63±13 
 
19 (18) 
46 (44) 
26 (25) 
12 (13) 
 
64±13 
 
12 (15) 
35 (45) 
20 (26) 
11 (14) 
Hemodialysis n (%) 
Dialysis sessions per week (n) 
Duration of dialysis session (hours) 
Single pool Kt/V 
Interdialytic weight gain relative to estimated  
dry weight (%) 
68 (66) 
3 
4.6±0.7 
1.57±0.3 
1.9±1.0 
48 (61) 
3 
4.7±0.7 
1.58±0.3 
2.4±1.1 
 
Peritoneal dialysis n (%) 
Volume of peritoneal dialysis solution exchanged 
per 24 hours (L) 
Four hour D/P creatinine 
Weekly Kt/V 
35 (34) 
8 (8-9.5) 
 
0.72±0.1 
2.02 (1.76-2.52) 
30 (39) 
8 (8 – 8.9) 
 
0.72±0.1 
1.93 (1.76 – 2.25) 
Time on dialysis (years) 4 (2-6.3) 6 (4-9.5) 
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Body Mass Index (kg/m2) 28.7±6.4 29.3±6.4 
Systolic blood pressure (mmHg) 129±18 128±20 
Diastolic blood pressure (mmHg) 69±13 70±13 
Diabetes mellitus n (%) 59 (43) 35 (45) 
Current or former smoker n (%) 59 (57) 48 (61) 
Ischemic heart disease n (%) 41 (39) 32 (41) 
Peripheral- and/or cerebro-vascular disease n (%) 16 (15) 13 (16) 
Hydration status 
Ratio of extracellular to total body water 
Proportion overhydrated n (%) 
Male 
Female 
 
0.49±0.04 
 
31 (48) 
27 (53) 
 
0.49±0.03 
 
29 (57) 
20 (71) 
Residual renal function (mL/min) 0 (0-2) 0 (0-3) 
Antihypertensive agents 
Median number of anti-hypertensive agents 
Proportion on beta-blocker n (%) 
Proportion on ACE-I or ARB n (%) 
 
1 (0-3) 
56 (54) 
32 (31) 
 
1(1-2) 
45 (58) 
27 (34) 
NT-proBNP (pg/mL) 
Median (IQR) 
Distribution n (%) 
< 300 pg/mL 
300 – 899 pg /mL 
900 – 4999 pg/mL 
5000 – 19,999 pg/mL 
≥ 20,000 pg/mL 
 
2299 (956-11697) 
 
4 (4) 
14 (13) 
45 (44) 
25 (25) 
15 (14) 
 
3344 (1080-9786) 
 
4 (5) 
9 (12) 
34 (44) 
20 (27) 
11 (12) 
Left ventricular structure and function 
Left ventricular mass indexed to BSA (g/m2) 
 
-------------- 
 
119 (97-146) 
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Left ventricular hypertrophy n (%) 
Nil 
Mild 
Moderate 
Moderate 
Ejection fraction (%) 
Global longitudinal strain (%) 
Left ventricular systolic dysfunction n (%) 
Ejection fraction 
Global longitudinal strain 
Diastolic dysfunction n (%) 
Nil 
Grade 1 
Grade 2 
Grade 3 
 
-------------- 
-------------- 
-------------- 
-------------- 
-------------- 
-------------- 
 
-------------- 
-------------- 
 
-------------- 
-------------- 
-------------- 
-------------- 
 
26 (33) 
10 (13) 
15 (19) 
27 (35) 
54 (49-62) 
-14±3.2 
 
25 (32) 
44 (56) 
 
12 (16) 
33 (42) 
26 (33) 
7 (9) 
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Table 2. Correlation of plasma NT-proBNP and hydration status by dialysis modality and 
cardiomyopathic features. Meta-regression of correlation coefficient between plasma NT-proBNP 
concentration and ratio of extracellular water volume to total body water volume by dialysis modality, 
left ventricular (LV) systolic function, and severities of left ventricular diastolic dysfunction and 
hypertrophy. 95% CI = 95% confidence interval 
 
 
 
 
 
 
   
Sub-group Correlation coefficient (95% CI) p-value 
 
Dialysis modality 
Haemodialysis 
Peritoneal dialysis 
 
0.303 (0.211 – 0.391) 
0.203 (0.059 – 0.337) 
 
0.23 
LV systolic dysfunction 
Absent 
Present 
 
0.224 (0.125 – 0.320) 
0.350 (0.227 – 0.461)     
 
0.11 
LV diastolic dysfunction 
Nil 
Grade 1 
Grade 2 
Grade 3 
 
0.245 (0.086 – 0.392) 
0.316 (0.180 – 0.440) 
0.245 (0.100 – 0.380) 
0.286 (-0.016 – 0.539) 
 
0.87 
 
LV hypertrophy 
Nil 
Mild 
Moderate 
Severe 
 
0.252 (0.125 – 0.372) 
0.253 (0.028 – 0.420) 
0.319 (0.118 – 0.497) 
0.283 (0.135 – 0.419) 
 
0.94 
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Chapter 11 – Conclusion. 
 
 
The findings presented in this thesis advance understanding of the pathophysiological factors 
underpinning NT-proBNP and hs-cTnT in the dialysis population and improve interpretation of 
serial measurements of these biomarkers in clinical practice. The five studies presented yielded 
novel and important findings, which are summarized below.  
 
N-terminal B-type natriuretic peptide (NT-proBNP) 
 
There has been considerable debate regarding the ideal strategy for applying NT-proBNP testing in 
the dialysis population. To date, most studies have pursued an absolute cut-off strategy whereby a 
single threshold concentration would be used to rule out left ventricular hypertrophy, systolic 
dysfunction or volume overload.  The findings of the biological variation and longitudinal studies 
presented in this thesis greatly inform this debate and argue in favour of an alternate, relative 
monitoring strategy.  
 
The biological variation study of plasma NT-proBNP in the dialysis population was the first of its 
kind to be performed and reported in the dialysis population, and found that plasma NT-proBNP 
has a low index of individuality in the dialysis population. This finding suggests threshold values to 
rule out cardiac pathology and/or hypervolaemia would need to be set at the extremes of the 
frequency distribution of NT-proBNP concentrations in the dialysis population, and would therefore 
have poor sensitivity and specificity for the target pathology and be of limited clinical utility. 
Instead, the study’s findings strongly argue in favour of a relative monitoring strategy whereby a 
significant change in serial values may alert physicians to patients at increasing risk of adverse 
cardiovascular events and who require more detailed evaluation to determine which 
pathophysiological factor(s) require intervention. The within-person coefficients of variation 
estimated in the biological variation study will also be invaluable for guiding the interpretation of 
changes in serial measurements of NT-proBNP in any future monitoring strategy and for making 
appropriate adjustments for regression-to-the-mean effects in interventional and observational 
studies using plasma NT-proBNP as an outcome or exposure, respectively. 
 
The findings of the cross-sectional investigation of the pathophysiological associations of plasma 
NT-proBNP in the dialysis population also support the use of a relative monitoring strategy. The 
study found that NT-proBNP was independently associated with left ventricular systolic 
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dysfunction, hydration status, left ventricular hypertrophy and residual renal function whereas 
previous studies had demonstrated an association with either cardiomyopathy or hydration status 
but not both. This novel finding can be attributed in part to the use of left ventricular global strain as 
the measure of left ventricular systolic function in the study. These findings lend support to the 
conclusion that NT-proBNP testing is likely to be better applied in the dialysis population using a 
relative change testing strategy as any single threshold value is unlikely to have sufficient 
sensitivity or specificity to exclude overhydration, left ventricular systolic dysfunction and 
hypertrophy concurrently. The findings of the study also identify pathophysiologic associations that 
may serve as targets of intervention in a potential future NT-proBNP monitoring strategy. 
 
The longitudinal study investigating the correlation of serial measurements of plasma NT-proBNP 
and hydration in dialysis patients is the largest and most comprehensive study of its kind performed 
to date. It demonstrated, for the first time, that longitudinal changes in plasma NT-proBNP and 
hydration status were independently correlated thereby providing the most clinically relevant 
support to date for the role of NT-proBNP testing for monitoring hydration state and its impact on 
prognosis in the dialysis population. However, the correlation coefficient of 0.273 also indicates 
that NT-proBNP is not solely a marker of volume status in the dialysis population. 
 
High sensitivity cardiac troponin-T (hs-cTnT) 
 
The biological variation study of plasma hs-cTnT concentrations in the dialysis population was the 
most comprehensive such investigation to have been performed and reported in a dialysis 
population to date. It found that serial hs-cTnT concentrations need to increase by at least 33% or 
fall by at least 25% over one week to exclude changes due to biological variation alone with 99% 
confidence. These findings help to inform the interpretation of serial hs-cTnT concentrations 
measured in the acute setting for the diagnosis of myocardial injury. In addition, should hs-cTnT 
monitoring be adopted in clinical practice, the within-person coefficients of variation estimated in 
this study will be invaluable for guiding the interpretation of changes in serial measurements of hs-
cTnT concentrations and for making appropriate adjustments for regression-to-the-mean effects in 
interventional and observational studies using plasma hs-cTnT as an outcome or exposure, 
respectively. 
 
The cross-sectional investigation of the pathophysiological associations of plasma hs-cTnT in the 
dialysis population yielded the novel findings that plasma hs-cTnT concentration was independently 
associated with hydration status and possibly also with pulse wave velocity. These findings suggest 
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that hs-cTnT testing may additionally have a role, either alone or together with plasma NT-proBNP 
concentration, in identifying patients with increasing overhydration and monitoring their response 
to therapy. The association of plasma hs-cTnT concentration with pulse wave velocity could be 
explained by myocardial hypoperfusion during diastole due to vascular calcification, and generates 
further potential targets for intervention, although it should be noted that the association was only 
demonstrated using imputed data. Thus, whilst this observed relationship is biologically plausible, it 
requires further confirmation. 
 
Future directions 
The findings of the aforementioned studies suggest the NT-proBNP and hs-cTnT are both 
associated with important pathophysiological processes in the dialysis population and represent the 
essential preliminary steps required to devise a cardiac biomarker monitoring strategy in the dialysis 
population. However, important questions persist regarding the accuracy and lead time of such a 
monitoring strategy for predicting adverse clinical events, precise decision limits, and potential 
targets of intervention. Further analyses of the MONITOR study are expected to answer these vital 
questions. 
 
Accuracy of clinical, biomarker, and bioimpedance based monitoring strategies for predicting 
adverse clinical events. 
 
The accuracy and lead time of a monitoring strategy for predicting adverse clinical events are 
among the most critical factors determining its utility. The ideal strategy should identify adverse 
clinical events accurately and with sufficient lead time to allow intervention to potentially reduce 
the risk of future adverse events. In addition, such a strategy should be superior in both accuracy 
and lead time to clinical monitoring so as to justify a change in practice. 
 
As detailed in chapter 5A and Appendix 1, the MONITOR study performed serial measurements of 
the cardiac biomarkers NT-proBNP and hs-cTnT, bioimpedance spectroscopy, and clinical 
assessments including weight, blood pressure, and the truncated Framingham heart failure score. 
The study also collected data on the occurrence of non-fatal cardiovascular events, all cause 
hospitalisation, fatal cardiovascular events, and all-cause mortality – each of which will be 
adjudicated by investigators blinded to the patient’s biomarker and bioimpedance measurements.  
The accuracy and time to event of each monitoring strategy will be investigated using mixed 
models that allow the joint modelling of longitudinal and time to event data. The study will 
individually examine the Framingham truncated heart failure score, bioimpedance spectroscopy, hs-
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cTnT and NT-proBNP monitoring in this manner, in addition to assessing the incremental benefit, 
or otherwise, of the latter three strategies to clinical monitoring alone. In addition, we will explore 
whether a combination strategy employing both NT-proBNP and hs-cTnT is superior to a 
monitoring strategy which only uses a single biomarker.  
 
Longitudinal association of cardiac biomarkers with therapeutic interventions and 
pathophysiological processes 
 
Should NT-proBNP and/or hs-cTnT be shown to predict adverse clinical events in a timely and 
accurate manner, then further evaluation of the longitudinal association between the cardiac 
biomarkers and both therapeutic interventions and pathophysiologic processes will be essential to 
guiding intervention(s) based on monitoring.  
 
The analyses presented in the thesis have already demonstrated an association between NT-proBNP 
concentrations and both left ventricular global strain and volume status in cross-sectional studies 
and a longitudinal correlation between NT-proBNP concentrations and volume status. The latter 
association will be examined further using both time series analysis and mixed models to explore if 
a lag exists in the correlation, which may in turn alter the strength of the correlation. Similar 
methods will also be used to examine the longitudinal association between NT-proBNP 
concentrations and changes in cardiac structure, systolic and diastolic function, systemic 
inflammation, vascular stiffness, cardiac pharmacotherapy, and the dialysis prescription. Similar 
analyses will also be performed with hs-cTnT. By determining the relative contribution of each of 
these therapeutic and pathophysiological factors to changes in cardiac biomarker concentrations, 
these analyses will guide the development of a hierarchical intervention strategy to be tested in a 
pilot randomised study of biomarker guided therapy.  
 
Should a pilot randomised study prove to be safe and feasible, we would endeavour to perform a 
large randomised study with the goal of assessing if biomarker based monitoring improves patient 
outcomes and quality of life and is cost-effective which is the definitive pre-requisite for instituting 
biomarker monitoring in clinical practice. 
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Appendix 1 
 
SERIAL NT-PROBNP MONITORING IN THE DIALYSIS POPULATION FOR THE 
PREDICTION OF MAJOR CARDIOVASCULAR EVENTS 
STUDY PROTOCOL VERSION 3.0 
 
Title: Serial NT-proBNP Monitoring in the Dialysis Population for The Prediction of Major 
Cardiovascular Events 
Study Rationale 
Introduction 
The all-cause mortality rate in the dialysis population is 15% per annum with cardiovascular 
disease being the leading cause of death (34%). Compared with the general population, dialysis 
patients have a 100-fold increased risk of cardiac arrest which has been attributed to traditional 
and non-traditional risk factors including extracellular volume expansion leading to 
cardiomyopathy(1-3). This appallingly high mortality has remained largely unchanged over the 
last decade. Current tools to identify patients at high risk of adverse cardiac events and guide dry 
body weight, cardiac pharmacotherapy and the dialysis prescription are inadequate and there is 
urgent need for novel tools to guide interventions.  
 
In the dialysis population, cardiomyopathy rather than coronary artery disease is the major risk 
factor for sudden death. Volume overload and hypertension have been identified as critical risk 
factors for cardiomyopathy, and pilot studies of anti-hypertensive and beta-blockade therapy in 
dialysis have yielded promising results. Progress has been hampered, however, by the fact that 
current tools to assess patients’ hydration and cardiac risk status are insensitive, and a validated 
tool to guide dry body weight, cardiac pharmacotherapy, and the dialysis prescription does not 
exist. The development of a tool that accurately identifies patients at high risk of future adverse 
events, and may also be used to guide therapy has been labelled a priority. 
N-terminal proBNP  
In the non-dialysis population, the amino terminal fragment of the cardiac hormone proBNP (NT-
proBNP) has demonstrated excellent diagnostic utility for excluding cardiac systolic / diastolic 
dysfunction and accurately predicts prognosis in individuals with established cardiac failure. There 
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is also increasing evidence from randomised controlled trials and meta-analyses that among 
individuals aged under 75-years of age, heart failure pharmacotherapy guided by NT-proBNP 
concentrations produces superior clinical outcomes compared to best clinical practice alone(4, 5). 
 
The amino terminal fragment of the cardiac hormone B-type natriuretic peptide (NT-proBNP) has 
emerged as an extremely strong candidate biomarker for monitoring cardiovascular disease in the 
dialysis population. NT-proBNP is a biologically inactive 76 amino-acid peptide secreted in 
equimolar amounts to the biologically active hormone BNP. Twenty percent of the peptide is 
excreted unchanged by the kidneys and the remainder is eliminated by passive endocytosis. The 
ventricular myocardium is the major site of synthesis of NT-proBNP which occurs primarily in 
response to ventricular strain or stretch, reflecting underlying hypertrophy or dilatation. Other 
stimuli include ischaemia/hypoxia, endothelin-I, angiotensin-II, interleukin-Iβ, and adrenergic 
agonists(6, 7). Thus from a physiological stand point, NT-proBNP reflects left ventricular 
structural and functional injury in response to a milieu of pathological stimuli known to be 
prevalent in the dialysis population. Indeed, if the general population cut-off for NT-proBNP is 
applied to the dialysis population, NT-proBNP concentrations are universally elevated in the order 
of 2-15 times the upper limit of normal. This marked elevation primarily reflects the widespread 
prevalence of left ventricular structural and functional abnormalities in the dialysis population and 
far exceeds the elevation that can be attributed to impaired renal excretion alone. 
NT-proBNP in the Dialysis Population 
The prognostic value of NT-proBNP in dialysis has been demonstrated in both haemo- and 
peritoneal- dialysis patients. In a cohort of 965 peritoneal dialysis patients followed for a minimum 
of 2-years,  Paniagua et al demonstrated that NT-proBNP concentrations at baseline were highly 
predictive of cardiovascular and all-cause mortality at 30-months after controlling for 
demographic factors, co-morbidity, dialysis treatment dose, inflammatory markers, and residual 
renal function. In this study, patients with NT-proBNP concentrations below the lowest quintile 
(3465 pg/ml) had a relative risk of all cause mortality of 0.64 compared to patients with higher 
concentrations (95% CI 0.45 – 0.92, p = 0.016)(8). Similarly, Madsen et al investigated the 
prognostic value of NT-proBNP in a cohort of 109 haemodialysis patients followed for a mean 
duration of 20-months. A multivariate Cox regression analysis using demographic factors, co-
morbidities, inflammatory markers, left ventricular ejection fraction, left ventricular mass, and 
NT-proBNP as independent variables found that only NT-proBNP (HR 1.52 95% CI 1.18-1.92 p 
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= 0.001) and age (HR 1.04 95% CI 1.01 – 1.06 p = 0.009) were independent predictors of all cause 
mortality(9).  
 
Cross-sectional studies have also demonstrated a strong inverse correlation between NT-proBNP 
and left ventricular ejection fraction(9-11) and a strong direct correlation between NT-proBNP 
and left ventricular mass indexed for body surface area(9, 12) in both haemo- and peritoneal 
dialysis patients. NT-proBNP concentrations measured pre- and post- single dialysis sessions have 
not been shown to correlate with ultrafiltration volume(9),  however, a strong direct correlation 
has been demonstrated between NT-proBNP and extracellular fluid volume assessed by 
multifrequency bioimpedance at 2-monthly intervals over 6-months in a cohort of 44 
haemodialysis patients(13), suggesting that NT-proBNP is a marker of medium-term extracellular 
fluid volume. 
 
Of greatest interest are the findings of a study of 585 incident haemodialysis patients in whom NT-
proBNP was measured at dialysis inception and again 3-months later to evaluate the association 
between longitudinal change in NT-proBNP over the first 90 days of dialysis and mortality at 1-
year (14). Kaplan-Meier estimates of survival were significantly worse in subjects with a net 
increase in NT-proBNP compared with those with a net decrease over the first 90-days of dialysis. 
When examined in a multivariate Cox regression analysis adjusted for baseline NT-proBNP, age, 
sex, race, aetiology of renal disease, and albumin, the highest tertile of delta NT-proBNP had a 2.4 
fold greater risk of all-cause mortality and a 2.9 fold greater risk of cardiovascular mortality than 
patients in the lowest tertile. 
 
Moving Forward: Formulating a Serial Monitoring Strategy 
Whereas current studies support the hypothesis that changes in NT-proBNP predict changes in 
extracellular volume, cardiac structure and adverse clinical events their design does not provide 
the critical information needed to develop a clinically useful serial monitoring model. Specifically, 
the vast majority of published studies use single or very small numbers of repeated measures of 
NT-proBNP, subjective assessments of fluid state, and have focused on fatal clinical outcomes 
only. A clinically useful serial monitoring model needs to:  
1. Distinguish between changes in concentration that accurately predict adverse events and 
should therefore prompt clinical action versus those related to expected biological variation 
that can be ignored. This can only be defined through serial testing. 
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2. Predict non-fatal clinical outcomes and early physiological derangements to enable timely 
intervention in order to improve outcomes. 
3. Provide an estimate of the time interval between a change in a longitudinal marker and the 
outcome of interest (time to event). 
4. Improve on established monitoring strategies by providing earlier and/or more accurate 
detection of  the disease of interest 
5. The next step in the evolution of NT-proBNP as a clinically useful tool is to develop a serial 
monitoring model that incorporates absolute value cut-offs and a magnitude of serial change 
that accurately predict adverse events. 
 
The use of a biomarker in serial monitoring has several similarities to a screening program. The 
aim is to use the test (biomarker) to identify a pre-clinical stage of the condition of interest before 
the condition becomes irreversible, allowing earlier intervention and leading to an improved 
outcome. The major difference between traditional screening tests and serial monitoring are that 
serial monitoring is often applied to diseased populations, and places more importance on change 
in the test/biomarker rather than using a fixed cut-off for case identification. Nevertheless, it is 
worthwhile applying the criteria for a screening program to the serial monitoring model. In order 
to justify a screening program several criteria need to be satisfied(15): 
 
 The condition needs to be ‘important’ to the population of interest, being either  common 
and/or severe – cardiomyopathy, cardiovascular disease and sudden cardiac death in the 
dialysis population certainly satisfy this criterion 
 The natural history of the condition needs to be understood well enough to justify screening. 
We need to be reasonably confident that early detection will capture a reversible stage of the 
disease and that intervening at this earlier stage will result in superior outcomes compared with 
usual practice.  
 In this regard, there is mounting evidence that sudden cardiac death in the dialysis population 
is related more closely to cardiomyopathy than coronary artery disease, and that fluid overload, 
hypertension and cardiac fibrosis represent integral mechanisms in the pathogenesis of 
cardiomyopathy. Unfortunately there are no large randomized trials of interventions in the 
dialysis population demonstrating improved cardiovascular outcomes with any intervention, 
however, a recent meta-analysis of randomized control trials of blood pressure control reported 
reduced cardiovascular event rates, and reduced cardiovascular and all cause mortality 
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associated with use of blood pressure lowering agents(16) while a number of other trials of 
fluid control, and beta-blockade have demonstrated improvement in surrogate cardiovascular 
measures. 
 The test needs to acceptable, easily applied, and accurate. This is the focus of this study. 
 The screening program needs to formally evaluated to ensure that it is able to be implemented 
effectively and produces superior outcomes compared with established practice.  
 Economic analyses need to be performed to determine the cost-effectiveness of screening and 
ensure that adequate resources/facilities exist to deal with the outcomes of screening. 
 
Research Questions 
1. In prevalent dialysis patients, is there a magnitude of change in serial NT-proBNP 
concentrations that predicts future adverse clinical events? Over what time frame and how 
accurately? Do progressively larger changes predict increasingly severe events (non-fatal vs 
fatal)? 
2. In prevalent dialysis patients, is there a magnitude of change in serial NT-proBNP 
concentrations that accurately correlates with progressive over-hydration and predicts evolving 
cardiac dysfunction.  
3. In prevalent dialysis patients, is there an absolute concentration(s) of NT-proBNP that 
diagnoses over-hydration and/or established cardiac dysfunction, and predicts adverse clinical 
events? Over what time frame and how accurately? 
4. How do these derived change/absolute values of NT-proBNP compare with patient symptoms 
and/or bioimpedance for predicting evolving cardiac dysfunction and adverse clinical events? 
Does it do it earlier and more accurately? Is its predictive value modified by bioimpedance 
analysis and/or patient symptom score? 
5. What are the clinical, physiological and biochemical characteristics (potential therapeutic 
targets) of the individuals who have these abnormal absolute NT-proBNP values and/or 
abnormal change values? 
Hypotheses 
In the prevalent dialysis population, progressive elevation of serial NT-proBNP concentrations of 
a magnitude exceeding biological variation will accurately correlate with: 
 Overhydration on bioimpedance analysis 
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 Patient reported symptoms of congestive heart failure 
and predict: 
 Fatal and non-fatal cardiovascular events 
 Evolving adverse cardiac structural and functional changes  
 All cause mortality 
 
In the prevalent dialysis population, NT-proBNP concentrations exceeding an absolute value will 
accurately diagnose: 
 Overhydration on bioimpedance analysis 
 Established cardiac structural and functional abnormalities 
and predict: 
 Fatal and non-fatal cardiovascular events 
 All cause mortality 
Aims 
A. Predictive Aims 
 
1. Establish a magnitude(s) of change in serial NT-proBNP concentrations that accurately 
predicts: 
a. Fatal and non-fatal cardiovascular and clinical adverse events 
b. Evolving adverse cardiac structural and functional changes  
2. Establish the time to event (lead time) between the determined change value(s) and the adverse 
outcome(s). 
3. Determine if changes of progressively increasing magnitude predict increasingly severe 
adverse events (fatal vs non-fatal events) 
4. Establish an absolute value(s) of NT-proBNP that accurately diagnoses: 
a. Over-hydration 
b. Established cardiac dysfunction / abnormal cardiac structure 
and predicts: 
c. Adverse clinical events 
5. Establish the time to event (lead time) between the determined absolute concentration and the 
adverse event 
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B. Comparative Accuracy 
 
1. Compare the accuracy and time to event of the derived NT-proBNP change value with the 
accuracy and time to event of: 
a. Change in bioimpedance (normal hydration to over-hydration) 
b. Change in symptom score (from < 2 to ≥ 2) on truncated Framingham score 
for: 
 Adverse cardiovascular and clinical events 
 Evolving cardiac dysfunction / adverse structural change 
 Determine if the predictive accuracy of the derived NT-proBNP change value for adverse 
clinical events is modified by: 
 concurrent change in patient symptom score on the truncated Framingham heart failure 
score 
 concurrent change in hydration state on bioimpedance analysis 
C. Mechanistic Aims 
 
1. Evaluate the correlation between change in NT-proBNP concentrations and change in: 
a. Symptom score on the truncated Framingham heart failure score 
b. Hydration state on bioimpedance 
c. Indices of cardiac systolic and diastolic function 
2. Determine the clinical, physiological, biochemical and therapy-related patient associations of 
the derived NT-proBNP change and absolute values. 
Study Design and Sample 
Study Design: Prospective Cohort Study 
 
Study Population:  Prevalent peritoneal dialysis and in-centre haemodialysis patients 
 
Sample Size:  150 participants in total consisting of 50-70% haemodialysis and 30-50% peritoneal 
dialysis patients to reflect the proportions of these dialysis modalities in the dialysis centre. 
Methodology for calculating samples sizes in longitudinal studies investigating the predictive 
value of biomarkers is not established. 
 
  
 
253 
 
The sample size in this study is chosen based on: 
Event rate: The all cause mortality rate of prevalent haemodialysis patients is 19.3 per 100 patient 
years in the first year following dialysis inception and 7.3 per 100 patient years in the second year 
following dialysis inception. For prevalent peritoneal dialysis patients, the all cause mortality rate 
is 12.5 per 100 patient years in the first year following dialysis inception and 15 per 100 patient 
years in the second year following dialysis inception (Princess Alexandra Hospital ANZDATA 
Unit Report 2008). Estimates of non-fatal morbid event rates are not available, but are expected to 
exceed fatal event rates. 
Feasibility: It is anticipated that study visits will be conducted by Dr Fahim and a study nurse. 150 
participants is the maximum number of participants that can followed monthly by this study staff. 
Generalizability: The proposed sample sizes represent approximately 33% of all haemo- and 
peritoneal- dialysis patients at the Princess Alexandra and Logan Hospitals and should provide a 
participant case mix that is representative of both the study units’ and Australasian dialysis 
populations. 
 
Setting : In-centre haemo-, Minimal care haemo- and peritoneal- dialysis units of the Princess 
Alexandra Hospital, Brisbane, and Greenslopes Hospital, Brisbane, QLD, Australia. 
 
Recruitment and Selection : Participants meeting entry criteria will be selected consecutively. 
Inclusion Criteria 
 In-centre haemo- or peritoneal dialysis patients established on dialysis for ≥ 90-days  
 Established on a single dialysis modality for ≥ 30 days 
 Aged 18-years or older 
 Temporary or permanent vascular access 
 Able to provide informed consent 
Exclusion Criteria 
 Advanced malignancy and/or current malignancy undergoing evaluation and/or treatment 
– excludes skin cancers 
 Permanent pacemaker and/or implantable cardiac defibrillator 
 Coronary artery stent 
 Limb amputee 
 Living donor renal transplant planned within 3-months of enrolment 
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 Home haemodialysis 
 Congenital heart disease (excluding haemodynamically insignificant patent foramen ovale) 
 Acute renal impairment with the expectation of spontaneous recovery of renal function  
 Pregnancy 
 
Target Condition / Outcomes 
 
Primary:  
 
Non-fatal coronary vascular events - New onset stable angina pectoris, or unstable angina pectoris, 
or non-fatal ST or non-ST elevation myocardial infarction or coronary artery revascularisation - 
angiographic or surgical. 
Non-fatal heart failure (with/out unscheduled dialysis) 
Unscheduled dialysis for hypertension (symptomatic or asymptomatic) 
Non-fatal peripheral vascular events – Stroke (thrombotic or haemorrhagic), or intervention for 
peripheral vascular disease – revascularization or amputation including carotid revascularization 
procedures. 
Arrhythmic events: 
New onset atrial fibrillation requiring initiation of rate control therapy 
Atrial flutter 
Ventricular tachycardia 
Ventricular fibrillation 
2nd or 3rd degree atrioventricular  block 
Resuscitated cardiac arrest 
Death due to coronary artery disease 
Death due to heart failure 
Sudden cardiac death 
Death due to stroke 
Death due to peripheral vascular disease 
Cardiovascular death (composite of 7-11) 
Secondary outcomes:  
Death due to any cause 
Hospitalisation for any cause 
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Dialysis modality change from peritoneal to haemo- dialysis attributed to ultrafiltration failure 
Deterioration in indices of left ventricular systolic function: 
Ejection fraction – relative change within or across diagnostic categories by 10% OR change from 
> 50% to < 50% 
Global longitudinal strain  by 8% 
Left ventricular volumes by 12% 
Deterioration in indices of left ventricular diastolic function: 
Left atrial volume by 10% 
Deceleration time by 10% OR from Mild (Stage 1) to moderate or severe diastolic (Stage 2 or 3) 
dysfunction. 
E/e’ by 15% OR from normal filling pressure (E/e’ <8) to elevated filling pressure (E/e’ >15) 
 
 For each outcome event, a record will be made of whether or not emergency department review 
and/or hospital admission was required for the event. 
 
NOTE: In situations where more than one event occurs concurrently, only the most severe event 
will be recorded the outcome for that time point. 
Index Tests 
Change in serial NT-proBNP concentrations 
Absolute NT-proBNP concentration 
Bioimpedance analysis 
Truncated Framingham Heart Failure Assessment Score 
Reference Standard for Target Condition  
The reference standard is clinical review as per standard clinical practice undertaken in the dialysis 
unit and/or nephrology clinic either as a routine or initiated by the patient. Outcome definitions are 
detailed in Appendix 6
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Methods 
Flow Chart 24 - MONTHS 
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Method Description 
Informed consent. 
Information will be collected about eligible participants who refuse to participate for comparison 
with the study group to determine if they are comparable. 
All participants will be reviewed at monthly intervals as outpatients. 
Outpatient review  
Participants will be instructed to avoid strenuous exercise prior to attending the baseline and 
assessment visits. 
All baseline and assessment visits will be performed on the same day of the week: 
Mid-week, pre-dialysis for haemodialysis patients. 
Mid-week for peritoneal dialysis patients. 
Baseline data collection (see Appendix 1 for Baseline Visit Procedure). 
Assessment visits and clinical outcome ascertainment will be conducted monthly (see Appendix 2 for 
Assessment Visit Procedure). 
Investigational measures will be conducted at varying intervals (see schedule in  Appendix 5). 
Participants will be followed up for 24-months or until transplant, death, withdrawal from dialysis or 
transfer out of the study centres. 
 
Study Measures 
Physical examination and Heart failure assessment score  
 
These assessments will be performed by Dr Magid Fahim throughout the study who will be blinded 
to the NT-proBNP concentrations throughout the study. In addition, this assessment will always be 
performed prior to bioimpedance analysis, so that Dr Fahim will be blinded to the bioimpedance 
analysis at the time of clinical assessment. 
 
NT-proBNP and undesignated plasma collection and storage  
 
15 ml of whole blood will be collected into a lithium heparin tube pre-dialysis from the participant’s 
AV fistula/graft or central venous catheter (if on haemodialysis) or  from his/her arm (if on peritoneal 
dialysis).  
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Samples will be stored at 4°C for a maximum of 1-hour before undergoing centrifuge. Plasma will 
be pipetted into 2ml aliquots and stored at -80°C. Samples for NT-proBNP will be analysed in batches 
at 6-month intervals on the Elecsys 2010 (Roche Diagnostics) after a quality control specimen 
analysis. 
 
Undesignated plasma will be stored for up to 15-years and re-analysed in the future for new 
biomarkers relevant to the area. HREC approval will be sought prior to such analysis and participants 
will be consented for this at enrolment. 
 
12-lead ECG and Bioimpedance analysis 
 
These procedures will be performed by Dr Magid Fahim and/or a study nurse in accordance with 
manufacturer’s instructions. ECG interpretation will be performed by Dr Magid Fahim and any 
queries referred to Assoc Prof Richard Troughton. 
 
Echocardiograms 
 
Echocardiograms will be: 
Performed mid-week on a non-dialysis day (the day after the second dialysis of the week) throughout 
the study 
Performed by the one of four echocardiographers who will be blinded to all clinical and biochemical 
information including NT-proBNP concentrations 
Assoc Prof Richard Troughton will assess a random sample of serial Echo’s (all 3 Echo’s from a 
given patient) in a blinded fashion to ensure measurements are accurate (quality control procedure) 
 
Carotid intimal thickness, and Pulse wave velocity 
Carotid intimal thickness and pulse wave velocity will be performed by the same operator throughout 
the study, mid-week pre-dialysis (after the second dialysis of the week for haemodialysis).  
Outcome Ascertainment 
Clinical outcomes will be ascertained by: 
Monthly participant interview 
Monthly review of dialysis notes (redundancy procedure) 
Monthly review of local hospital computer admission records (redundancy procedure) 
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Monthly review of Princess Alexandra and Logan Hospitals’ computerized nephrology database 
(redundancy procedure) 
Death certificate review (if applicable) 
 
Any potential clinical outcomes detected by these methods will be confirmed by review of the 
participant’s medical notes and/or death certificate to ensure that the event satisfies the required 
definitions. Confirmatory reviews will be carried out by Dr Magid Fahim and in cases where there is 
any ambiguity, the notes/cases will be referred to Assoc Prof Carmel Hawley and Dr Scott Campbell 
for further review.  
 
Cardiac functional/structural outcomes will be ascertained by comparison of serial echocardiograms. 
Echocardiograms from all time points for a single patient will be measured (interpreted) by a single 
interpreter blinded to patient clinical and biochemical data at the end of the study. 
Serial changes in carotid intimal thickness and pulse wave velocity will be ascertained by comparison 
of serial recorded images. Images from all time points for a single patient will be measured 
(interpreted) by a single interpreter blinded to patient clinical and biochemical data at the end of the 
study. 
 
Statistical Analysis 
Time to cardiovascular event/outcome will be analysed using survival analysis, with NT-proBNP 
being included as a time-varying covariate.  We will also analyse the data using recently developed 
statistical methods that allow joint modelling of time-to-event data and longitudinal data (NT-
proBNP). To determine whether BNP monitoring provides an incremental benefit over symptom 
monitoring, we will include both BNP and symptoms in our models.  Other relevant clinical and 
demographic variables will be included in the model as covariates.  We will determine the best 
combinations of monitoring (BNP,bioimpedance  and symptoms) by checking the ability of our 
models to discriminate between patients who do or do not have the primary outcomes of interest. 
To examine the relationship between longitudinal change in NT-proBNP concentrations and 
longitudinal change in (i) bioimpedance measurements and (ii) echocardiographic outcomes we will 
fit a longitudinal model with NT-proBNP as the time-varying covariate outcome and the other 
variables (echo + fluid state change) as outcomes. 
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Losses to follow-up and withdrawal of consent 
Patients’ data will be censored at time of death, renal transplant, transfer out of study centre, and 
withdrawal of consent. Any data collected prior to these events will be included in the analysis. 
Safety and Monitoring 
An adverse event is classified as ‘serious’ (SAE) if it meets any one of the following criteria: 
Death 
Life threatening:  The subject was at substantial risk of dying at the time of the adverse event or it is 
suspected that the use or continued use of the product would result in the subject’s death. 
Hospitalisation (initial or prolonged):  Required admission to the hospital or prolongation of a hospital 
stay. 
Disability:  Resulted in a significant, persistent, or permanent change, impairment, damage or 
disruption in the subject’s body function/structure, physical activities or quality of life. 
Congenital anomaly / birth defect 
Important Medical Event:  Other medically important events that, in the opinion of the investigator, 
may jeopardise the subject or may require intervention to prevent one of the other outcomes listed 
above. 
 
This study is purely observational with no investigational drugs or interventions and no deviations 
from current standard practice.  We will seek an exemption from reporting Serious Adverse Events 
unless they are ‘unexpected’ or deemed ‘clinically significant’ by the Principal Investigator/s. 
 
Clinical findings consistent with life threatening heart failure or other relevant life threatening clinical 
pathology will be reported to the participant’s usual doctor at the time of the study visit for further 
review and/or intervention. 
 
Bioimpedance spectroscopy readings have been validated against models of total body water but have 
not been shown to be related to adverse clinical outcomes. Thus both bioimpedance measures and 
NT-proBNP concentrations will NOT be communicated to the clinicians caring for the participants. 
Investigators 
 
Principal Investigator 
 
Dr Magid Fahim 
PhD Candidate and Nephrologist  
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Appendix 1 - Baseline Data Items & Investigations 
 
Study participant ID number 
ANZDATA number 
Age 
Gender 
Ethnicity 
Renal diagnosis 
Time from referral to renal service to dialysis commencement (weeks) 
Date of dialysis commencement and duration of dialysis (months) 
Dialysis access at dialysis commencement – temporary vs permanent 
Single dialysis modality since commencement (Y/N) – if ‘No’ – Record (i) dialysis modalities used, 
(ii) duration of each modality (weeks), and (iii) reason for change of modality 
Duration of dialysis on current modality 
Current vascular access – CVC (tunnelled or non-tunnelled), AV fistula, AV graft, PD catheter 
If AV fistula / graft  - record 2 most recent flow rates and dates  
Current dialysis prescription and adequacy 
Haemodialysis – frequency, duration of session, dialysis membrane ultrafiltration coefficient, blood 
flow rate, dialysate flow rate, dialysate sodium concentration, dialysate potassium concentration 1.0 
mmol/l (Y/N), last two single-pool Kt/V and dates, average monthly inter-dialytic weight gain as a 
percentage of estimated dry body weight in the month prior to assessment ( [Total inter-dialytic 
weight gain across entire month /  number of haemodialysis sessions] / estimated dry body weight) x 
100.  
Peritoneal dialysis – CAPD vs CCPD vs NIPD, total volume of exchanges per 24-hours, transporter 
status, last recorded weekly Kt/V and number of episodes of peritonitis 
Residual renal function (measured within 3-months of enrolment) 
History of transplantation (Y/N) – if ‘Yes’ – record (i) number of transplants, (ii) duration of dialysis 
independent graft function and (iii) reason for graft failure. 
Current medications – generic names, dose and frequency (including IV iron) 
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ESA dose – type and dose as mcg or mg/kg per g/l Hb 
Co-morbidities 
Cardiovascular 
Ischaemic Heart Disease  
Angina  
Method of diagnosis – Clinical only (probable) (Y/N) vs clinical and (i) non-invasive stress test 
(record date, type of test and result) or (ii) evidence of > 50% stenosis of epicardial coronary artery 
on coronary angiography (definite) 
Severity on Canadian Cardiovascular Society grading of angina pectoris (see Appendix 4) 
Current and past therapy – medical, PTCA, and/or coronary surgery 
Myocardial infarction (MI) – type, number and therapy: 
ST elevation MI and therapy – thrombolysis / PTCA / conservative 
Non-ST elevation MI  
Document most recent (i) non-invasive cardiac stress test (type, date, and result) and/or (ii) coronary 
angiogram if performed (even if normal) 
Congestive Heart Failure / Cardiomyopathy 
Previous admission for congestive heart failure (Y/N) 
Current or previous: 
Left ventricular systolic dysfunction and/or  
Dilated cardiomyopathy 
Hypertrophic obstructive cardiomyopathy 
Document measures of most recent echocardiogram and date 
Valvular Heart Disease  
Document valve(s) involved, type of dysfunction, and severity from most recent echocardiogram.  
Valve surgery and date. 
Arrhythmia  
Type, rate (from ECG), and therapy 
Peripheral Vascular and Carotid Artery Disease  
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Diagnosis - clinical only (probable) and/or doppler ultrasound or angiography (document date and 
results) (definite) 
Therapy - Angioplasty, endarterectomy, stenting, or amputation 
Cerebrovascular Disease  
Transient ischaemic attack  
Thrombotic or haemorrhagic stroke 
Subarachnoid haemorrhage 
IF NO IMAGING – classify as probable 
Dyslipidaemia 
Record most recent lipid profile – total cholesterol, LDL, HDL, and TAG concentrations – date and 
fasting or not 
Diabetes 
Duration and therapy 
Hypertension – (Y/N) 
Smoking history 
Current / former / never – if current/former document pack years 
Pulmonary Disease 
Restrictive or obstructive (document respiratory function test results and date) 
Hepatic  
Viral hepatitis, alcoholic or non-alcoholic steatohepatitis, cirrhosis – record investigational evidence 
of any clinical diagnosis 
Peptic Ulcer Disease – record if endoscopically proven (definite) or not (probable) 
Endocrine – type of disorder 
Alcohol consumption – standard drinks per week 
Neurological (non-cerebrovascular) 
Previous Malignancies – excluding non-melanoma skin cancer  
Examination 
Weight 
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Height 
Waist circumference 
BMI 
Pulse rate and rhythm 
Manual sitting blood pressure 
Heart failure assessment scale (see Appendix 3) 
Investigations 
Full blood count and differential (FBC) 
Urea, creatinine and electrolytes – Na+, K+, Cl-, HCO3-, Corr. Ca2+, PO43-, Urea, Creatinine 
Albumin and liver enzymes 
Ferritin, and transferrin saturation  
Troponin T (TnT) 
C-reactive protein (CRP) 
Parathyroid hormone (PTH) 
Fasting lipid profile 
25-hydroxy vitamin D 
NT-proBNP 
Hs-cTnT 
5-ml plasma to be stored at -80°C for future analysis of relevant biomarkers (patient will be consented 
for this) 
Residual renal function 
ECG 
Bioimpedance analysis 
Echocardiogram (mid-week on non-dialysis day) 
Carotid intimal thickness 
Pulse wave velocity 
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Appendix 2 - Follow-up Assessment Visit and Outcome Ascertainment Redundancy 
Procedures 
 
Visits will be conducted mid-week pre-dialysis for haemodialysis patients and mid-week for 
peritoneal dialysis patients – visits will always be performed on the same day of the week 
throughout the study  
Patient Visit 
History – (Monthly) 
Enquiry regarding clinical events since previous assessment: 
presentation to dialysis service for unscheduled dialysis 
presentation to emergency department - presenting complaint and diagnosis 
admission to hospital - presenting complaint and diagnosis 
cardiac investigations and/or interventions and indication 
vascular investigations and/or interventions and indication 
change in dry body weight target and indication 
change in dialysis modality or prescription and indication 
change in angina severity on Canadian Cardiovascular Society grading of angina pectoris (see 
Appendix 4) 
Medication list review – record changes and reasons for changes 
Examination – (Monthly) 
Weight using identical set of scales throughout study for all participants 
Pulse rate and rhythm 
Manual sitting blood pressure 
Heart failure assessment scale (see Appendix 3) 
Investigations – TO BE PERFORMED PRE-DIALYSIS 
Full blood count and differential (FBC) – (Monthly) 
U & E’s – Na+, K+, Cl-, HCO3-, Corr. Ca2+, PO43-, Urea, Creatinine – (Monthly)  
Albumin and liver enzymes – (Monthly) 
Ferritin and transferrin saturation – (3-monthly) 
High sensitivity cardiac troponin T (hs-cTnT) – (3-monthly) 
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C-reactive protein (CRP) – (3-monthly) 
Parathyroid hormone (PTH) – (3-monthly) 
25-hydroxy vitamin D – (Yearly) 
NT-proBNP – (Monthly) 
5-ml plasma to be stored at -80°C for future analysis of relevant biomarkers (patient will be consented 
for this) – (Monthly) 
ECG – (Monthly) 
Residual renal function (3-monthly) 
Bioimpedance analysis – (Monthly) 
Imaging 
Echocardiogram (mid-week on non-dialysis day) – (Yearly) 
Carotid intimal thickness – (2-yearly) 
Pulse wave velocity – (6-monthly) 
 
Redundancy Procedures for Ascertaining Outcomes 
Local hospital admission records and the nephrology database will be reviewed monthly to check if 
the patient has been admitted to hospital. If an admission is found then the patient’s hospital record 
will be retrieved and the following information recorded: 
Indication for admission 
Diagnosis  
Relevant diagnostic procedures 
Medication and dialysis prescription changes  
Dialysis notes will be reviewed monthly for: 
 mean post-dialysis blood pressure across the entire month. 
 average interdialytic weight gain over month as percentage of estimated dry body weight 
 unscheduled dialyses and indication 
If a patient fails to attend a follow-up visit and cannot be contacted directly: 
Local hospital records and the nephrology database will be checked to determine if they have been 
admitted to hospital. 
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If it transpires that the participant is deceased, a copy of the death certificate will be obtained. 
(Permission from the Australian Institute of Health and Welfare will be obtained.) 
If it transpires that the patient has withdrawn from dialysis, the reason for this shall be ascertained 
through the patient’s medical records and discussion with the physician responsible for their care 
If the patient transfers out of the study centre then they shall still be followed up for mortality 
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Appendix 3 - Heart Failure Assessment Scale 
 
Truncated Framingham Heart Failure Assessment Score 
 
Symptom / Sign Value Patient Score 
Orthopnoea 0.5  
Paroxysmal nocturnal dyspnoea 1.0  
Reduction in exercise tolerance 0.5  
Resting sinus tachycardia ( > 100 / min) 0.5  
Jugular venous pressure > 4 cm 0.5  
Hepatojugular reflex positive 1.0  
Third heart sound 1.0  
Bibasal crackles 1.0  
Hepatomegaly 0.5  
Peripheral Oedema 0.5  
Total 
 
From: Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham 
Study. J Am Coll Cardiol 1993; 22: 6A-13A 
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Appendix 4 - Canadian Cardiovascular Society grading of angina pectoris 
 
Grade  Description 
Grade I Ordinary physical activity does not cause angina, such as walking 
and climbing stairs.  
Angina with strenuous or rapid or prolonged exertion at work or 
recreation 
Grade II Slight limitation of ordinary activity.  
Walking or climbing stairs rapidly, walking uphill, walking or stair 
climbing after meals, or in cold, or in wind, or under emotional 
stress, or only during the few hours after awakening.  
Walking more than two blocks on the level and climbing more than 
one flight of ordinary stairs at a normal pace and in normal 
conditions 
Grade III Marked limitation of ordinary physical activity.  
Walking one or two blocks on the level and climbing one flight of 
stairs in normal conditions and at normal pace 
Grade IV Inability to carry on any physical activity without discomfort, 
anginal syndrome may be present at rest 
 
From: Campeau Lucien. Grading of angina pectoris. Circulation 1976; 54: 522-523 
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Appendix 5 - Study Procedure Schedule  
 
 Baseline M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13 
History X X X X X X X X X X X X X X 
Examination X X X X X X X X X X X X X X 
CCS angina severity X X X X X X X X X X X X X X 
Heart Failure score X X X X X X X X X X X X X X 
FBC X X X X X X X X X X X X X X 
U & E X X X X X X X X X X X X X X 
LFT X X X X X X X X X X X X X X 
Iron studies X - - X - - X - - X - - X - 
TnT X - - X - - X - - X - - X - 
CRP X - - X - - X - - X - - X - 
PTH X - - X - - X - - X - - X - 
Lipids X - - - - - - - - - - - - X 
25-OH Vit D X - - - - - - - - - - - - X 
NT-proBNP X X X X X X X X X X X X X X 
5-ml plasma  X X X X X X X X X X X X X X 
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ECG X X X X X X X X X X X X X X 
Bioimpedance X X X X X X X X X X X X X X 
Residual renal function X - - - - - X - - - - - X - 
Echocardiogram X - - - - - - - - - - - X - 
Carotid intimal thickness X - - - - - - - - - - - - - 
Pulse wave velocity X - - - - - X - - - - - X - 
Clinical outcome assessment - X X X X X X X X X X X X X 
 
 
 M14 M15 M16 M17 M18 M19 M20 M21 M22 M23 M24 
History X X X X X X X X X X X 
Examination X X X X X X X X X X X 
CCS angina severity X X X X X X X X X X X 
Heart Failure score X X X X X X X X X X X 
FBC X X X X X X X X X X X 
U & E X X X X X X X X X X X 
LFT X X X X X X X X X X X 
Iron studies - X - - X - - X - - X 
TnT - X - - X - - X - - X 
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CRP - X - - X - - X - - X 
PTH - X - - X - - X - - X 
Lipids - - - - - - - - - - - 
25-OH Vit D - - - - - - - - - - - 
NT-proBNP X X X X X X X X X X X 
5-ml plasma  X X X X X X X X X X X 
ECG X X X X X X X X X X X 
Bioimpedance X X X X X X X X X X X 
Residual renal function - - - - X - - - - - X 
Echocardiogram - - - - - - - - - - X 
Carotid intimal thickness - - - - - - - - - - X 
Pulse wave velocity - - - - X - - - - - X 
Clinical outcome assessment X X X X X X X X X X X 
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Appendix 6 - Outcome Definitions 
Non-fatal Myocardial Infarction (ST elevation or Non-ST elevation myocardial infarction) 
A rise and/or fall of cardiac Troponin from a previous or baseline measurement by ≥20%, with at 
least one level above the upper reference limit (defined as a level exceeding the 99th percentile of 
a reference population at which the assay has a coefficient of variation 10%) together with at 
least one of the following: 
Symptoms of myocardial ischaemia (various combinations of chest, upper limb, jaw, or epigastric 
discomfort at rest or on exertion with/out accompanying dyspnoea, diaphoresis, nausea and/or 
syncope lasting ≥ 20 minutes); 
ECG changes – 
ST elevation in two contiguous leads of ≥0.2mV in men or ≥0.15mV in women in V2 or V3 and/or 
≥0.1mV in other leads OR 
New horizontal/down-sloping ST depression ≥0.05mV in two contiguous leads, OR 
T-wave inversion ≥0.1mV in two contiguous leads (with prominent R or R/S ratio>1) OR 
New left bundle branch block OR 
Any Q-waves in leads V2-V3 ≥ 0.02 s or QS complex in leads V2 and V3  OR 
Q-wave ≥ 0.03 s and ≥ 0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4-V6 in any two 
leads of a contiguous lead grouping. 
Imaging evidence of new loss of viable myocardium or new regional wall abnormality. 
From: Thygesen K et al. Universal Definition of Myocardial Infarction. Circulation. 2007;116: 
2634-2653. 
New Onset Stable Angina Pectoris 
New onset of symptoms of angina pectoris (various combinations of chest, upper limb, jaw, or 
epigastric discomfort with/out accompanying dyspnoea, diaphoresis, nausea and/or syncope) 
occurring on moderate to severe exertion (CCS class I and II) 
 
AND one of: 
Positive non-invasive cardiac stress test demonstrating reversible ischaemia 
OR 
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Coronary arteriography demonstrating at least one 50% stenosis in one or more epicardial 
coronary arteries. 
From: Hemmingway et al. Incidence and Prognostic Implications of Stable Angina Pectoris 
Among Women and Men.  JAMA. 2006; 295: 1404-1411 
 
Unstable Angina Pectoris 
Symptoms of myocardial ischaemia (various combinations of chest, upper limb, jaw, or epigastric 
discomfort with/out accompanying dyspnoea, diaphoresis, nausea and/or syncope) meeting any 
one of the following criteria: 
Rest angina - Angina occurring at rest and prolonged, usually greater than 20 min 
New-onset angina - New-onset angina of at least CCS class III severity 
Increasing angina severity - Previously diagnosed angina that has become distinctly more frequent, 
longer in duration, or lower in threshold (i.e., increased by 1 or more CCS class to at least CCS 
class III severity) 
With or without ECG changes 
New horizontal/down-sloping ST depression ≥0.05mV in two contiguous leads, OR 
New T-wave inversion ≥0.1mV in two contiguous leads  
AND 
In the absence of ST elevation on the ECG or detectable quantities of a marker of myocardial 
injury (troponin I (TnI), troponin T (TnT), or CK-MB) based on 2 or more samples collected at 
least 6 h apart, with a reference limit of the 99th percentile of the normal population. 
From: Anderson J et al. ACC/AHA 2007 Guidelines for the Management of Patients With 
Unstable Angina/Non_ST-Elevation Myocardial Infarction: A Report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee 
to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non_ST-
Elevation Myocardial Infarction) Developed  in Collaboration with the American College of 
Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the 
Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and 
Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Col Cardiol 
2007; 50: e1 – 157 
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Heart Failure 
 
New onset or worsening dyspnoea at rest, exertional dyspnoea, paroxysmal nocturnal dyspnoea, 
or orthopnoea AND  
Chest X-ray consistent with pulmonary congestion AND  
Echocardiogram performed before or at presentation demonstrating left ventricular systolic and/or 
diastolic dysfunction AND 
Improvement in symptoms following diuresis, ultrafiltration, and/or systemic vasodilator therapy 
 
From: Zannad et al. Heart Failure as  an endpoint in heart failure and non-heart failure 
cardiovascular clinical trials: the need for a consensus definition. Eur Heart J. 2008; 29: 413-421 
Stroke 
New focal neurological dysfunction attributable to brain or retinal ischaemia that lasts more than 
24 hours (unless death occurs within 24 hours, in which case it will be classified as a fatal stroke) 
or where brain imaging demonstrates an acute infarction or haemorrhage consistent with the 
presentation. 
 
Coronary Revascularisation 
 
Percutaneous transluminal coronary angioplasty with or without stent.  NOT diagnostic coronary 
angiograms. OR 
Coronary artery bypass graft surgery.   
 
Evidence in the form of a hospital discharge summary or procedure sheet will be required. 
 
Unscheduled Haemodialysis for Hypertension 
 
Haemodialysis / ultrafiltration procedure performed outside the participant’s usual schedule where 
the primary indication is a blood pressure > 170/100 with/out documented clinical evidence of 
overhydration with/out symptoms/signs of hypertensive encephalopathy (headache, nausea, 
confusion, seizure, papilloedema, retinal haemorrhages or exudates) 
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Unscheduled Haemodialysis for Shortness of Breath 
 
Haemodialysis / ultrafiltration procedure performed outside the participant’s usual schedule where 
the primary indication is a complaint of dyspnoea at rest or exertion, or paroxysmal nocturnal 
dyspnoea, or worsening orthopnoea and clinical evidence of overhydration with or without a chest 
X-ray demonstrating pulmonary congestion.  
Intervention for peripheral vascular disease  
 
Revascularisation of the lower limb by percutaneous or surgical means. 
Lower limb amputation that is not directly caused by trauma or infection, but where vascular 
insufficiency is deemed the primary reason for the amputation. 
Death Due to Coronary Artery Disease 
Any one of the following: 
Death attributed to myocardial infarction (as defined above) 
Sudden, unexpected death involving cardiac arrest with symptoms consistent with myocardial 
ischaemia and accompanied by new ST-elevation, or new LBBB and/or evidence of fresh 
thrombus by coronary angiography and/or autopsy and/or pathological evidence of acute 
myocardial infarction but death occurring before blood samples could be obtained or at a time 
before cardiac biomarkers would be expected to be abnormal. 
Death following cessation of dialysis if coronary artery disease is the primary reason for cessation 
of dialysis. 
Death during coronary revascularization procedure. 
From: Thygesen K et al. Universal Definition of Myocardial Infarction. Circulation. 2007;116: 
2634-2653. 
Death due to Heart Failure 
Death in a patient who presents with heart failure OR  
Death following cessation of dialysis if heart failure is the primary reason for cessation of dialysis  
Death due to Stroke  
Death following presentation with stroke OR  
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Death following cessation of dialysis if stroke is the primary reason for cessation of dialysis. 
Death due to Peripheral Vascular Disease 
Death following presentation with a peripheral vascular disease event such as an ischaemic or 
gangrenous lower limb, where vascular insufficiency and not infection or trauma is the reason for 
the ischaemia OR Death following cessation of dialysis if peripheral arterial disease is the primary 
reason for cessation of dialysis 
Resuscitated Cardiac Arrest 
Sudden collapse of a participant that is witnessed, with either documented absent circulation or 
ventricular tachy- or brady-arrhythmia and where the patient responds to standard 
cardiopulmonary resuscitation procedures. 
Sudden Cardiac Death 
Death within one hour of new cardiac symptoms or an unexpected, unwitnessed death in a person 
without any known non-cardiac illness that could be expected to become rapidly fatal and/or no 
alternative cause of death on autopsy if autopsy is performed.  
Peritoneal Dialysis Ultrafiltration Failure 
Clinical syndrome of overhydration (various combinations of dyspnoea at rest or on exertion, 
orthopnoea, paroxysmal nocturnal dyspnoea, hypertension, tachycardia, Bibasal crepitations, 
pleural effusion, and/or oedema.) AND 
An ultrafiltration volume of < 400 ml after 2-hour dwell of 2 litres of 4.25% peritoneal dialysis 
fluid 
AND 
Exclusion of constipation, peritoneal leak, catheter entrapment, obstruction, or malposition. 
From: Mujais et al. Evaluation and management of ultrafiltration failure problems in peritoneal 
dialysis. Perit Dial Int 2000; 20(S4): S5 - S21 
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Appendix 7- Measurement of Residual Renal Function 
Residual renal function (rGFR adjusted for body surface area) will be estimated as the mean of 
creatinine and urea clearances using formula: 
 
rGFR (ml/min/1.73m2) = ½ (Creatinine clearance + Urea clearance) (1.73/BSA) 
Haemodialysis  
 Example for patients on Monday, Wednesday, Friday Schedule 
    Monday                   Wednesday         Friday 
    
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
Procedure 
 
Urine collection starts at the beginning of the mid-week dialysis: 
Prior to dialysis the patient is asked to empty their bladder 
All urine from the start of the mid-week haemodialysis session and for the next 48-hours is to be 
collected into the supplied container 
The patient is asked to empty their bladder into the container just prior to their final dialysis of the 
week. This concludes the urine collection 
Start 48-hr 
urine 
collection at 
BEGINNING 
of mid-week 
dialysis 
Blood sample 
for Urea and 
Creatinine 
collected 
immediately at 
END of mid-
week dialysis 
Blood sample for 
Urea and 
Creatinine 
collected 
immediately at 
BEGINNING of 
final dialysis of the 
week 
Urine collection 
ends 
Pre-dialysis Pre-dialysis Post-dialysis 
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Blood sampling 
Blood to be collected POST-MID WEEK DIALYSIS AND 
PRE-FINAL WEEK DIALYSIS for urea and creatinine concentrations 
 
Pre-Haemodialysis Blood Sampling Procedure 
When using an AV fistula or graft, 
Obtain the blood specimen from the arterial needle prior to connecting the arterial blood tubing or 
flushing the needle. Ensure that no saline and/or heparin is present in the arterial needle and tubing 
prior to drawing the sample for measurement of plasma urea. 
Do not draw a sample for use as pre-dialysis bloods if haemodialysis has been initiated. 
 
When using a venous catheter, 
Use a 5ml syringe, and withdraw any heparin and saline from the arterial port of the catheter, along 
with blood, to a total volume of 5ml. Discard the contents of this syringe. 
Connect a new syringe and draw the sample for plasma urea measurement. 
Do not draw a sample for use as pre-dialysis bloods if haemodialysis has been initiated. 
 
Post-Haemodialysis Blood Sampling Procedure 
At the completion of haemodialysis, turn off the dialysate flow and decrease the ultrafiltration rate 
(UFR) to 50ml/h, (to the lowest TMP/UFR setting, or off). 
Decrease the blood flow to 100ml/min for 15s (longer if the bloodline volume to the sampling port 
exceeds 15ml). 
Proceed to obtain the blood sample. 
 
Calculations 
 
Creatinine clearance (ml/min) = (UCr V1)/ [0.5(PreCr + PostCr)t] 
UCr is the urinary creatinine concentration (μmol/L) in the interdialytic urine collection  
V1 is the volume (ml) of the interdialytic urine collection  
PreCr is the plasma creatinine concentration (μmol/L) at the beginning of the final dialysis of the 
week  
PostCr is the plasma creatinine concentration (μmol/L) immediately post the middle dialysis of the 
week  
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t is time (min) of inter-dialytic period 
 
Urea clearance (ml/min) = (Uur V1)/ [0.5(PreUr + PostUr)t] 
Uur is the urinary urea concentration (μmol/L) in the interdialytic urine collection  
V1 is the volume (ml) of the interdialytic urine collection  
PreUr is the plasma urea concentration (μmol/L) at the beginning of the final dialysis of the week  
PostUr is the urea concentration (μmol/L) immediately post the middle dialysis of the week  
t is time (min) of inter-dialytic period 
 
Residual GFR (residual renal function) =  
rGFR (ml/min/1.73m2) = ½ (Creatinine clearance + Urea clearance) (1.73/BSA) 
Peritoneal Dialysis 
Any day of the week 
 
 
 
 
 
 
 
 
 
 
Procedure 
Can be performed on any day of the week 
Empty bladder into toilet prior to start of 24-hour collection 
Start 24-hour urine collection 
Empty bladder into collection bottle immediately at the end of 24-hour collection and obtain blood 
sample for urea and creatinine concentrations.  
 
 
 
24-hrs 
Start 24-hr urine 
collection 
Finish 24-hr urine 
collection and 
blood sample for 
urea and 
creatinine 
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Calculation 
 
rGFR (ml/min/1.73m2) = ½ (Creatinine clearance + Urea clearance) (1.73/BSA) 
 
Creatinine clearance (ml/min): (UCr V)/1440PCr 
Where UCr is the urinary creatinine concentration in 24-hour urine collection (μmol/L), V is the 
volume of the 24-hour urine collection (ml), PCr is the plasma creatinine concentration at the end 
of the 24-hour urine collection (μmol/L)  
 
Urea clearance (ml/min): (Uur V)/1440PUr 
Where UUr is the urinary urea concentration in the 24-hour urine collection (mmol/L), V is the 
volume of the 24-hour urine collection (ml), PUr is the plasma urea concentration at the end of the 
24-hour urine collection (mmol/L)  
 
Body Surface Area (BSA) (m2): Dubois formula 
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Appendix 8 - Echocardiography Protocol 
 
Echocardiograms will be performed mid week on a non-dialysis day throughout the study. 
Echocardiograms will be performed by the same sonographers/scientist who will be blinded as to 
the patient’s clinical status throughout the study. 
Measurements will be performed at the end of the study with the scientist/sonographer blinded to 
the sequence of the echocardiograms, and the patient’s clinical and biochemical details. 
Assoc Prof Richard Troughton will assess a random sample of serial Echo’s (all 3 Echo’s from a 
given patient) in a blinded fashion to ensure measurements are accurate (quality control procedure) 
Digital cine loops of three (3) cardiac cycles will be acquired and stored for offline analysis. 
   
Parasternal Long Axis view: 
2D loop at moderate (50-70/min) frame rate. 
2D loop with colour tissue Doppler at high (>120/min) frame rate 
M-mode (still frame) of aortic root/left atrium 
M-mode (still frame) of left ventricle 
 
Parasternal Short Axis view: 
2D loop at aortic valve level 
2D loop at basal left ventricular level at moderate frame rate 
2D loop with colour tissue Doppler at basal left ventricular level at high frame rate 
2D loop at mid left ventricular level 
2D loop at apical left ventricular level 
 
Apical Four Chamber View: 
2D loop at moderate frame rate focusing on left and right ventricles 
2D loop with colour tissue Doppler at high frame rate focusing on left and right ventricles 
2D loop at high frame rate to include both atria and pulmonary veins 
Pulsed wave Doppler of the right upper pulmonary vein (sweep) 
Pulsed Doppler of the mitral inflow (sweep) 
Pulsed Doppler of the left ventricular outflow (sweep) 
Pulsed Doppler of the tricuspid inflow (sweep) 
Continuous wave Doppler of the mitral, aortic and tricuspid valve flows (sweep) 
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Pulsed tissue Doppler of the right ventricular free wall annulus 
Pulsed tissue Doppler of the septal mitral annulus 
Pulsed tissue Doppler of the lateral mitral annulus. 
 
Apical Two Chamber view: 
2D loop at moderate frame rate focusing on left ventricle 
2D loop with colour tissue Doppler at high frame rate focusing on left ventricle 
2D loop at high frame rate to include left atrium and pulmonary veins 
 
Apical Long Axis view: 
2D loop at moderate frame rate focusing on left ventricle 
2D loop with colour tissue Doppler at high frame rate focusing on left ventricle 
3D Echocardiography: 
Full volume 3D left ventricular acquisition of four (4) cardiac cycles (X2) 
 
Measurements: 
M-mode Aortic root and left atrial AP diameter (Ao/LA) 
  Left ventricular end diastolic diameter (LVEDD) 
  Left ventricular end systolic diameter (LVESD) 
  Septal wall thickness (diastole) (IVS) 
  Posterior wall thickness (diastole) (PW) 
2D  Left ventricular end diastolic volume (4 chamber and 2 chamber) (LVEDD) 
Left ventricular end systolic volume (4 chamber and 2 chamber) (LVESD) 
  Left ventricular mass and mass index (LMV/LVMI) 
Left atrial area (4 chamber and 2 chamber) (LAA) 
  Left atrial volume (4 chamber and 2 chamber) (LAV) 
  Twist and untwist velocities and rates (Torsion) 
  Global longitudinal strain and strain rate (GLS) 
Doppler-- Pulmonary vein S, D and a velocities and a duration 
  Mitral E, A velocities, E/A ratio, deceleration time 
    Isovolumic relaxation and contraction times (IVRT and IVC) 
  Aortic and mitral valve opening and closing  
  Aortic valve velocity and velocity time integral (VTI) 
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  Tricuspid valve regurgitant velocity (TR) 
Tissue Doppler—Left ventricular S’, E’ and A’ velocities 
  Right ventricular S’ velocity 
  Left ventricular filling pressure (E/E’) 
3D--  Left ventricular end diastolic volume 
  Left ventricular end systolic  
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Appendix 2 
 
Awards, invited lectures and research grants during candidature  
 
AWARDS 
1. National Health and Medical Research Council Postgraduate Scholarship (2010 -2013) 
2. Finalist - Young Investigator of The Year. Short and Long Term Variation of High Sensitivity 
Troponin-T and N-Terminal B-Type Natriuretic Peptide in The Stable Dialysis Population. Australia 
& New Zealand Society Of Nephrology (ANZSN) Annual Scientific Meeting, Brisbane, Australia 
(2013) 
 
INVITED LECTURES 
1. ‘Biological Variation of NT-proBNP in the Stable Dialysis Population’ Presented June 20th 2012 at 
Screening Test Evaluation Program (STEP) seminar series, Sydney University 
2. ‘Biological Variation in Clinical and Research Practice’ Presented on 17th March 2012, Shire 
Clinical Insights Meeting 2012, Hilton Hotel, Sydney 
 
RESEARCH GRANTS 
Dr Magid Fahim (the candidate) was responsible for authoring the successful research grant proposals 
list below and all associated reviewer rebuttals in their entirety 
 
Year(s) 
Awarded 
Nature of Funding Funding Body Peer 
Reviewed 
Role Value 
(AUD) 
2010 - 13 Postgraduate 
Medical Research 
Scholarship 
National Health & 
Medical Research 
Council, Australia 
Y Principal 
Investigator 
102,750 
2010 - 13 In-kind Equipment 
Support 
Fresenius Medical Care, 
Australia 
Y Chief 
Investigator 
65,000 
2011 - 12 Project Grant Princess Alexandra 
Research Foundation, 
Australia 
Y Chief 
Investigator 
75,000 
2011 - 12 Project Grant Kidney Health Australia Y Chief 
Investigator 
55,000 
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Year(s) 
Awarded 
Nature of Funding Funding Body Peer 
Reviewed 
Role Value 
(AUD) 
2012 - 13 Project Grant National Health & 
Medical Research 
Council, Australia 
Y Chief 
Investigator 
281,193 
2011 Infrastructure 
Support Grant  
Princess Alexandra 
Research Foundation, 
Australia 
Y Chief 
Investigator 
7,500 
2012 Equipment Support Roche Diagnostics, 
Australia 
Y Chief 
Investigator 
20,000 
2012 - 13 Equipment Support Roche Diagnostics, 
Switzerland 
Y Chief 
Investigator 
156,723 
2012 Infrastructure 
Support Grant 
Princess Alexandra 
Research Foundation, 
Australia 
Y Chief 
Investigator 
7,100 
 
